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Hepatocellular Carcinoma (HCC) is one of the most common human cancers 
in the world and it caused more than 695,000 deaths annually.  Despite its high 
mortality rate, the molecular pathogenesis of HCC remained unclear. In this 
thesis, the implication of one of the main epigenetic changes in HCC, which is 
DNA methylation, was elucidated. Methylation profiling of 59 tumors and 
adjacent non-tumors of HCC patients were carried out with Infinium 
Methylation27 platform.  
 
A total of 4416 differentially methylated CpG loci that separate tumor from 
adjacent non-tumors were identified through this study. Hypermethylated CpG 
sites were mostly found in CpG island, while hypomethylation of CpG loci 
were generally located in non-CpG island. Novel differentially methylated 
genes (SPRR3, CYB11B1, PKDREJ, SPDY1, ZNF154, CYB5R2, TSPYL5 
and TUBB6) and hypermethylation of well-studied tumor suppressor genes, 
SPINT2 and GSTP1, were successfully validated through pyrosequencing.  
 
When methylation data was integrated with respective gene expression profile, 
536 genes were found deregulated. These genes were later shown to be 
enriched in inflammation pathway according to Ingenuity Pathway Analysis. 
This integrated data was also used to uncover potentially important gene, 
CYB5R2. This gene was validated to be hypermethylated and repressed in 
tumorous tissue compared to adjacent non-tumorous tissue. Liver cancer cell 
lines, Hep3B and SNU449, which do not express CYB5R2, proliferated 
xi 
 
slower when this gene was re-expressed under adenoviral vector system, 
indicating its tumor suppressive function.  
 
Lastly, consensus hierarchical clustering with iterative feature selection was 
used to subdivide the tumors into different subgroups. One group of patients 
was shown to exhibit worse survival outcomes compared to the rest of the 
patients. Overall, methylation profile provides another layer of understanding 




List of Tables 
Table 1.1  Potential biomarkers in HCC. 
Table 3.1  Clinicopathological characteristics of 59 HCC patients. 
Table 3.2  Top 20 most significantly (A) hyper- and (B) hypo- methylated CpG 
sites in tumors compared to adjacent non-tumors. 
Table 3.3  Overlapping CpG sites found in 4 independent studies.  
Table 4.1  Potential upstream regulators predicted by Ingenuity® knowledge 
base.  
Table 4.2.  Top 20 CpG sites that were most significantly hypermethylated and 
associated with down-regulation of gene expression in tumors. 
Table 5.1  Top 5 most significantly hypermethylated genes with significant 
down regulation of gene expression.  
Table 5.2  Correlation between patients of high and low CYB5R2 expression 
with clinicopathological parameters in HCC samples. 
Table 6.1  Correlation between tumor subgroups and clinicopathological 
parameters in HCC samples. 
Table 6.2  Univariate and multivariate analysis of clinicopathological variables 
for overall and disease free survival in 58 patients.  
Table 6.3  Correlation of Group A and Group B with clinicopathological 
parameters in HCC samples.  
Table 6.4  Forty four genes that were associated with either prognosis or 




List of Figures 
Figure 1.1 Three interrelated epigenetic mechanisms.  
Figure 1.2 Respective functions of histone modifications.  
Figure 1.3 Structures of deoxycytidine and 5-methyl-deoxycytidine.  
Figure 1.4 Repression of genes by methylation.  
Figure 1.5 Bisulfite modification of denatured DNA and its effect on DNA upon 
PCR amplification.  
Figure 1.6 Enzyme reactions in pyrosequencing.  
Figure 1.7 Infinium assay reaction.  
Figure 1.8 Age-standardized liver cancer incidence rates sorted by gender and 
global regions.  
Figure 3.1 Quality assessment and biological reproducibility of 
HumanMethylation27 Beadchips.  
Figure 3.2  Methylation profiling of 59 HCC patients.  
Figure 3.3  Characteristics of differentially methylated CpG sites.  
Figure 3.4  Pathway analyses of significantly differentially methylated genes.  
Figure 3.5  Validation of hypomethylated genes in tumors compared to adjacent 
non-tumors.  
Figure 3.6  Validation of hypermethylated genes in tumors compared to adjacent 
non-tumors.  
Figure 3.7  Overlapping of CpG sites between other independent studies. 
Figure 4.1  Assessment of merged gene expression data from Illumina and 
Agilent platforms.  
Figure 4.2  Gene expression profiling of 59 HCC paired samples.  
Figure 4.3  Integrated analyses of methylation and gene expression profiles of 59 
HCC samples.  
xiv 
 
Figure 4.4  Characteristics of methylation profile of 536 differentially expressed 
genes.  
Figure 4.5  Pathway analyses of 536 genes with significant and differential gene 
expression and methylation.  
Figure 4.6  Proposed mechanistic network.  
Figure 4.7  Validation results for TSPLY5, SH3YL1, CYB5R2, SPINT2, GSTP1 
and TUBB6.  
Figure 4.8  Effect of 5AzaDC on gene expression of TSPYL5, SH3YL1, 
CYB5R2, SPINT2 and TUBB6 in HepG2 cells.  
Figure 5.1  Methylation and gene expression profiling of CYB5R2, SH3YL1, 
and TSPLY5 in cell line models.  
Figure 5.2  Validation of methylation and expression status of CYB5R2 in 20 
HCC patients. 
Figure 5.3  Characterization of CYB5R2 in liver cell lines. 
Figure 5.4  Potential transcription binding sites predicted in putative promoter 
region of CYB5R2.  
Figure 5.5  Transfection versus infection on NehepLxHT cells.  
Figure 5.6  Optimization of infection efficiency for AdControl and AdCYB5R2 
in respective cell lines. 
Figure 5.7  Cells proliferated slower when CYB5R2 was re-expressed in 
SNU449 and Hep3B cells. 
Figure 5.8  Kaplan-Meier survival curves between patients with high and low 
CYB5R2 expression.  
Figure 6.1  Methylation clustering of 59 HCC tumors reveals 3 subgroups.  
Figure 6.2  2D hierarchical clustering of tumors using the probes identified in 
CHC-IFS.  
Figure 6.3  Clustering of 59 HCC tumors using gene expression profiles.  
Figure 6.4  Kaplan-Meier survival curves between tumor subgroups.  
xv 
 
Figure 6.5 Pathway analyses of genes that were significantly different in 
methylation between Group A and Group B.  
Figure 6.6 Methylation profiles of six genes in HCC tumors that were associated 
with prognosis and disease progression.  
Figure 6.7 Validation results for genes that were differentially methylated 




List of Abbreviations 
5AzaDC 5-aza-2’-deoxycytidine 
ADP   Adenosine diphosphate 
AFB1  Aflatoxin B1  
AFP  Alpha-fetoprotein 
ANOVA Analysis of variance 
ATP  Adenosine triphosphate 
∆β  Change of beta value 
bp  Base pairs 
CGI  CpG island 
CHC  Consensus hierarchical clustering 
CI  Confidence interval 
CoBRA Combined bisulphite restriction analysis  
CpG  Cytosine and guanine separated by only one phosphate 
Ct  Threshold cycle number 
CT   Computed tomography  
CTCF  CCCTC-binding factor  
DNA  Deoxyribonucleic acid 
DNMT  DNA methyltransferase 
dNTP  Deoxyribonucleotide triphosphate 
dT  Deoxy-thymine  
EDTA  Ethylenediaminetetraacetic acid 
FDR  False discovery rate 
g  Relative centrifugal force 
GC  Guanine and cytosine 
gDNA  Genomic DNA 
H3K27  Histone H3 Lysine 27 
H3K4  Histone H3 Lysine 4 
H3K9  Histone H3 Lysine 9 
HAT  Histone acetyltransferase 
HBV  Hepatitis B virus 
HBx  Hepatitis B virus X protein 
HCC  Hepatocellular Carcinoma 
HCl  Hydrochlroric acid 
HCV  Hepatitis C virus 
HDAC  Histone deacetylase 
HPLC  High-performance liquid chromatography 
HR  Hazard ratio 
IFC  Integrated fluidic circuit  
IFS  Iterative feature selection 
IGF2  Insulin Growth Factor 2 
IPA  Ingenuity® Pathway Analysis 
KCl  Potassium Chloride 
MBD  Methyl binding domain  
MeCP2  Methyl CpG binding protein 2 
MeDIP  Methylated DNA immunoprecipitation 
mg  miligram 
MgAc2  Magnesium Acetate 
MgCl2  Magnesium Chloride 
MIRA  Methylated CpG island recovery assay  
MiRNA microRNA 
ml  mililiter 
mM  miliMolar 
xvii 
 
MOI  Multiplicity of infection 
mRNA  Messenger RNA 
MSP  Methylation specific PCR 
NaOH  Sodium Hydroxide 
(NH4)2SO4 Ammonium Sulfate 
ng  nano gram 
nm  nano meter 
NuRD  Nucleosome remodeling and histone deacetylase  
PBS  Phosphate buffered saline  
PCA  Principle component analysis 
PCR  Polymerase chain reaction 
PVDF  Polyvinylidene difluoride  
qPCR  quantitative PCR  
R2  Squared of correlation coefficient 
RNA  Ribonucleic acid  
rpm  Revolutions per minute 
SAM   S-Adenodyl-methionine 
SDS  Sodium dodecyl sulfate  
TSS  Transcription start site 
ug  micro gram 
ul  micro liter 
uM  microMolar 
V  Volt  
xviii 
 
List of Published Abstracts 
 
1. Tay, C.*, Mah, W.C*, Lee, C.G. Hepatocellular carcinoma 
diagnostics, treatments and potential theragnostics in the Asia-
Pacific (2012) Current Pharmacogenomics and Personalized 
Medicine, 10 (2), pp.159-169. Published review. 
 
2. Mah, W.C and Lee C.G. DNA methylation: potential biomarker in 
Hepatocellular Carcinoma (2014) Biomarker Research, 2(1):5. 
Published review. 
 
3. Mah, W.C, Thomas, T, Toh, H.C, Chow P.K.H, Chung A.Y.F, Ooi, 
L.P.J, Lee, C.G. Comprehensive Profiling of DNA methylation in 
Hepatocellular Carcinoma (2012) Epigenetics-4th Australian Scientific 
Conference, Adelaide, Australia. Oral presentation.  
 
4. Mah, W.C, Thomas, T, Liu, L.Z, Lee, C.G. Exploring the effect of 
Hepatitis B virus X protein in deregulating the DNA methylation 
profile of Hepatocellular Carcinoma (2012) 24
th
 Lorne Cancer 
Conference, Victoria, Australia. Poster Presentation. 
 




Chapter 1: General Introduction 
1.1 Epigenetics 
“Epigenetics” refers to the study of alterations in gene expression due to 
mechanisms other than alterations of DNA sequence. These changes are 
heritable mitotically and meiotically as they maintain cellular identity [1]. 
Epigenetic changes are important during cellular differentiation and 
development because they ensure cells to have different phenotypes at the end 
of the process even though they have the initial same DNA sequences. 
Examples of well-studied epigenetics changes include post-translational 
histone modification, expression of non-coding RNA and DNA methylation 
(Figure 1.1). In this thesis, the studies have been centered upon DNA 
methylation and Hepatocellular Carcinoma, thus it will be discussed in greater 
details in the later sections. 
 
Figure 1.1 Three interrelated epigenetic mechanisms. Activity of miRNA, 
histone modifications, and DNA methylation are three main mechanisms that 
work synergistically in regulating epigenetic profile of cells. Figure was 
adapted with permission from Karouzakis et al [2]. 
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1.1.1 Histone Modification 
Histone proteins (namely H2A, H2B, H3 and H4) are responsible in packing 
and organizing DNA into nucleosome. Two H2A-H2B heterodimer and two 
H3-H4 heterodimers form an octamer that allows about 146 base pairs (bp) of 
DNA to wrap around it in 1.65 turns. Nucleosomes will then be joined by 
linker DNA and further compacted into chromatin structure. To ensure 
effective replication and transcription, histone tails are able to be post-
translationally modified, and thus permit nucleosome to adopt either 
euchromatin (“open”) or heterochromatin (“condensed”) state [3]. Histone 
modifications include phosphorylation, acetylation, methylation, deimination, 
sumoylation, ubiquitination, ADP-ribosylation, and proline isomerization. 
These modifications exist mainly on the amino terminals of histones, which 
project out from nucleosome (i.e. histone tails) [4]. As various combination of 
modifications can occur within or between histone tails, a “histone code” was 
eventually proposed, where it consists of specific histone modifications that 
were recognized by other molecules and lead to a defined downstream 
molecular events [5]. Presently, the two most well-known histone 
modifications are methylation and acetylation.         
 
Acetylation occurs at the lysine residues of histone proteins. Histone 
acetylation is often associated with open configuration of chromatin (e.g. 
euchromatin). This is due to the weakening of nucleosome-DNA interaction 
by acetylated lysine residues on histone. It was suggested that acetylation 
actually neutralizes the positive charge of lysine residue on histone and thus 
disrupting the electrostatic interaction between DNA and nucleosome. In 
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addition, active gene transcription is usually accompanied by histone 
acetylation as well because less compact chromatin conformation allows 
transcriptional machinery to access and transcribe DNA more readily [6, 7]. 
Histone acetylation is a reversible process and two key enzymes responsible 
for this reaction are histone acetyltransferases (HATs), enzymes that attach 
acetyl group onto histones, and histone deacetylases (HDACs), enzymes that 
remove acetylation. Both enzymes do not work alone as they are part of a 
multi-protein complex that modifies histones synergistically [8].  
 
Unlike acetylation, histone methylation is a more complex phenomenon. 
Lysine residues on histone could potentially be methylated by different types 
of histone methyltransferases and they can be mono-, di- or tri-methylated [9]. 
In addition, chromatin conformation changes according to both the physical 
position and methylation status of lysine residues on histone. For example, 
methylation of H3 lysine 27 (H3K27) and H3 lysine 9 (H3K9) lead to 
compacting of chromatin and therefore are implicated in silencing of gene 
expression; while methylation of histone 3 lysine 4 (H3K4) is associated with 
gene transcription (Figure 1.2) [7, 10]. 
 
Figure 1.2 Respective functions of histone modifications.  
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Figure 1.2 Respective functions of histone modifications. (Continued…) 
Histone modifications were represented as “switches” or “dials”, where they 
fine-tune gene expression levels in (A) promoters, (B) gene bodies, (C) 
enhancers, and (D) on large-scale repression. Figure was adapted with 
permission from Zhou et al [10]. 
 
1.1.2 non-coding RNA 
Gene expression can also be regulated post-transcriptionally by non-coding 
RNA. This additional level of epigenetic mechanism involves mainly long 
non-coding RNA, e.g HOX antisense intergenic RNA (HOTAIR) and small 
regulatory non-coding RNA, e.g. small interfering RNA (siRNA) and 
microRNAs (miRNA) [11-13]. MicroRNA is by far the most studied non-
coding RNA, and it was proposed that 30% of human genes are modulated by 
microRNAs [14]. MicroRNA is single stranded and is shown to affect the 
stability of mRNAs by binding to their 3’ untranslated complementary 
sequences. Besides miRNA, increasing number of non-coding RNAs have 
been discovered with the advent of sequencing technologies, and more studies 
have pointed out that this epigenetic mechanism could potentially regulate 
gene expression at an extent greater than previously thought [13, 15]. 
 
1.1.3 DNA methylation 
DNA methylation occurs when a methyl group is attached to the 5
th
 carbon of 
cytosine nucleotide. This process is catalyzed by DNA methyltransferases 
(DNMTs), in which S-adenosyl-methionine (SAM) acts as a methyl donor 
(Figure 1.3) [16]. Cytosine methylation occurs in animals and plants, but not 
in yeast and Caenorhabditis elegans. In vertebrate such as human, methylation 
occurs mainly in CpG dinucleotide context, where cytosine is linked to 
guanine by a phosphodiester bond and they are diagonally symmetrical [17].  
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In human genome, despite having about 41% of G/C nucleotides content, CpG 
dinucleotide is less frequently observed. This is because methylated cytosines 
in CpG dinucleotides are more susceptible to spontaneous deamination, and 
subsequently converted to thymine. During DNA replication, thymine:guanine 
mismatched will then be repaired as thymine:adenine instead of the original 
cytosine:guanine pair [18, 19]. Generally, we can find high levels of CpG 
dinucleotides in repetitive sequence located in intronic and intergenic regions, 
transposable elements and CpG islands in human genome [20].  
 
Figure 1.3 Structures of deoxycytidine and 5-methyl-deoxycytidine. DNA 
methylation occurs when a methyl group is attached to the 5
th
 carbon of 
cytosine, where DNMT serves as enzyme and SAM acts as the methyl group 
donor. Figure was adapted from http://www.ous-research.no. 
 
1.1.3.1 CpG island 
Presently, there is no strict definition for CpG island. Simply, it is described as 
region with a minimum size of 500bp that has GC content greater than ~55% 
and a higher frequency of observing CpG dinucleotide compared to a similar 
size region (i.e. observed versus expected ratio of more than 0.6) [21]. About 
70% of human genes are associated with CpG island, where about 50% of the 
CpG islands are located within promoter and first intron region of a gene [22, 
23]. It is generally accepted that CpG dinucleotides within gene-associated 
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CpG islands are often unmethylated regardless of the gene expression, while 
CpGs outside of CpG islands are primarily methylated [24]. However, there 
are exceptions as some CpG islands are clearly methylated during 
development or cell differentiation. For instance, CpGs on the inactivated X-
chromosome or imprinted genes are both heavily methylated [25, 26]. In 
Section 1.2, we will see that methylation of CpG islands is deregulated in 
cancer as well.  
 
1.1.3.2 DNA methyltransferase 
Cytosine of CpG dinucleotide is methylated by two types of enzymes, namely, 
DNMT1 (DNA methyltransferase 1), and DNMT3 (either DNA 
methyltransferase 3a, DNMT3a or DNA methyltransferase 3b, DNMT3b). 
DNMT1, first cloned by Bestor et al, is involved in maintaining methylation 
pattern in cells. DNMT1 was shown to have higher affinity towards hemi-
methylated DNA [27]. During DNA replication, DNMT1 uses the hemi-
methylated DNA as template and methylates the newly synthesized daughter 
strand DNA according to the methylation pattern of nascent DNA [28-30]. 
Dnmt1-/- mice suffered developmental arrest at E8.5, and their genome was 
hypomethylated [31]. DNMT1-null mouse embryonic stem cells are viable but 
enter cell death after enter differentiation [32, 33]. All these studies further 
suggest the importance of DNMT1 in ensuring the heritability of methylation 
pattern during DNA replication. 
 
DNMT3 is responsible for de novo methylation [34]. Both types of DNMT3s, 
namely DNMT3a and DNMT3b, are required for embryo development, 
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however, they play different roles in establishing new methylation pattern in 
the genome. As shown by Okano et al, DNMT3a -/- mice died at about 4 
weeks after it was born, with deformed intestines and impaired 
spermatogenesis. DNMT3b-/- mice on the other hand were embryonic lethal. 
These mice have malformed neural tube and their satellite repeat sequences  
contained pronounced loss of methylation [34]. DNMT3b was later shown to 
play a role in methylation of pericentromeric satellite repeats [35] and 
mutation of DNMT3b will lead to immunodeficiency, centromeric instability 
and facial anomalies (ICF) syndrome where ICF patients have 
hypomethylation at their pericentromeric repeats [36].  
 
There are also 2 other molecules which share sequence and structure similarity 
with DNMT1 and DNMT3, they are DNMT2 and DNMT3L. DNMT2 was 
initially thought to methylate cytosine at DNA level, but later studies revealed 
that DNMT2 actually catalyzes the methylation of cytosine at position 38 in 
aspartic acid transfer RNA (tRNA) [37]. Thus, it was renamed as TRDMT1 
(tRNA aspartic methyltransferase 1). On the other hand, DNMT3L has 
sequence and structure homology to DNMT3, but lacks the C-terminal 
catalytic domain of a methyltransferase [38]. Subsequent studies revealed that 
it is an important regulatory factor for DNMT3, where it stabilizes DNMT3s 
and enhance their activity [39, 40].   
1.1.3.3 Methylation and gene expression 
Methylation of promoter CpG sites is primarily linked to gene repression. For 
instance, imprinted genes are methylated and thus not expressed [41]. 
Similarly, X-chromosome is inactivated through methylation [42]. 
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Nonetheless, there are also a few incidences where methylation is linked to 
activation of gene expression. One classic example is the imprinting of 
H19/IGF2 locus. Maternal allele of H19/IGF2 locus is not methylated and thus 
insulator protein, CCCTC-binding factor (CTCF) is able to bind and silence 
gene expression. Paternal allele, on the other hand, is methylated and prevents 
CTCF binding. As a result, IGF2 is expressed at paternal allele [43, 44].  
 
Currently, two mechanisms were proposed to explain how DNA methylation 
affects gene expression (Figure 1.4). Firstly, steric hindrance of methylation 
directly prevents binding of transcription factors or insulators onto DNA, as 
exemplified by the case of H19/IGF2 locus imprinting. Second mechanism 
suggested that DNA methylation regulates gene expression by forming 
complex machinery that includes crosstalk between histone modifications, and 
chromatin remodeling proteins.  
 
Notably, the second mechanism often involves methyl-CpG binding proteins, 
where they recruit other proteins to modify the chromatin and subsequently 
silence gene expression. Examples of methyl binding domain (MBD) proteins 
are MBD1, MBD2, MBD3, and MeCP2. MBD1 was shown to interact with 
histone H3 lysine 9 (H3K9) methyltransferases, SETDB1 (SET domain, 
bifurcated 1). They formed a complex which will facilitate histone H3K9 
methylation that leads to gene repression [45]. MBD2 is associated with 
transcription repression through interaction with nucleosome remodeling and 
histone deacetylase (NuRD) complex. NuRD complex consists of HDAC1, 
HDAC2 and ATP-dependent chromatin remodeling protein. MBD2 was also 
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reported to interact with H4R3 histone methyltransferase in this complex [46]. 
MBD3, on the other hand, does not bind to methylated DNA as it lacks 
methyl-CpG binding domain. Nonetheless, it is still being recruited to the 
NuRD complex and plays a role in gene repression [47, 48]. 
 
Lastly, MeCP2 is the most studied molecule among the MBD family. It binds 
to methylated DNA through its methyl binding domain, and interacts with 
other repressors with its transcriptional repression domain. Briefly, MeCP2 
promote the formation of transcription silencing complex by recruiting co-
repressors Sin3a and HDACs. As a result, histone H3K9 is de-acetylated, 
chromatin become condensed and gene transcription is halted [47, 49].  
 
Overall, all MBD proteins discussed above are shown to be involved in DNA 
methylation- mediated gene repression. They are generally able to recruit 
histone modifying proteins and chromatin remodeling proteins that cause 
chromatin to condense [47].  
 
Figure 1.4 Repression of genes by methylation. Genes can be silenced by 
methylation either by blocking the binding site of transcription factor or 
recruiting co-repressors such as HDACs and MBDs. Figure was adapted with 




1.2 Aberrant DNA methylation in cancer 
We now know that cancer is a complex disease and that it does not occur due 
to genetic mutations alone. Evidences begin to reveal that epigenetic 
deregulation contributes to the development of cancer as well [51].  Aberrant 
methylation in cancer was first proposed by Andrew Feinberg and Bert 
Vogelstein in 1983. They found that genomic DNA was hypomethylated in 
cancer cells [52]. In the 1980s, the concept of tumor suppressor genes surfaced 
and a few groups showed that some tumor suppressor genes were 
hypermethylated and repressed in cancer [53-55]. Since then, more evidences 
pointed out that both hypomethylation and hypermethylation were linked to 
cancer. 
 
1.2.1 DNA hypomethylation in cancer 
Global hypomethylation often associates with cancer [56].  It occurs mainly on 
transposable elements, satellite repeats, coding and intron regions [57]. 
Hypomethylation on these regions leads to re-expression of transposable 
elements [57], activation of proto-oncogenes [58, 59], re-expression of 
imprinted genes [60, 61], chromosome instability [62] and aneuploidy [63, 64]. 
All these eventually contribute towards carcinogenesis. Currently, the actual 
mechanisms for global and site-specific hypomethylation are still not known. 
It was generally believed that it is a specific and selective process, and not a 
random phenomenon [65].  Studies have shown that it may be due to 




1.2.2 DNA hypermethylation in cancer   
As mentioned earlier, a few groups of scientists successfully correlated 
methylation with silencing of tumor suppressor genes in 1980s [53-55]. Since 
then, many studies were carried out to identify novel tumor suppressor genes 
that were repressed by site specific hypermethylation in cancer [51, 67]. Many 
of these methylated and silenced tumor suppressor genes were associated with 
major pathways such as cell death, cell cycle, angiogenesis and DNA repair 
[67]. The exact mechanism of aberrant methylation in tumor is still not known. 
Some proposed that it was due to deregulated DNMTs, whilst others suggested 
that it was due to loss of CpG protection mechanism against methylation 
machinery [51, 68, 69]. In addition, it is also unclear whether hypermethylated 
tumor suppressor genes are the driver of tumorigenesis or by-products of 
deregulated methylation machinery. More studies are needed to further resolve 
this dilemma in near future.  
 
1.3 Methods in measuring DNA methylation 
Many techniques are available for analysis of DNA methylation. However, not 
all methods are the same; in fact, different methods are used to answer 
different research questions.  One of the primary limitations of methylation 
analysis is that the methylation signature will be lost upon PCR. In order to 
retain the methylation information, DNA has to be treated with sodium 
bisulfite first. Such chemical treatment will deaminate unmethylated cytosine 
to uracil, whilst methylated cytosine will be unaffected [70, 71]. Upon PCR, 
the uracil will be converted to thymidine, and methylated cytosine will retain 
as cytosine itself (Figure 1.5). With this modification, we can now obtain the 
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methylation status of DNA more readily. Most analyses of methylation require 
bisulfite treatment, while some depends on antibody that recognizes 
methylated DNA. In addition, methylation analysis can generally be grouped 
into 2 categories, namely gene specific approach and genome-scale approach. 
Subsequent Sections will briefly describe these methods.  
 
 
Figure 1.5 Bisulfite modification of denatured DNA and its effect on DNA 
upon PCR amplification. Cytosines are labeled in red and converted 
cytosines are in bold. 
 
1.3.1 Site specific gene-centric DNA methylation analysis  
1.3.1.1 Methylation specific PCR (MSP) 
Methylation Specific PCR (MSP) adopts the principle that only primers that 
are specific to the methylation site will amplify the region of interest. DNA 
has to be first bisulfite converted, and two sets of primers have to be designed 
so that one pair recognizes the methylated template, while the other pair 
recognizes the non-methylated template [72]. MSP is a cheap, fast and 
sensitive assay but it also has many shortcomings. One has to know the actual 
methylation status of the DNA before specific primers are designed. 
Furthermore, too many PCR cycles and low annealing temperature for primers 
can also create false positive MSP result. Thus, carefully designed PCR 
primers are the key for successful MSP assay.  
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1.3.1.2 Combined bisulfite restriction analysis (CoBRA) 
This method uses methylation sensitive restriction enzymes to digest PCR-
amplified bisulfite-treated DNA. The most commonly used enzyme is BstUI, 
which recognizes sequence 5’…CGCG…3’. The restriction digest will occur 
when the CGCG sites are present. In bisulfite-converted DNA, methylated 
CGCG will be cleaved by BstUI, but the non-methylated CGCG, which will 
be converted to TGTG by sodium bisulfite, will not be recognized by BstUI 
anymore and thus remained uncut.  The restriction digested fragments can then 
be visualized through DNA gel electrophoresis [73]. Undeniably, CoBRA is 
also a relative cheap, fast and efficient way of determining methylation status 
of CpG loci. However, it is low throughput, and DNA fragment of interest has 
to contain the recognizable motif of restriction enzyme. 
 
1.3.1.3 Bisulfite sequencing of PCR products 
Both CoBRA and MSP results are not quantitative, and one method to 
circumvent this is direct sequencing of PCR products of bisulfite converted 
DNA. PCR products of bisulfite treated DNA are cloned into vector and 
transformed into bacteria. Colony PCR is subsequently carried out [74] and 
PCR fragment is cleaned-up for downstream normal Sanger sequencing [75]. 
Each bacteria colony actually represents one single allele, and by combining 
all the clonal results, we will be able to determine the methylation status of the 
allele of interest. This method is still the gold standard in measuring the 
methylation level at single base resolution. However, it is laborious, time 





Pyrosequencing is another recently developed quantitative method that 
directly measures the methylation status of specific DNA locus. 
Pyrosequencing is done on PCR-enriched bisulfite treated DNA products. This 
sequencing method differs from normal Sanger sequencing method. Its 
enzymatic reactions were depicted in Figure 1.6. Briefly, nucleotides are 
dispensed into reaction volume according to pre-determined sequence. When 
the nucleotide is incorporated by DNA polymerase onto denatured single-
stranded, bisulfite-treated DNA, pyrophosphate will be released as a side 
product of the elongation reaction. ATP sulfurylase will then convert 
pyrophosphate into ATP, which will eventually be used by luciferin to 
generate light  [76].  At the CpG locus, where either a cytosine (methylated) or 
thymidine (not methylated) could be incorporated onto the single DNA strand, 
the light emitted by incorporating these 2 nucleotides respectively will 
determine the methylation level of the CpG locus. Shortcomings of this 
method include short read length and less cost effective due to expensive 
equipment and reagents. Nevertheless, due to the sensitiveness and robustness 
of the assay, many validation studies use pyrosequencing [77, 78]. 
 
Figure 1.6 Enzyme reactions in pyrosequencing.  
15 
 
Figure 1.6 Enzyme reactions in pyrosequencing. (Continued…) Denatured 
DNA templates are mixed with four enzymes that involved in pyrosequencing 
in a well of microtiter plate. In a stepwise manner, different nucleotides will 
be injected into the same well, where polymerase will incorporate the 
matching nucleotide and release pyrophosphate (PPi) molecule. PPi molecule 
will then be converted to ATP by ATP sulfurylase and light is emitted when 
luciferase reaction occurred. Excess nucleotides are degraded by apyrase, thus 
enable addition of subsequent nucleotide. Figure was obtained with permission 





This method is also quantitative as it uses Taqman
TM
 quantitative PCR (qPCR) 
system (Life Technologies, USA). Specific Taqman probe that can recognize 
the bisulfite-converted sequence is first synthesized, and by performing qPCR, 
one can measure the levels of methylation located within the probe sequence 
[79]. It is a sensitive, rapid and cost effective method, but each analysis can 




 mass spectrometry method 
Another method that quantitatively analyzes methylation is EpiTYPER, which 
utilizes Mass Spectrometry, commercialized by Sequenom, USA. Under this 
protocol, bisulfite-converted DNA is amplified by PCR and transcribed into 
single strand RNA in vitro. The RNA species are subsequently cleaved into 
fragments and passed through Mass Spectrometry. By measuring the mass 
difference within RNA fragments, one can quantitate the percentage of 
methylation of CpG site. This method is expensive and analyzes short 




1.3.2 Genome scale DNA methylation analysis 
1.3.2.1 Gene expression microarray after 5-aza-2’-deoxycytidine 
treatment 
In this method, gene expressions were measured after cells were treated with 
5-aza-2’-deoxycytidine, a drug that inhibits DNMTs. Genes that are silenced 
under hypermethylation will be re-expressed as a result of loss of methylation 
on promoter when DNMTs were depleted. Many tumor suppressor genes were 
identified using this method, for instance, in colorectal cancer [83], lung 
cancer [84], and renal cell carcinoma [85]. Nonetheless, data obtained from 
this method should be analyzed with caution. Some genes that are not 
regulated by methylation can still be up-regulated as a result of re-expressed 
upstream transcriptional regulators. Furthermore, 5-aza-2’deoxycytidine 
treatment itself may up-regulate drug response genes that are not regulated by 
methylation. Combined analysis between gene expression and methylation 
profile may be a more accurate analysis for identifying tumor suppressor 
genes that are truly silenced by DNA methylation [86].  
 
1.3.2.2 Enrichment of methylated DNA using pulldown assay 
There are two commonly used strategies to pull-down the methylated DNA in 
the genome. One of them is by using antibody that recognizes methylated 
cytosine, a method called MeDIP (methylated DNA immunoprecipitation). 
Weber et al first used this method to profile methylation in cancer [87]. 
Another method is by using methyl binding domain (MBD) proteins that are 
glutathione-S-transferase (GST)-tagged. Methylated DNA will bind to these 
proteins and pulled down with glutathione-coated GST beads. This method is 
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often called methylated CpG island recovery assay (MIRA). Examples of 
studies using this assay include Dunwell et al and Rauch et al [88, 89]. 
Enriched methylated DNA by both methods can then be analyzed by either 
promoter microarray or direct sequencing.  
 
1.3.2.3 Analysis of bisulfite converted DNA using beadarray 
This technology was developed by Illumina, USA, where bisulfite-converted 
DNA are whole-genome amplified, and directly hybridized to bead array for 
methylation analyses. CpG loci were probed (see Figure 1.7 for exact 
mechanism) and methylation was reported as beta values. Beta value 1 means 
CpG is fully methylated and beta value zero means no methylation. Illumina 
provides three types of bead chip array, namely GoldenGate, Infinium 
HumanMethylation27 and Infinium HumanMethylation450. They differ in 
their number of CpG locus being probed. GoldenGate array covers about 1500 
CpG loci; Infinium27 covers about 27000 CpG loci; whilst Infinium450 
covers 450000 CpG loci, the most comprehensive profiling on microarray so 
far.  Plethora of papers reported methylation profile of cancer using either 
GoldenGate or Infinium27 bead array. As Infinium450 is still a relatively new 




Figure 1.7 Infinium assay reaction. DNA was first bisulfite-converted and 
whole genome amplified. They were then hybridized to a pair of bead-bound 
probes. This pair of probes (labeled as U and M probes) could differentiate the 
presence of T or C by hybridization and single-base extension with labeled 
nucleotide. Methylated C will bind to M probe, while unmethylated C, which 
is now converted to T, can only bind to U probe. Signal intensities from the 
incorporated labeled nucleotide will be used to compute β values. (Figure was 
obtained from public domain image, http://commons.wikimedia.org) 
 
1.3.2.4 Methylation analysis using high throughput sequencing  
With massively parallel high throughput sequencing made available by  
Roche’s (Basel, Switzerland) 454, Illumina’s (CA, USA) Solexa and Life 
Technologies’ (CA, USA) SOLiDTM system, one can either directly sequence 
bisulfite-converted DNA that are digested with restriction enzyme [90] or 
coupled it with MeDIP [91] or MIRA assay [92] (i.e. MeDIP-seq or MIRA-
seq). High throughput sequencing is more superior to microarray as it detects a 
larger population of DNA methylation loci. However, cost and bioinformatics 
analysis of sequencing results are two huge challenges for this method. More 
streamline analysis of high throughput sequencing result will definitely 
improve the discovery of differential methylated genes in the near future. 
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1.4 Hepatocellular Carcinoma 
1.4.1 Epidemiology of liver cancer 
Liver cancer is one of the largest cancer burdens worldwide as it was ranked 
the fifth most diagnosed cancer in men and seventh in women [93]. Cases of 
cancer-associated death are also high for this type of tumor with more than 
695000 patients died because of liver cancer globally in year 2008. It was the 
second most common cause of cancer death in men, and sixth rank for women. 
Presently, men are more susceptible to liver cancer as men to women ratio for 
this disease is 2.4. Regions with high rate of liver cancer include East and 
South East Asia, and in Middle and Western Africa (Figure 1.9) [93]. 
Nonetheless, we also see an increasing trend of HCC incidence in Western 
countries for the past 30-50 years [94] . In Singapore, liver cancer in men is 
the fourth most common cancer, while it is not common in women [95]. As for 
cancer associated death, it is ranked third in male population and fourth in 
female cohort according to Singapore Cancer Registry year 2007-2011.  
 
Liver cancer exists in different histological types, they include hepatocellular 
carcinoma (HCC), intrahepatic bile duct carcinoma (cholangiocarcinoma),  
epitheliod haemangioendothelioma, bile duct cystadenocarcinoma, 
hepatoblastoma and haemangiosarcoma [96]. About 85% of the liver cancer 
patients are diagnosed with Hepatocellular Carcinoma subtype [93]. 







Figure 1.8 Age-standardized liver cancer incidence rates sorted by gender 
and global regions. Figure was obtained with permission from Jemal et al 
[93]. 
 
1.4.2 Etiology of HCC 
HCC is one of the few cancers with known etiology. Different etiological 
factors account for the distinct geographical incidence of HCC. Examples of 
known risk factors include Hepatitis viral infection, Aflatoxin B1 exposure, 
alcohol consumption, smoking, obesity and diabetes [96]. Here we will focus 




Hepatitis viral infection was proposed as the main leading cause of HCC in 
sub-Saharan Africa and parts of Asia because of its high prevalence in these 
area [97]. These regions have the highest rate of HCC cases, where almost half 
of the cancer deaths and newly diagnosed cases are found in China [98]. The 
two hepatitis viruses associated with HCC are Hepatitis B virus (HBV) and 
Hepatitis C virus (HCV). Chronic HBV infection is the main etiological factor 
for HCC in Asian countries such as Malaysia, Korea, China, Thailand and 
Philippines, [99], whereas chronic HCV infection is associated with the 
majority of HCC cases in Japan [100]. 
 
HBV is a partially double stranded DNA virus that belongs to hepadnaviridae 
family. It was shown to integrate into human genome [101, 102] and its viral 
proteins, such as Hepatitis B virus X protein (HBx) are implicated in 
carcinogenesis [103, 104]. Hepatitis C virus, on the other hand, belongs to 
flaviviridae family. It is a RNA virus, so it cannot integrate into genome.  
Similar to HBV, viral proteins coded by HCV genome are implicated in 
hepatocarcinogenesis. For instance, HCV core protein was shown to promote 
hepatic steatosis and lead to HCC in mice [105]. Both HBV and HCV 
infections are able to elicit immune response from host cells [106]. Chronic 
infection of either virus will create hepatocyte inflammation, cell necrosis and 
subsequent regeneration. Continuous cycles of such processes will eventually 
lead to carcinogenesis [107].  
 
Aflatoxin B1 (AFB1) is another risk factor that is often implicated in HCC. It 
is a mycotoxin produced by Aspergillus fungi and often found in food 
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contaminated with the fungi [108]. Aflatoxin B1 was shown to be a 
carcinogen because once it is digested, its side product can form DNA adduct, 
which was shown to cause mutation in p53 codon [109, 110].  Currently, 
AFB1 associated HCC are commonly found in Southeast Asia and China. And 
patients with both AFB1 and HBV infection were reported to have greater risk 
of having HCC compared to patients having only one of these factors [111]. 
The exact mechanism underlying AFB1 carcinogenic is still not known.  
 
Another important risk factor for HCC is chronic alcohol consumption. 
Alcohol was shown to promote inflammation in liver cells [112]. Repeated 
cycles of inflammatory cytokine exposure will cause liver cells to undergo 
necrosis and eventually develop into cirrhosis [113, 114]. Patients with liver 
fibrosis and cirrhosis are known to be more susceptible to develop HCC in 
later stage [115].      
 
1.4.3 Screening and diagnostics of HCC 
Current screening programs for HCC incorporates known knowledge of 
etiological factors into identifying at-risk patients [116]. In Asia, majority of 
HCC screening programs adopt hepatic ultrasonography for every 6 months in 
patients with chronic liver disease and measurement of serum alpha-
fetoprotein (AFP) concentration [117]. There are differences as well between 
screening programs of different countries. For example in Japan, where HCV 
infection is more prevalent, they categorized patients with hepatitis C-
associated cirrhosis as super-high-risk population. Thus, they undergo 
screening at more frequent intervals such as 3 to 4 months [118]. Presently, 
23 
 
there are still no sufficient evidences to conclude that screening program 
improves prognosis of HCC patients [116]. This is partly due to the limitations 
such as sensitivity and specificity of current available screening methods [119, 
120] .  
 
For diagnosis of HCC, AFP levels and imaging tools such as ultrasonography, 
spiral computed tomography (CT) and magnetic resonance imaging (MRI) 
were used. In Japan, two other markers, AFP-L3 and DCP levels were used on 
top of AFP levels and imaging [118]. HCC diagnosis is confirmed when 
patient’s serum has concentration of AFP greater than 400ng/mL in the 
context of chronic hepatitis or liver cirrhosis and visible tumor under MRI or 
CT [117]. Current diagnostic tools are far from perfect as some HCC patients 
have AFP concentration that is lower than 20ng/mL [121], and also, CT scans 
are  associated with radiation exposure and the cost of scans are relatively 
expensive. Undeniably, new biomarkers are needed for a better diagnosis and 
surveillance program for HCC. 
 
1.4.4 Potential biomarkers for HCC 
Many efforts have been carried out to identify the next ideal biomarker for 
HCC. Scientists have been exploring different molecules for this purpose, for 
instances, DNA polymorphism, mRNA expression, protein levels, and 
epigenetic markers such as miRNA expression and DNA methylation levels. 
Table 1.1 shows the summary of potential biomarkers that were recently 
discovered. These markers were not mutually exclusive or exhaustive. In fact, 
markers like DCP and AFP-L3 were used in combination with current clinical 
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markers for diagnosis of HCC [122]. Theragnostics was recently coined to 
indicate treatment strategy that combines therapeutics with diagnostics [123]. 
In the era of personalized medicine, it is hoped that a good biomarker not only 
allows early detection of HCC, but also ensures appropriate therapy is 
administered to patients [124].  
 
Table 1.1 Potential biomarkers in HCC. Protein level, HBV DNA, DNA 
polymorphism, miRNA and DNA methylation have been proposed to be 




Marker Correlation References 
Protein level 
DCP Up-regulation associated with HCC Nakamura et al.[125] 
AFP-L3 Up-regulation associated with HCC Taketa et al.[126] 
GPC3 Up-regulation associated with HCC Hippo et al.[127] 
GGTII Up-regulation associated with HCC Cui et al.[128] 
AFU Up-regulation associated with HCC Tangkijvanich et al.[129] 
GS Up-regulation associated with HCC Long et al.[130] 
HBV DNA HBV DNA gradient 
Associated with increased risk of HCC in 
HBV-infected individuals without presence of 
cirrhosis or other risk predictors 
Chen et al.[131] 
DNA 
polymorphism 
Cytochrome P450 1A1 
Variants Mspl and lle-
Val 
Associated with increased risk of HCC in 
smoking HBV-infected individuals 
Yu et al.[132] 
N-Acetyltransferase 
2*4 Allele 
Associated with increased risk of HCC in 
smoking HBV-infected individuals 
Yu et al.[133] 
XRCC1 Gln Genotype 
Associated with increased risk of HCC in 
chronic HBV carriers 
Yu et al. [134] 
p53 Pro Variant Allele 
Associated with increased risk of HCC in HBV 
individuals with chronic liver disease 
Yu et al. [135] 
TGF-beta-1 CC 
Genotype 
Associated with increased risk of HCC in 
HBV-infected individuals 




Associated with decreased risk of HCC in 
chronic HBV carriers 
Yu et al. [134] 
miRNA 
miR-21 Up-regulation associated with HCC 
Wang et al.[137] 
Jiang et al.[138] 
miR-221 Up-regulation associated with HCC 
Wang et al.[137] 
Jiang et al.[138] 
Gramantieri et al.[139] 
miR-222 Up-regulation associated with HCC Wang et al.[137] 
miR-224 Up-regulation associated with HCC 
Wang et al.[137] 
Murakami et al.[140] 
miR-25 Up-regulation associated with HCC Li et al. [141] 
miR-375 Up-regulation associated with HCC Li et al. [141] 
Let-7f Up-regulation associated with HCC Li et al. [141] 
miR-122 Down-regulation associated with HCC Gramantieri et al.[139] 
miR-199a Down-regulation associated with HCC 
Jiang et al.[138] 
Murakami et al.[127] 
DNA 
methylation 
P16 Methylation associated with HCC Zhang et al.[142] 





1.4.5 Treatments of HCC 
HCC is often associated with poor prognosis because patients are diagnosed at 
very late stage. More than 50% HCC patients died within 12 months post 
diagnosis, and less than 6% of them have an average survival rate of 5 years 
[144]. Surgical resection and transplantation are the only two curative 
therapies available if patients are diagnosed early with HCC. Otherwise, 
current treatments are mostly non-curative. 
 
1.4.5.1 Resection 
Patients diagnosed with early stage of HCC and have favorable tumor 
characteristics, such as having adequate hepatic reserve, solitary tumors, and 
no presence of vascular metastases, are suitable for surgical resection because 
it provides better prognosis compared to other treatments [145, 146]. It is 
crucial to choose patients who have enough liver reserves before resection 
because the main risk factor for postoperative complication is the degree of 
liver function [147, 148]. Many hospitals use the fifteen minute retention rate 
of indocyanine green (ICG-15) to assess patients’ liver function before 
recommending them for resection [149, 150]. 
 
1.4.5.2 Transplantation 
Liver transplantation will be the choice of treatment when resection is not 
feasible because of impaired liver function. However, patients who qualified 
for this treatment have to be carefully selected based on stringent criteria such 
as Milan criteria for liver transplantation [151]. In the case where both 
transplantation and resection are indicated, studies have revealed that patients 
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with tumor that have little vascular invasion, unilobarly distributed and less 
than 5cm in size, they performed better with liver transplant compared to liver 
resection. Nonetheless, due to possibilities of dropouts during 
pretransplantation period and lack of donors suggest that surgical resection 
should still be the primary treatment for patients who satisfy the conditions for 
resection [152]. 
 
1.4.5.3 Neoadjuvant and Adjuvant Therapy 
Neoadjuvant therapy is administered to HCC patient in attempt to reduce 
tumor size sufficiently so that resection could be conducted. Current available 
neoadjuvant therapies for HCC include systemic chemoimmunotherapy, 
regional irradiation, hepatic-artery infusion of radiolabelled lipiodol and 
transarterial chemoembolization (TACE). There is still insufficient data to 
show that neoadjuvant therapy actually allows better overall survival of HCC 
patients. This is mainly because not all patients response to neoadjuvant 
therapy [153, 154]. Adjuvant therapy, on the other hand, is given to patients 
after their primary treatment so as to increase their long term survival. 
Examples of adjuvant therapy methods for HCC are acyclic retinoids, 
systemic chemotherapy, interferon, and intra-arterial iodine 131-labelled 
lipiodol [155-157]. Intra-arterial iodine-131-labelled lipiodol was shown to 
have the greatest efficacy with 5- and 10-year overall survivals of 66.7% and 





1.4.5.4 Local Ablation Therapy 
Local ablation therapy like radiofrequency ablation (RFA) or percutaneous 
ethanol injections (PEI) are usually administered to patients who are not 
qualified for resection. RFA has slowly replaced PEI recently because RFA 
treated patients have lower recurrence risk, higher survival rates and can attain 
better necrosis rates with lesser treatment session compared to PEI [158, 159]. 
Studies have also shown that RFA can attain similar survival benefits as 
hepatic resection in early small HCC with fewer invasions [160, 161].  
 
1.4.5.5 Selective Internal Radiotherapy 
Selective internal radiotherapy uses radioactive isotopes, Yttrium-90 in an 
attempt to irradiate tumor cells. These isotopes were packed in either resin 
microspheres or glass, and delivered into liver by hepatic arteries. It is 
assumed that it will reach tumor due to preferential blood supply by hepatic 
arteries [162]. This treatment is well tolerated and usually recommended for 
patients who are not eligible for local ablation therapy and surgical resection 
[163, 164].  
 
1.4.5.6 Molecular Targeted Therapy  
Sorafenib, a tyrosine kinase inhibitor, is currently the only molecular targeted 
therapy approved by the United States of America Food and Drug 
Administration (FDA) for advanced HCC treatment. Two large clinical trials 
were conducted, namely, the Sorafenib HCC Assessment Randomized 
Protocol (SHARP) and a similar study conducted in China. Both trials found a 
slight but significant overall survival benefit in the sorafenib group compared 
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to the placebo group [165, 166]. Side effects of Sorafenib include diarrhea and 
hand-foot skin reactions, but they seldom lead to its discontinuation [165]. 
Despite being a promising molecular targeted drug, the expensive cost of 
sorafenib therapy prevents it from being widely used in developing countries. 
 
1.4.6 HCC genetics 
Genetic changes in liver cells are implicated in hepatocarcinogenesis. With the 
advance of high throughput sequencing technology, HCC genomes were 
sequenced, and CTNNB1, TP53, ARID1A and AXIN1 were found to be 
frequently mutated in HCC [167, 168]. This agrees with previous studies 
where conventional sequencing and immunohistochemical methods were used 
to identify mutation in TP53 [169, 170], CTNNB1 which codes for β-catenin 
[171, 172], and AXIN1 [173, 174]. ARID1A is a chromatin regulator that 
recently found to be mutated in HCC [167]. Normal functions of liver cells are 
deregulated as a result of these somatic mutations. For example, mutated TP53 
leads to chromosome instability, while mutated CTNNB1 and AXIN1 
deregulate the WNT signaling pathway. Mutations in ARID1A are believed to 
affect the chromatin remodeling complex.  
 
High throughput sequencing experiments also reveal that HBV preferably 
integrates into TERT (Telomerase Reverse Transcriptase) locus and enhances 
TERT expression [102, 175]. In fact, up-regulation of TERT which correlates 
with the activation of telomerase activity, were observed in more than 90% of 
HCC [176, 177]. Studies have shown that re-expression of telomerase 
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facilitate HCC progression [178] and associated with recurrence of HCC after 
surgical resection [179].  
 
One prominent cytogenetic feature of HCC is aneuploidy. It occurs when 
chromosomes failed to segregate properly during mitosis. Using tools like 
chromosomal comparative genomic hybridization (CGH) and single-
nucleotide polymorphism (SNP) oligonucleotide arrays, regions of copy 
number change and allelic imbalances in HCC can be located [180-182]. 
These genomic alterations often lead to oncogene amplification and loss of 
tumor suppressor gene [96]. For instance, the loss of TP53 loci at 17p [183, 
184], and amplification of MYC loci at 8q [185] were both found in HCC. 
 
1.4.7 HCC epigenetics 
In addition to genetic alterations, changes in epigenetic profiles also contribute 
towards liver cancer. Interestingly, genetic alterations were considered rare 
compared to epigenetic changes [167, 186]. This underscores the significant 
role of epigenetic modifications in pathogenesis of liver cancer. Aberrant 
DNA methylation, deregulated histone modifications and differential non-
coding RNA expression are found in HCC.  These alterations could either 
function itself or cooperatively exert their effect on gene regulation.  
 
1.4.7.1 Aberrant histone modifications in HCC 
Presently, there is lack of comprehensive analysis of histone alterations in 
HCC [187]. Nonetheless, studies have reported that high expression of 
trimethylation at H3K27 (H3K27me3) and trimethylation at H3K4 (H3K4me3) 
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were frequently observed and associated with poor prognosis of HCC [188, 
189]. More importantly, histone modifying enzymes are often deregulated in 
liver cancer. Overexpression of histone methyltransferases EZH2 and SMYD3 
were implicated in HCC [190, 191]. These methyltransferases methylate 
lysine residues 27 and 4 respectively at histone H3 and create marks for 
transcriptional activation. Genes activated by methylation activity of SMYD3 
was shown to promote cell proliferation [192], and EZH2 was reported to 
down regulates the expression of Wnt antagonists [193]. On the contrary, 
PRDM2, another histone methyltransferase is silenced in HCC [194, 195]. 
PRDM2 is responsible for histone H3 lysine 9 (H3K9) trimethylation and it 
was proposed as putative tumor suppressor gene [196]. Reduction of H3K9 
trimethylation probably leads to open chromatin state and increase the 
susceptibility for genomic instability.  
 
Expression of SIRT1 [197, 198], HDAC1, HDAC2 and HDAC3 [199, 200] 
were found higher in HCC compared to adjacent non-tumor samples, 
suggesting their role in histone deacetylation and thus chromatin remodeling 
during hepatocarcinogenesis. Among these deacetylases, high HDAC2 and 
SIRT1 expression were shown to be associated with patients’ poor survival 
rate [198, 200].  
 
Worthy to note also, viral protein also influence the histone modifications in 
HCC. Hepatitis B virus X protein (HBx) was shown to deregulate transcription 
machinery by interacting with HDAC1 in liver cancer cells [201, 202]. HCV 
infection, on the other hand, increases the expression of Protein Phosphatase 
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2A which binds to protein arginine methyltransferase 1 (PRMT1) and 
rendered it non-functional  [203]. These observations clearly indicate various 
risk factors are also responsible for aberrant histone modifications in liver 
cancer. 
 
1.4.7.2 Aberrant microRNA expression in HCC 
MicroRNAs (miRNAs or miRs) are implicated in HCC because of their ability 
to degrade mRNA. Many studies have in fact shown that miRNAs are 
deregulated in HCC [204-207]. Up-regulation of miR-221 and miR-21 were 
often associated with HCC. Functional assays show that these two miRNAs 
promote hepatocarcinogenesis; for instance, miR-221 was shown to enhance 
proliferation [208, 209] and miR-21 promotes migration and invasion [210, 
211].  On the other hand, miR-122 and miR-199a were consistently down-
regulated in HCC. miR-122 was proposed to be tumor suppressor miRNA 
[212], and indeed, Tsai et al showed that mice lacking miR-122 developed 
HCC [213]. However, more studies are still needed to ascertain its tumor 
suppressing role as another study has shown that expression of miR-122 is 
only weakly correlated with patient’s survival data [205]. Presently, there are a 
few down-regulated miRNAs that associate with poor patient survival, among 
them notably is miR-199a [205]. Hou et al not only showed that miR-199a 
was an independent predictor for reduced tumor-free survival of HCC patients, 
they also proved that re-expression of miR-199a inhibits the growth of liver 
cancer cells. More of such miRNAs will emerge as high throughput 
sequencing and microarray technology become more available and affordable 




1.4.7.3 Aberrant DNA methylation in HCC 
Deregulated DNA methylation is a frequent event in HCC. The most common 
forms of aberrant methylation are global hypomethylation and site specific 
regional DNA methylation. Both were shown to contribute towards 
hepatocarcinogenesis, but in different mechanisms. Global hypomethylation 
affects the structural-nuclear function by promoting chromosomal and 
genomic instability, while regional hypermethylation is often associated with 
silencing of tumor suppressor genes [214]. Despite the widespread global 
hypomethylation, DNMT1, DNMT3A and DNMT3B were all shown to be up-
regulated in liver cancer [215, 216]. Whether increased expression of DNMTs 
associated with hypermethylation of genes is still a matter of controversy as 
the exact mechanism has yet to be elucidated [216, 217].  
 
1.4.7.3.1 DNA hypermethylation in HCC 
Many genes were found to be silenced by promoter hypermethylation and 
significantly associated with development of HCC [218].  These genes are 
often tumor suppressor genes that involve in critical biological pathways such 
as cell proliferation, cell cycle and DNA repair.  
 
E-cadherin (CDH1) was one of the earliest genes identified to be 
hypermethylated and silenced in HCC [218, 219]. These reports indicated that 
CpG methylation at CDH1 promoter could be detected at about 33-49% of 
HCC cases. Wnt signaling pathway is often activated as a result of β-catenin 
accumulation in HCC [220]. Under normal condition, CDH1 recruits β-catenin 
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to cell membrane and prevents it from being accumulated in cytoplasm [221]. 
Silencing of CDH1 will enable β-catenin to be retained in cytoplasm and 
subsequently translocated into nucleus for downstream gene activation, a 




 is another frequently silenced tumor suppressor gene in HCC. 
Promoter hypermethylation of this gene was often found to occur in more than 
50% of HCC cases [222, 223]. p16
INK4a
 slows down cell cycle by inactivating 
cyclin-dependent kinase 4 (CDK4). However, when p16
INK4a
 expression is 
repressed, cell cycle will be deregulated as a result. 
 
DNA mismatch repair system could possibly be affected by hypermethylation 
of DNA repair genes as well [224, 225]. Liver cells are prone to DNA 
mutations when they are exposed to cytotoxic agents and mutagens. Normally, 
DNA repair mechanism will ensure genome integrity is maintained. 
Sometimes, cancer cells evade DNA repair mechanism by down-regulating 
DNA repair genes such as O
6
-methylguanine DNA methyltransferase 
(MGMT). MGMT was found to be hypermethylated in about 39% of HCC 
patient tumors and its promoter methylation was associated with the loss of its 
expression in HCC [226]. Silencing of MGMT gene in HCC increases the 
chances of mutated DNA not being repaired during DNA replication, thus 
promotes carcinogenesis.  
  
Beside these 3 tumor suppressor genes, GSTP1 [227], RASSF1A [228], 
SOCS1 [229] and SOCS3 [230] are frequently methylated and silenced in 
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HCC as well. Certainly, the list of differentially methylated genes is not 
exhaustive. Previously, due to methodology limitations, only a few genes 
could be studied at a time. Today, high throughput sequencing and microarray 
allow the discovery of many more tumor suppressor genes that are 
hypermethylated and suppressed in HCC [231, 232]. Furthermore, data 
integration from different platforms allows researchers to identify bona fide 
tumor suppressor genes that are implicated in hepatocarcinogenesis. Two 
papers that best exemplify this approach were published recently. Matsumura 
et al combined MeDIP-array with gene expression profiling data of different 
liver cell lines and identify MZB1 as tumor suppressor gene that is frequently 
methylated in HCC [233]. Also, Neumann et al integrated DNA copy number 
alterations with genome-scale methylation profiling data and validated both 
PER3 and IGFALS to be consistently methylated in HCC compared to normal 
liver tissue [234]. Undeniably, integrative research will speed up the process 
of tumor suppressor genes discovery in time to come.  
 
1.4.7.3.2 DNA hypomethylation in HCC 
DNA hypomethylation is less studied compared to hypermethylation of tumor 
suppressor genes. Nonetheless, genome-wide hypomethylation is associated 
with many types of cancers, including HCC [235-238].  It often occurs at 
DNA repeats and leads to genomic instability. Thus, it is not surprising that 
DNA hypomethylation is associated with poor prognosis of HCC [239]. Long 
interspersed nuclear element (LINE-1), which is heavily methylated in normal 
cells, was shown to be hypomethylated in HCC [238, 240]. Study has shown 
that it occurred exclusively in HCC but not surrounding cirrhotic tissues [241].  
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Activated LINE elements may lead to retrotransposition and eventually 
chromosomal rearrangement [242]. Besides the well-studied LINE-1, recently, 
increasing number of studies also reported the characterization of DNA 
hypomethylation in HCC [240, 243-245] . Notably, Stefanska et al 
systematically mapped out genes that were activated in HCC as a result of 
hypomethylation at their promoter region using MeDIP-array approach [245]. 
Their studies provided evidence that DNA hypomethylation not only leads to 
genomic instability in HCC, but also activation of proto-oncogene.  
 
1.4.7.3.3 Aberrant DNA methylation and etiological factors 
Just as different epidemiological exposures are associated with different 
mechanisms in hepatocarcinogenesis, studies have also revealed that different 
etiological factors lead to distinct patterns of DNA methylation. For instance, 
there are attempts to distinguish HCC of different viral infections using 
genome wide profiling methods. Hernandez-Vargas et al was able to associate 
methylation signatures with HBV and HCV infection respectively [246]. Deng 
et al could also separate HCC tumors of HBV infection from HCV-related 
HCC using Methylated DNA immunoprecipitation-chip (MeDIP-Chip) 
method [232].  Apart from genome-wide studies, there are also gene-centric 
studies which focus on methylation signature of only a few genes. Using 
MethyLight assays, Feng et al showed that SFRP1, HOXA9, and RASSF1A 
were methylated more frequently in HBV-infected HCC patients compared to 
HCV-positive HCC cases [247]. On the other hand, Lambert et al uses 
pyrosequencing method to distinguish HCC of different etiological factors. 
They found hypermethylation of GSTP1 to be associated with HBV infected 
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HCC and hypomethylation of MGMT to be associated with alcohol 
consumption [248].  
 
Etiological factors were not only associated with aberrant methylation, studies 
have in fact shown that these factors actually cause methylation in vitro as 
well. Hepatitis B virus X (HBx), a viral protein encoded by HBV is one good 
example. Recent studies elucidated the possible role of HBx on promoting 
hypermethylation on tumor suppressor genes such as CDH1 [249, 250], 
GSTP1 [251], p16INK4a [252, 253] and RAR-β2 [254]. HBx was shown to 
interact with DNMT3A physically and mediate the hypermethylation of tumor 
suppressor genes in cancer cells [201, 255].  Hepatitis C virus core protein was 
also shown to have ability to methylate tumor suppressor genes such as 
p16INK4a [256] and RAR-β2 [257]. Currently, the mechanism on how HCV 
core protein deregulates DNA methylation remained unclear.  
 
1.4.7.3.4 Clinical implications of DNA methylation in HCC 
Aberrant DNA methylation occurs in the early stage of cancer progression and 
studies have shown that these changes were associated with clinical 
parameters [56] . As a result, DNA methylation was suggested as potential 
early biomarker in many cancers [258]. This applies to HCC as well because 
deregulated DNA methylation in liver was identified as early as during 
cirrhotic state [259, 260]. p16
INK4a
 was reported to be only hypermethylated in  
both cirrhotic and cancer tissues but not in normal liver tissues [260]. These 
hypermethylated region could be detected in serum of HCC patients [261], 




In fact, researchers were able to detect many other methylated DNA fragments 
in HCC patients’ serum and they were correlated with poor prognosis of the 
disease [142]. Yeo et al found the hypermethylation of RASSF1A is detectable 
in over 40% of matched plasma and it is correlated with tumor size [143]. 
Wong et al was able to detect p15 methylation at about 25% of HCC serum, 
and hypermethylation of p15 was associated with clinical metastasis [262]. 
TFPI2 methylation, which was recently discovered to be correlated with 
progression of TNM stage, were also detectable at 46% of HCC serum [263]. 
Taken together, these methylation markers could potentially be used as 
prognostic factors for HCC patients.  
 
Currently none of the potential methylation markers are translated into clinical 
use yet. This is due to difficulty in detection method and specificity of test is 
still gene dependent. Nevertheless, the future for methylation biomarkers is 
promising as more candidate markers are discovered through high throughput 





1.5 Aims of study 
The Introduction Chapter has briefly outlined the importance of studying DNA 
methylation profile in Hepatocellular Carcinoma (HCC). The increasing 
incident rate of HCC in South East Asia further propels us to study the 
epigenetic changes of this disease in the context of Asian population. In this 
thesis, DNA methylation profile of 59 HCC patients from Singapore were 
interrogated with InfiniumMethylation27 beadchips, the most comprehensive 
methylation profiling platform at the time of study. The specific aims for this 
study were listed below: 
 
1. We aim to characterize the methylation patterns of HCC patient 
samples and identify CpG loci that differentiate between tumor and 
adjacent non-tumors. We are also interested to elucidate genes with 
deregulated gene expression as a result of aberrant methylation. For 
this purpose, we integrated methylation profile with gene expression 
data in a genome-scale manner. Through this analysis, we seek to 
uncover biological pathways that were affected by these deregulated 
genes. Understanding these specific pathways that went awry will 
benefit future translation research such as rationalized epigenetic drug 
design.  
 
2. Integrated analysis of methylation and gene expression data will enable 
us to identify novel genes which are silenced by methylation in tumor. 
In this study, we will highlight one candidate gene that may be 
implicated in carcinogenesis. To ascertain its regulation by 
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methylation, we will use 5-aza-2’deoxycytidine (5AzaDC), a 
demethylating agent to examine its re-expression. Its tumor 
suppressive function will also be determined using cell-based assay. 
We seek to establish a standard work flow that will facilitate future 




3. Using the methylation profile in tumor, we aim to cluster the patients 
into different subgroups and associate them with clinical parameters. It 
is hoped that methylation data could provide another layer of 
discriminative power on patients subgrouping. CpG loci that are able 
to discriminate between these groups of patients will be potentially 
useful for prognostic markers discovery in time to come. 
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Chapter 2: Materials and Methods 
This Chapter describes the overall materials and methods used during the 
course of PhD. Standard operating procedures with proper risk assessments 
were adhered to and in accordance with the National Cancer Centre of 
Singapore (NCCS) and National University of Singapore (NUS) health and 
safety policies. 
 
2.1 Primers and reagents  
Primers were ordered and synthesized by Integrated DNA Technologies Pte 
Ltd (IDT). Reagents and materials used in experiments were cited within text. 
 
2.2 Cell lines 
Liver cancer cell lines used in this study were Huh7, HepG2, Hep3B, and 
SNU449. We also used immortalized normal liver cells, THLE3 and 
NehepLxHT cells. HEK293 cells were used for adenoviral vector propagation. 
All cell lines were obtained from the American Type Culture Collection 
(ATCC, USA), except Huh7. Huh7 cells were kindly donated by Adjunct 
Associate Professor Paula Lam, Department of Physiology, Yong Loo Lin 
School of Medicine, National University of Singapore.  
 
2.3 Tissue samples 
Paired tumorous and adjacent non-tumorous liver tissues of 59 Hepatocellular 
Carcinoma patients were collected from the National Cancer Centre of 
Singapore (NCCS) / SingHealth Tissue Repository with patients’ written 
informed consent. Tissue samples were surgically resected, flash-frozen in 
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liquid nitrogen and stored at -80
o
C until use.  All research protocols were 
approved by the SingHealth Centralized Institutional Review Board (CIRB; 
approval 2008/440/B).   
 
2.4 HCC tumor and adjacent non-tumor DNA and RNA samples 
DNA and RNA samples from discovery and validation cohorts were either 
available as laboratory stock prepared previously or freshly extracted from 
patients’ tumor and adjacent non-tumor samples. More specifically, 20 HCC 
samples were received from Associate Professor Caroline Lee’s laboratory, 
and 39 HCC samples were collected from Dr Toh Han Chong’s laboratory 
(Department of Medical Oncology, NCCS). All samples were obtained with 
patients’ written informed consent. 
 
2.5 DNA Extraction 
Genomic DNA (gDNA) was extracted from cell line pellet and patients’ tissue 
using QIAamp DNA mini kit (Qiagen, Germany) according to manufacturer’s 
protocol with modifications. Modified steps include samples were treated with 
RNase A (Roche Applied Science, Germany) to remove RNA contamination 
before passing through the spin column. And gDNA product was eluted in 
150ul of nuclease-free water (Ambion, USA) and stored at -20
o
C until use. 
 
2.6 RNA extraction 
RNA from cell pellet was extracted using Qiagen RNeasy mini kit (Qiagen, 
Germany) according to manufacturer’s protocol. RNA was eluted in 50ul 
nuclease-free water (Ambion, USA) and stored at -80
o
C until use. RNA from 
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patient sample was extracted using Trizol reagent (Life Technologies, USA) 
and purified using Qiagen RNeasy mini kit (Qiagen, Germany) according to 
manufacturers’ protocol. 
 
2.7 Quantification of nuclei acids 
NanoDrop 1000 Spectrophotometer (Thermo Scientific, USA) was used to 
quantitate the extracted RNA and DNA. Absorbance at 260nm and 280nm of 
each sample were measured and computed into concentration of nucleic acid, 
where water was used as reference for zero absorbance.  
 
2.8 Agarose gel electrophoresis 
PCR products were run on 1% (w/v) agarose gel (1
st
 Base, Singapore) with 
ethidium bromide (Biorad, USA). Briefly, 1 gram of agarose was melted with 
100ml 1xTBE (Tris-Borate-EDTA) (1
st
 Base, Singapore). 1ul of 10mg/ml 
ethidium bromide was added into gel solution when it was cooled down 
sufficiently. Samples and alongside with a 100bp ladder (Fermentas, USA) 
were loaded into agarose gel with 1x of 6X DNA loading dye (Fermentas, 
USA). Gel was electrophoresed at 120V for 30 minutes. When run complete, 
DNA bands were visualized under UV light using Gel Doc
TM
 XR+ system 
(Biorad, USA). 
 
2.9 Bisulfite treatment of DNA 
DNA was bisulfite modified using Qiagen Epitect kit (Qiagen, Germany) 
according to manufacturer’s protocol. 800ng of gDNA were used for each 
sample conversion. Bisulfite converted DNA was purified using Qiagen 
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Epitect spin column and final DNA product was eluted twice with 20ul 
nuclease-free water (Ambion, USA) each time. Eluted DNA was stored at -
20
o
C until use. 
 
2.10 Bisulfite PCR primer design 
Bisulfite converted DNA sequence was used as template for primer design. 
Methprimer program (http://www.urogene.org/methprimer/index) was initially 
used to screen for potential primers. In cases where no suitable primers were 
found by Methprimer, primers were designed manually. Certain guidelines 
were followed, briefly, primers have to be 20-25bp long, the last three to five 
nucleotides are not homopolymer, primer should not contain long 
complimentary bases so as to avoid hairpin loops, CpG should ideally not be 
included within primer sequence, and last nucleotide should preferably be G.  
 
Primer Design and Search Tool (http://bisearch.enzim.hu/) was used to check 
the specificity of primer pair based on artificially bisulfite converted genome 
DNA. In CpG dense fragment, primers were allowed to contain at most one 
CpG dinucleotide. In such cases, a degenerate base was incorporated into 
primer (i.e. CpG change to (T/C)pG ) or a non-watson crick base pairing was 
introduced ( i.e. (T/C)pG replaced by ApG dinucleotide). ApG will still base 
pair with GpC at complimentary strand. Lastly, PCR amplified fragment 
should not be greater than 300bp. Larger PCR product will be difficult to 





The sequencing primers, biotinylated PCR primers and their paired primers 
used in this study were listed in Appendix A. Biotinylated primers were HPLC 
purified so that no free biotin is competing with streptavidin binding, and as a 
result, it improves signal strength.   PCR was generated in a 20ul reaction 
volume, which contained 2ul of 10Xbuffer (Tris.Cl, KCl, (NH4)2SO4, 15mM 
MgCl2), 0.5mM dNTP mix, 0.5uM forward and reverse primers, 1 unit of 
Hotstar Taq polymerase (Qiagen, Germany), 20ng of bisulfite converted DNA 
as template, and water. PCR program used was shown in Appendix B.   
 
Pyrosequencing reaction required single-stranded biotinylated PCR products 
to be immobilized to Streptavidin Sepharose beads. To achieve that, PyroMark 
Q24 Vacuum Workstation (Qiagen, Germany) was used. Briefly, 3ul of 
Streptavidin Sepharose beads (GE Healthcare Life Sciences, USA) was added 
with  40ul binding buffer (10 mM Tris-HCl, pH 7.6, 2 M NaCl, 1 mM EDTA, 
0.1% Tween 20),  followed by 20 ul PCR product and 20 ul water. Reaction 
mixture was covered with adhesive film (3M, USA) and mixed for 20 min at 
room temperature using high speed orbital shaker (Biometra, Germany). 
Streptavidin beads with immobilized PCR products were then captured on 
filter probes by vacuum suction. These captured beads were first washed with 
70% ethanol for 5 seconds, followed by denaturation solution (0.2 M NaOH) 
for 5 seconds, and then washing buffer (10 mM Tris-acetate, pH 7.6) for 5 
seconds. The beads were released into a 24-well plate (Qiagen, Germany) that 
contains 45ul annealing buffer (20 mM Tris-acetate, 2 mM MgAc2, pH 7.6) 
and 0.3 μM sequencing primer. Pyrosequencing was carried out according to 
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manufacturer's protocol using Pyromark Q24 (Qiagen, Germany) which 
contained the nucleotides, enzyme, and substrate.  
 
2.12 cDNA synthesis 
Superscript III reverse transcriptase (Invitrogen, USA) and poly-dT primer 
(IDT, Singapore) were used to synthesize cDNA from 1ug of total RNA 
following manufacturer’s instructions. When analysis of single exon genes 
was required, RNA was first treated with RQ1 RNase-free DNase (Promega, 
USA) before transcribed into cDNA. DNase treatment was carried out 
according to manufacturer’s protocol. All cDNA were stored at -20oC until use. 
 
2.13 Quantitative PCR primer design 
For gene expression analysis using conventional qPCR platform, primers were 
designed preferably from the 3’ end of mRNA as it is where reverse 
transcription starts. Primer3 online program (http://frodo.wi.mit.edu/primer3/) 
was used to design qPCR primers. The desired length of PCR product was set 
between 150-350bp. Only primers that cross exons will be selected for gene 
expression analysis. In the case where primers amplified within one exon, 
RNA was treated with DNase first before cDNA synthesis as mentioned in 
earlier section. For genes that were difficult to design, where Primer3 also 
failed, primers were designed manually with guidelines as such: overall GC 
content is preferably 50%, length of primers is between 20-25bp, primer 
should not contain long complimentary bases so as to avoid hairpin loops, and 
3’ end of the primer is either C or G.  Shortlisted primers will be blast against 
human genome using NCBI BLAST to check whether it will amplify non-
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specifically. For gene expression analysis using Fluidigm platform, Taqman® 
Gene Expression Assay (Life Technologies, USA) were used instead.  
 
2.14 Real time quantitative PCR  
mRNA changes in gene expressions were determined using Bio-rad CFX96
TM
 
real-time PCR detection system (Bio-rad, USA) according to manufacturer’s 
protocol. Primers used for real time qPCR were listed in Appendix C. Briefly, 
real time PCR reactions were carried out in 10ul volumes in 96-well plate 
(Axygen, USA). Each reaction consists of 5ul of 2X Maxima
TM
 SYBR Green 
qPCR master mix (Fermentas, USA), 0.2uM of forward and reverse primers, 
and 1ul of 5-times diluted cDNA as template. PCR program used was listed in 
Appendix D. Real time PCR reactions were done in triplicates, and threshold 
cycle numbers (Ct) was determined at the level that showed the best kinetic 
PCR parameters. None-template control was used as negative control, and 
melting curves were obtained to confirm specificity of the PCR product. The 
2
-ΔΔCt 
method was used to measure the relative quantification of a target gene 
[264].  
 
2.15 Fluidigm 48.48 Dynamic Array real time quantitative PCR 
For larger throughput of real time quantitative PCR, Fluidigm 48.48 Dynamic 
Array (Fluidigm Corporation, USA) and Taqman® Gene Expression Assays 
were used. All PCR amplification reagents used in conjunction with Fluidigm 
platform were purchased from Life Technologies, USA. Taqman® Gene 
Expression Assays used in this thesis were found in Appendix E. Reverse 
transcription was carried out as described above. cDNA were first pre-
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amplified using pooled 48 TaqMan gene expression  assays at a final 
concentration of 0.2X  for each assay. Pre-amplification of cDNA was 
performed in 5ul reaction volume that consisted of 2.5ul TaqMan PreAmp 
Master Mix (2X), 1.25 ul of 48-pooled TaqMan assay mix (0.2X) and 1.25 ul 
of cDNA. The pre-amplification PCR program was carried out according to 
the manufacturer’s protocol. The product was subsequently diluted 1:5 with 
water (Ambion, USA) and stored at −80°C until use.  
 
Real time qPCR of the mRNA targets was performed on a 48.48 dynamic 
array according to manufacturer's instructions. Briefly, 5 µl reaction volume 
was set up for each sample containing 1X TaqMan Gene Expression Master 
Mix , 1X GE Sample Loading Reagent and individually diluted pre-amplified 
cDNA. 5ul of assay mix were prepared with 1X each of TaqMan gene 
expression assay and 1X Assay Loading Reagent. The dynamic array was first 
primed with control line fluid in the IFC controller. Samples and assays were 
pipetted into assigned inlets, and the chip was then loaded into the IFC 
controller for mixing and loading into individual reaction chambers. Lastly, 
chip was placed in the BioMark Instrument for qPCR run according to 
manufacturer’s protocol. The data was analyzed with Real-Time PCR 
Analysis Software in the Biomark instrument. Relative gene expression values 




2.16 Cell cultures 
Huh7, HEK293, HepG2, Hep3B and SNU449 cells were maintained in 
Dulbecco's Modified Eagle's Medium (DMEM) (NCCS Media Preparation 
48 
 
Room) supplemented with 10% fetal calf serum (Biological Industries, Israel). 
THLE3 cells were grown in Bronchial Epithelial Cell Growth Medium with 
modified BEGM bullet kit (Lonza, Switzerland). Gentamycin/ Amphotericin 
(GA) and Epinephrine in BEGM bullet kit were discarded; 5ng/ml EGF (Life 
Technologies, USA), 70 ng/ml Phosphoethanolamine (Sigma Aldrich, USA) 
and 10% fetal calf serum were supplemented additionally. NehepLxHT 
cells  were maintained in Dulbecco's Modified Eagle's Medium and Ham's F-
12 Nutrient Mixture supplemented with 10% fetal calf serum, HMM 
Hepatocyte Medium SingleQuot without the Gentamycin/ Amphotericin (GA) 
(Lonza, Switzerland), 1.2 gram of sodium bicarbonate, and 50 ug/ ml G418 
(Life Technologies, USA). All cell lines were maintained at 37
o
C in a 
humidified atmosphere of 5% CO2.  
 
2.17 Preparation of cell pellet 
Medium was first removed from culture flask. Attached cells were then treated 
with Trypsin (Nacalai, Japan) for 3 minutes at 37
o
C, and medium was 
subsequently added to neutralize it. Cells were spun down at 1000g for 3 
minutes at 4
 o
C. Supernatant was aspirated and pellet was rinsed with cold 1X 
Phosphate Buffered Saline (PBS) (NCCS Media Preparation Room) twice. 
Cells were centrifuged again, and supernatant was removed. Cell pellets were 
snap frozen in liquid nitrogen and kept in -80
 o
C until further use. 
 
2.18 Treatment of cell lines with 5-aza-2’deoxycytidine 
5-aza-2’deoxycytidine (5AzaDC) is a DNMT inhibitor that prevents 
methylation on CpG loci. 5azaDC can be incorporated into DNA only when 
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cell undergoes DNA replication. Thus, cells were seeded at only 30% 
confluence before treatment. Cells were treated with 5uM of 5azaDC 24 hours 
post-seeding, where medium with drug was changed daily for 4 days. Control 
cells were treated with Dimethyl Sulfoxide, DMSO (Sigma Aldrich, USA). 
Cells were harvested, pelleted, and snap frozen in liquid nitrogen. Cell pellets 
were kept at -80
o
C until use. 
 
2.19 Transfection of cell lines 
Cells were seeded at 70-80% confluency. 24 hours post seeding, cells were 
transfected with plasmids using Lipofectamine
TM
 2000 Transfection Reagent 
(Life Technologies) according to manufacturer’s protocol. 24 hours post 
transfection or otherwise stated in results section, cells were harvested. Cell 
pellets were snap frozen and kept at -80
o
C until later extraction. 
 
2.20 Preparation of cytoplasmic cell extracts 
Cell pellets prepared previously were resuspended with ice cold lysis buffer 
that contained 150 mM sodium chloride (Sigma Aldrich, USA), 1.0% NP-40 
(Sigma Aldrich, USA) and 50 mM Tris, pH 8.0 (1
st
 Base, Singapore). Lysis 
buffer was supplemented with EDTA-free Complete Protease Inhibitors 
(Roche, Switzerland). Cells were kept at 4
 o
C for 30 minutes, followed by 
vortexing for 2 minutes, and subsequently clarified by centrifugation at 13,000 
rpm for 20 minutes at 4
 o




2.21 Western blots 
Concentration of protein lysates obtained from cell lysis protocol were 
measured using Protein Assay (Bio-rad, USA) which based on Coomassie® 
Brilliant Blue G-250 dye that shifts from 465 nm to 595 nm when binding to 
protein occurs.  Different concentrations of bovine serum albumin (Sigma 
Aldrich, USA) were used as standards. 20ug of protein lysates were denatured 
with 2X Laemmli buffer that contained 4% SDS (1
st
 Base, Singapore), 10% 2-
mercaptoehtanol (Sigma Aldrich, USA), 20% glycerol (Sigma Aldrich, USA), 





C for 10 minutes before loading into well. 12% 
Acrylamide gel was usually used for SDS-PAGE (Sodium Dodecyl Sulfate 
PolyAcrylamide Gel Electrophoresis) unless otherwise stated. Gels were run 
under running buffer that contained 25 mM Tris base, 190 mM glycine, 0.1% 
SDS, and pH 8.3 (1
st
 Base, Singapore) at 100V. The size-separated proteins 
were then transferred from the gel onto PVDF membrane (Bio-rad, USA) at 
100V for 2 hours at 4°C. The transfer buffer consisted of 25 mM Tris base, 
190 mM glycine (1
st
 Base, Singapore), and 20% Methanol (Sigma Aldrich, 
USA). Next, PVDF membranes were blocked with blocking buffer containing 
2% Amersham ECL Prime Blocking Reagent (GE Healthcare Life Sciences, 
USA), PBS (1
st
 Base, Singapore) and 0.1% Tween 20 (Sigma Aldrich, USA) 
for 1 hour at room temperature. Blocked PVDF membranes were then 
incubated with primary antibody diluted in blocking buffer for one hour at 
room temperature or overnight at 4
 o
C. Washing buffer (PBS with 0.1% 
Tween 20) was used to wash away unbound antibody. After which, 
membranes were incubated with secondary antibody that were horseradish 
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peroxidase-conjugated at room temperature for 50 minutes. After incubation, 
membranes were washed extensively with washing buffer every 15 minutes 
for an hour. Finally, membranes were visualized using the Amersham ECL™ 
Advance Western Blotting Detection Kit (GE Healthcare and Life Sciences, 
USA). Expression level of protein of interest was quantified using the 
AlphaImager 2000 (Protein Simple, USA) where beta-actin of the same 
sample was used as normalizing factor. All the required dilutions of primary 
and secondary antibodies were listed in Appendix F. For re-probing of the 
same membrane with another antibody, membrane was first stripped with 
stripping buffer that contained 2% SDS (1
st
 Base, Singapore), 100mM 2-
mercaptoethanol (Sigma Aldrich), and 62.5mM Tris pH6.7 (1
st
 Base, 
Singapore) at 55°C for 50 minutes. Membranes were then rinsed with running 
water and blocked again with blocking buffer before re-probing with another 
primary antibody.  
 
2.22 Cloning into adenoviral vector 
CYB5R2 open reading frames (ORFs) sequence was amplified from genomic 
DNA of NehepLxHT cells using Expand High Fidelity PCR system (Roche, 
Switzerland) according to manufacturer’s protocol. CYB5R2 ORFs was C-
terminally tagged with FLAG sequence (DYKDDDDK). Amplified fragment 
was cloned into inactivated adenoviral vector, called pAdenoX-ZsGreen1 
adenoviral vector (Clontech, USA) using the In-Fusion® HD Cloning Kit 
(Clontech, USA) according to the manufacturer’s protocol. The vector map 
was included in Appendix H.  The control vector in this study was a 
pAdenoX-ZsGreen1 vector carrying a short random sequence that does not 
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express any gene. The primers used in this cloning were listed in Appendix G. 
All clones were sequenced to ensure no mutation exists.  
 
2.23 Sequencing reaction and ethanol precipitation  
Big Dye Terminator v3.1 (Applied Biosystems, USA) was used for 
sequencing reaction. The 10ul sequencing reaction volume consisted of 4ul of 
previously clean-up PCR product, 2ul of 5X sequencing buffer, 20pmol of 
sequencing primer (either T7 forward primer or SP6 reverse primer), 0.5ul of 
Big Dye, and water. The thermal cycling reaction was run according to 
manufacturer’s instruction. Samples were subjected to ethanol precipitation 
following sequencing reaction. Briefly, for each 10ul sequencing reaction, 
1.25ul of 250mM EDTA (1
st
 Base, Singapore) and 35ul of ice-cold 100% 
ethanol (Sigma Aldrich, USA) were added. And samples were mixed and then 
centrifuged with maximum speed at 4
o
C for 30 minutes. After which, 
supernatant was removed, and 50ul of 70% ethanol were added to wash the 
pellet. Samples were then centrifuged with maximum speed again for 20 
minutes at 4
o
C. After removing the supernatant, pellets were left air dried for 
15 minutes to remove excess ethanol. Pellets were resuspended in 10μl Hi-Di 
Formamide (Applied Biosystems, USA) and were run on 3130XL Genetic 
Analyzer (Applied Biosystems, USA). All output files were analyzed using 
sequencing analysis software (Applied Biosystems, USA). Multiple sequences 
of the same fragment were viewed and aligned using BioEdit V7.2.0 




2.24 Production of recombinant adenovirus  
In-Fusion® reaction mixture obtained from cloning was transformed into 
50μL of Stellar™ Competent Cells (Clontech, USA) according to the 
manufacturer’s instructions. Positive bacterial clones were verified by colony 
PCR and sequencing. They were grown to large culture and plasmids were 
extracted using the NucleoBond Xtra Plasmid Midi Kit (Macherey-Nagel, 
USA) according to the manufacturer’s manual. Purified plasmids were 
subsequently linearized with restriction enzyme, PacI (NEB, USA) and then 
transfected into HEK293 cells using the CalPhos Mammalian Transfection Kit 
(Clontech, USA) according to the manufacturers’ protocol. HEK293 cells 
were used for adenovirus rescue and amplification as they express E1 gene 
that pAdenoX-ZsGreen1 vectors lack. Recombinant viruses were harvested 
when cytopathic effects were observed in the infected cells. Briefly, cytopathic 
cells were collected as suspension by gently tapping the culture flask. To 
release the recombinant adenovirus, cell suspension was subjected to three 
consecutive freeze-thaw cycles in liquid nitrogen and 37°C water bath. 
Recombinant virus titer was determined before preparing for higher-titer virus 
stock using the exact protocol with a larger culture flask.  
 
2.25 Recombinant adenovirus titration  
HEK293 cells were seeded at 40% confluency in 24-well plate. Recombinant 




. 0.5ml of 
each serially diluted virus stock was used to transduce HEK293 cells in 
triplicates format. Forty eight hours post-transduction, the number of green 
fluorescent cells from each well was counted using fluorescent microscope 
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(Olympus, Japan). The titer of the virus was calculated as number of infectious 
units per ml of virus stock (IFU/ml). As the adenoviral vector expresses green 
fluorescence proteins (GFP), the number of fluorescing cells will equate to 
number of infectious units. Below is the formula to calculate the titer of virus 
stock. 
Virus titer = (Average number of green fluorescent cells x Dilution factor)/ 0.5ml   
 
2.26 Virus transduction optimization on cell lines  
24 hours before infection, cells were seeded into 6-well plates at 40% 
confluence. Viruses at respective multiplicity of infections (MOI) were added 
to each well the next day. Forty eight hours later, cells were harvested and 
expressions of genes were assessed by western blots. Appropriate MOI was 
chosen for subsequent infection experiments based on minimal cytotoxicity 
and detectable levels of gene of interest.  
 
2.27 Cell growth assay 
Cells were seeded at 40% confluency in 96-well Image Lock plates (Essen 
Instruments, UK).Twenty-four hours post seeding, cells were infected with 
either virus expressing gene of interest or control virus at respective MOIs. 
Twenty-four hours post infection, the rate of cell proliferation were 
determined by measuring the number of green fluorescence cells every 2 hours, 
for total 24 hours, using Incucyte live cell imaging system (Essen Instruments, 
UK). Assays were done in triplicates with three repeats. Each repeat was done 




2.28 Gene expression profiling 
Two different platforms were used to profile HCC patients’ gene expression. 
First batch of 20 samples were profiled as described previously [103]. Briefly, 
five hundred nanogram of total RNA from each sample was processed and 
hybridized to Agilent Whole Human Genome Oligo Microarray (Agilent 
Technologies, USA) according to manufacturer’s protocol (Feature number: 
G4112A, array contains 41,000 probes). Microarray images were processed 
and read out using Agilent Feature Extraction Software (Agilent Technologies, 
USA).  All gene expression microarrays were processed by Genomax 
Technologies Pte Ltd, Singapore. Second batch of 39 samples were profiled 
by our collaborators, namely Dr Toh Han Chong and Dr Yogen 
Saunthararajah. Briefly, seven hundred fifty nanogram of total RNA from each 
sample was processed and hybridized to Illumina HumanWG-6 expression 
beadchip (Illumina, USA) according to manufacturer’s manual (Array 
contains 47231 probes). All BeadChip assays were processed and imaged at 
the Duke-NUS Genome Biology Facility, Singapore.  
 
2.29 Gene expression analysis and data merging of two different 
platforms 
Data processing was performed by collaborators, Thomas Thurnhurr et al 
(unpublished data).  Briefly, log-transformed data of both platforms were 
loaded into R session. Annotation packages such as "lumiHumanIDMapping" 
[265] , "lumiHumanAll.db" [266] and "hgug4112a.db" [267] were used to map 
array probes to accession numbers. Accession numbers between platforms 
were matched and merged into a single table. Platform specific effects were 
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subsequently removed by batch correction method [268]. Differential 
expressions between samples were computed based on previously published 
method [269]. 
 
2.30 Methylation profiling 
Five hundred nanograms of extracted genomic DNA from each sample was 
bisulfite-converted using EZ DNA Methylation Kit (Zymo Research) and 
DNA methylation was subsequently measured using the Infinium 
HumanMethylation27 BeadChip (Illumina, San Diego, CA) according to 
respective manufacturer’s manual. Replicate samples of one subject were 
included as quality control for reproducibility of analysis. The Infinium 
BeadChip contains 27,578 CpG sites, covering 14,495 genes for interrogation. 
CpG probes with detection p-value of more than 0.05 were removed from 
subsequent analysis as they were not statistically different from the negative 
control probes and background noise. Methylation level of CpG sites were 
obtained as β-value from the Illumina®Genome Studio software (Illumina Inc., 
USA). β-value ranges from 0 to 1, where value of near 0 indicates low level of 
methylation, while β-value that close to 1 indicates high level of methylation. 
All BeadChip assays were processed at the Duke-NUS Genome Biology 
Facility, Singapore.  
 
2.31 Methylation data analysis 
β-values were imported into the Partek Genomics Suite (Partek Inc, USA) and 
subsequently quantile normalized.  CpG probes that have coverage <95% of 
total samples and probes located in sex chromosomes were excluded in the 
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analysis. ANOVA was used to ascertain differentially methylated CpG loci in 
tumor compared to adjacent non-tumor samples. P-value generated by 
ANOVA was subjected to FDR correction for multiple testing. The cutoffs for 
differentially methylated sites were FDR-adjusted p value < 0.05 and an 
absolute change of β-value, 0.1. Hierarchical clustering of the 4416 
differentially methylated probes was performed using euclidean distance and 
average linkage clustering. Information on CpG islands that linked to CpG 
probes were obtained from Illumina’s annotation file.       
 
2.32 Consensus hierarchical clustering with iterative feature selection 
Consensus clustering is a resampling-based class discovery method and is 
commonly used for clustering of gene expression data [270]. Here, we used a 
modified method called consensus hierarchical clustering with iterative feature 
selection (CHC-IFS) to identify HCC subgroups [271].  R package 
ConsensusClusterPlus was used to perform CHC [272]. Briefly, hierarchical 
clustering was performed on a random subset (80%) of the samples, repeated 
1000 times, using Pearson correlation as a metric of difference between 
samples. After CHC, the frequencies by which 2 samples clustered together in 
1000 repeats were recorded as consensus index. Consensus indices of each 
pair of tumors were then visualized as consensus matrix. Figure 6.1 A, C 
showed the heatmaps of consensus matrix. All consensus indices would be 
either 0 or 1 in an ideal matrix, signifying that every pair of tumors will never 
or always clustered together during resampling. To retain the probes that are 
more informative towards tumor subgroupings, we selected the probes 
(features) with largest difference between clusters after each round of CHC, 
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iteratively, for 1000 times. CHC-IFS significantly improved clustering 
stability (Figure 6.1 B, D). To validate the clustering found by CHC-IFS, we 
repeated the analysis with consensus k-means clustering method using the 
same package, ConsensusClusterPlus in R. To identify the specific probes for 
each subgroup, we used t-tests with FDR as multiple testing corrections.   
 
2.33 Pathway and gene ontology analysis 
Shortlisted gene lists were subjected to pathway and gene ontology analysis 
using Ingenuity Pathway Analysis (IPA) software (Ingenuity® Systems, 
www.ingenuity.com). Pathways and biological functions were considered 
statistically enriched in particular input gene lists when FDR-adjusted p values 
were less than 0.05 in Fisher’s Exact Test. Only the top 10 most significant 
pathways and biological functions were presented in the result sections of this 
thesis. For upstream regulator prediction, Z-score and overlap p-value were 
used to determine potential regulator. Z-score was computed based on the 
direction change of gene expression in the input data sets, where a positive Z-
score indicates that upstream regulator is “activated” while a negative Z-score 
indicates that it is “inhibited”. Overlap p-value on the other hand tests the 
probability of having the targets of upstream regulator in our input gene list by 
chance. In addition, IPA also algorithmically generates plausible networks 
based on molecules’ connectivity. A score will be assigned to each network to 




2.34 Gene information 
Functions and annotations of individual gene were derived from GeneCards 
(www.genecards.org), National Centre for Biotechnology Information (NCBI) 
Pubmed database (www.ncbi.nlm.nih.gov/pubmed) and Nextbio 
(www.nextbio.com). 
 
2.35 Statistical analysis 
All statistical tests were carried out by either Partek Genomics Suite (Partek 
Inc, USA) or statistical package in R. All p <0.05 was considered significant 
unless otherwise stated.  
 
2.35.1 Fisher’s exact Test 
Fisher’s Exact Test is used to test the significance of difference in frequencies 
of events within groups. It was used in the analysis of 2x2 contingency table 
as shown in Table 5.2 for example.  
 
2.35.2 Student’s t test 
It is used to test the significance of two means from two normally distributed 
populations. This test was used to examine whether validated data were 
significantly different between tumors and adjacent non-tumors. 
 
2.35.3 Mann Whitney U test 
When two groups have non normal distributions, we use Mann Whitney U test 




2.35.4 Analysis of variance (ANOVA) 
ANOVA is performed when we wanted to test for significant difference 
between two or more sample means. We used ANOVA to find CpG probes 
that have different methylation levels between tumor and adjacent non-tumors. 
 
2.35.5 Pearson’s correlation 
The extent of linear relationship between two variables is measured using 
Pearson’s correlation. Correlation values range from -1 to +1, where -1 means 
two variables are perfectly inversely correlated, +1 means two variables are 
perfectly positively correlated.   This test was used to examine the correlation 
within technical replicates. It was also used to measure the relationship 
between methylation and gene expression.  
 
2.35.6 Kaplan Meier analysis 
The probabilities of survival and recurrence in HCC patients were estimated 
with Kaplan Meier analysis. Kaplan Meier plot was used to display the 
survival difference between patient groups and Wilcoxon-Gehan test was used 
to test this difference.  
 
2.35.7 Cox regression analysis 
Cox regression model is a survival function for time-to-event data. Regression 
coefficient for a given predictor variable is used to compute its hazard ratio. 
Predictors that significantly associated with overall and disease free survival 
were identified through univariate cox proportional hazard model using 
Wald’s test. Only three most significant predictors were selected for 
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subsequent multivariate analysis. Recurrence and death were considered as 
events in disease free survival, while death was considered as event in overall 
survival.  
 
2.35.8 False discovery rate (FDR) 
When statistical tests were computed repeatedly in multiple comparisons, 
there may be higher chance of committing type I error (also known as false 
positive). In such situation, we need to control the false discovery rate (FDR), 
which was defined as proportion of false discoveries among all discoveries. 
FDR adjusted p value is analogous to minimum FDR at which the test may be 
called significant. Such adjustment is especially crucial when testing 




Chapter 3: DNA Methylation Profiling in HCC 
3.1 Introduction 
As outlined in the Introduction Chapter, HCC is a peculiar disease because 
even though its etiological factors are known, the exact mechanism of 
hepatocarcinogenesis remains largely unknown. There are attempts to 
associate HCC with somatic mutations, for instance, mutations in TP53 [169, 
170], CTNNB1 [171, 172], and AXIN1 [173, 174]. However, the frequencies 
of these mutations are inconsistent, some occur only in certain subtypes of 
tumor [187]. This again suggests that apart from genetic changes, epigenetics 
alterations may be contributing towards hepatocarcinogenesis.  
 
Aberrant DNA methylation is known to be implicated in HCC. Tumor 
suppressor genes such as CDH1 [218, 219], p16
INK4a
 [222, 223], MGMT [226], 
GSTP1 [227], RASSF1A [228], SOCS1 [229] and SOCS3 [230] are 
frequently methylated and silenced. LINE-1, on the other hand, was 
hypomethylated in HCC [238, 240]. Although the list of genes that harbor 
aberrant methylation in HCC is increasing, we are still far from knowing the 
overall methylation status in a genome-wide manner. Mapping DNA 
methylation in a higher resolution is definitely needed for better understanding 
of epigenetics in this disease.     
 
Previous studies focused only a few genes at one time because of the 
limitations in methodology. With the advances in technology, we can now 
interrogate genome-scale methylation status in high throughput manner. 
Presently, HumanMethylation450 Beadchip (Illumina, San Diego, CA), a 
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microarray platform that could assay about 485,000 CpG sites in the genome, 
by far, is the highest throughput microarray available in the market. During the 
course of my PhD, this chip is not available yet, thus our 59 patients samples 
were assayed in Infinium HumanMethylation27 Beadchips, predecessor of 
HumanMethylation450 Beadchip. This beadchip was the most comprehensive 
and affordable array available at the time of my study. High throughput 
bisulfite sequencing is the only method that has comparable throughput and it 
is able to probe methylation at single CpG level. However, due to its high cost 
and difficulty in bioinformatics analysis, this method was not favorable 
compared to Infinium platform. 
 
Presently, a few groups from different parts of the world have reported the 
methylation profile of HCC using various platforms. Two groups from Japan 
used Methylated CpG island amplification coupled with CpG island 
microarray (MCAM) method to profile 10 and 16 HCC patients respectively 
[231, 273]. Four other studies used the Infinium HumanMethylation27 
Beadchips. They are from Taiwan, 62 patients [274]; Korea, 62 patients [275] 
and two studies from Germany with 13 and 63 patients respectively [234, 259].  
We will be comparing some of their results with ours in result section. 
 
As a whole, we will be reporting the methylation profile of 59 liver tumors 
compared to adjacent non tumor tissues from a Singapore cohort. We seek to 






3.2.1 Clinicopathological characteristics of 59 HCC patients 
In this study, 90% of the patients are men, in agreement with what has been 
reported by Singapore Cancer Registry [95], where HCC was more prevalent 
in male patients. About 60% of the patients were infected with HBV, this 
further confirms the observation from epidemiological studies that viral 
infection such as HBV, poised as major risk factor for HCC, especially in Asia 
[276]. All patients were Asian, with median age of 65 years. Table 3.1 
describes the summary of the patients’ clinical and pathological characteristics 
in this study. 
Table 3.1 Clinicopathological characteristics of 59 HCC patients. 
 
 
Variables n % Available Data
Age at diagnosis (Median=65.3)
≥65 years old 31 53 59
<65 years old 28 47
Gender
Male 53 90 59
Female 6 10
HBV status
postive 36 61 59
negative 23 39
Tumor size 
≥5 cm 33 56 59
<5 cm 26 44
Differentiation (Edmonson)
 I 5 8 59
 II 23 39
 III 26 44
 IV 5 8
TNM staging




Absent 37 64 58
Present 21 36
Tumor Multifocality
Absent 45 82 55
Present 10 18
Tumor Encapsulation
Absent 35 66 53
Present 18 34
AFP level





3.2.2 Quality assessment and reproducibility of Infinium Beadchips 
We interrogated methylation status of 27568 CpG sites in 59 tumors and 59 
adjacent non-tumors using Illumina’s HumanMethylation27 Beadchip. To 
assess the reproducibility of the array, one tumorous sample was repeatedly 
assayed in three different beadchips. Correlation coefficients (R
2
) within these 
triplicates were consistently 0.96 (Figure 3.1A). Such high concordance was 
similarly observed in other studies [259, 274], thus confirming the technical 
reproducibility of the array. DNA extracted from different parts of the same 
tissue were also assayed so that we could determine whether there is 
difference in methylation profile within the same tissue sample. We repeated 
the methylation profiling for 3 pairs of samples, each pair of sample consists 
of DNA extracted from two different physical locations of the same tissue. As 
shown in Figure 3.1B, the correlation coefficients range from 0.92-0.94. 
Despite slightly lower than the correlation within technical replicates, overall, 
it is still highly reproducible. 
 
Figure 3.1 Quality assessment and reproducibility of 





Figure 3.1 Quality assessment and biological reproducibility of 
HumanMethylation27 Beadchips. (Continued…) (A) Assessment of one 
tumorous sample was repeated 3 times and correlations between replicates 
were measured. R
2
 value is the square value of Pearson correlation coefficient. 
(B) Three pairs of samples (50019264N, 76957025N and 60393303N), where 
each pair of sample consisted of DNA extracted from two different physical 
locations of the same tissue, were profiled separately to examine its 
reproducibility. 
 
3.2.3 Methylation profiling reveals aberrantly methylated CpG sites 
We used analysis of variance (ANOVA) method to uncover CpG loci that 
have different methylation levels between tumors and adjacent non-tumors. 
Using False Discovery Rate (FDR)-adjusted p-value (p<0.05) and mean 
methylation difference (|∆β|>0.1) as cutoff, we identified 4416 CpG sites that 
were significantly different between two groups. Volcano plot in Figure 3.2B 
showed the number of significantly deregulated CpG sites labeled in red. 2379 
CpG loci were hypomethylated, and 2037 CpG loci were hypermethylated in 
cancer compared to adjacent non-cancerous tissue. Figure 3.2A showed the 
heatmap of the 4416 aberrantly methylated CpG sites. Generally, these CpG 
sites allow tumor and adjacent non-tumor to be clustered into separate groups, 
except for a few misclassified tumors. 
 
3.2.4 Characteristics of differentially methylated CpG sites 
To have an overview of the distribution of the differentially methylated CpG 
sites on chromosomes, Manhattan plot was constructed by plotting the –log10 
(p-value) of the differentially methylated CpG sites against the chromosome 
distance. The plot, as shown in Figure 3.2C, showed that differentially 
methylated sites were randomly distributed across all chromosomes, except at 






































































































































































































































































































































































































































































































We next looked at the distribution of the 4416 significantly deregulated CpG 
sites in terms of their site specific location. As shown in Figure 3.3, most CpG 
sites were located in the promoter region (promoter region was defined as +/-
2000bp from TSS). This is expected as majority of the probes designed in 
Infinium HumanMethylation27 beadchip were located in the promoter region 
as well. Interestingly, when CpG sites were mapped back to their CpG island 
(CGI) location, 90% of the hypermethylated probes in HCC were located in 
CGI, slightly higher percentage compared to overall distribution of the 
Infinium HumanMethylation27 Beadchip probes (73%). On the other hand, 
majority of the hypomethylated probes were located in non CGI region (73%), 
where only 27% of the probes reside in CGI. Overall, our results were 
similarly observed in other studies [87, 274].  
 
Figure 3.3 Characteristics of differentially methylated CpG sites. 
Percentage of significantly hyper- or hypo- methylated CpG sites located in 
CGI (Brown) and promoter (Green) were compared against overall CpG sites 




3.2.5 Functional analyses of differentially methylated genes 
We were interested to know the biological functions or pathways that could 
possibly be affected by aberrant methylation. To answer that, 4416 
significantly and differentially methylated CpG loci were mapped back to the 





System, www.ingenuity.com). IPA is a web-based tool that seeks to explain a 
given biological data by integrating data from various experimental platforms. 
Figure 3.4A showed the top 10 most affected biological functions based on 
3239 unique genes that were mapped to 4416 differentially methylated CpG 
sites. Enrichment was calculated based on Fisher exact test with statistical 
significance, p-value cutoff of less than 0.05. Genes that harbored the 
deregulated CpG loci were enriched mainly in functions that involve cellular 
signaling and movement. Similarly, canonical pathways that are pertinent to 
cell signaling (e.g. cAMP-mediated signaling and G-Protein Coupled Receptor 
Signaling) and movement (e.g. granulocyte and agranulocyte adhesion and 
diapedesis) were also statistically enriched in pathway analysis (Figure 3.4B). 
Understanding the pathways enriched in this dataset allows us to propose a 
more informed hypothesis. For instance, about 35% of the 3239 genes were 
shown to be part of the pathway that regulates migration of leukocyte 
(granulocyte and agranulocyte adhesion and diapedesis). Such observation 
suggests that cellular movement of cancer cells may possibly be affected by 




Figure 3.4 Pathway analyses of significantly differentially methylated 
genes. (A) Top 10 biological functions that are most significantly enriched in 
our dataset. X axis shows the minus log10 of p-value for Fisher’s exact test. 
Values beyond orange line was significant based on FDR adjusted p-value 
<0.05. (B) Top 10 canonical pathways that are most significantly enriched in 
our dataset. Bottom X-axis is the minus log10 of p-value for Fisher’s exact test, 
and top X-axis is the percentage of genes in our dataset that overlapped with 
molecules within a pathway (numbers in bold). 
 
3.2.6 Validation of differentially methylated CpG sites in HCC patients       
Table 3.2 showed the 20 most significantly deregulated CpG sites in tumor 
compared to adjacent non-tumor samples. Top 6 genes were chosen to be 
validated initially, however, due to difficulty in designing primers in CpG 





excluded subsequently for validation. In addition, due to limitation on patients’ 
gDNA availability, validation was done on 20 out of 59 patients. As shown in 
Figure 3.5 and 3.6, two genes with hypomethylated CpG sites (CYB11P1 and 
SPRR3) and four hypermethylated genes (SPDY1, TSPYL5, PKDREJ and 
ZNF154) in cancer tissue were successfully validated by pyrosequencing. The 
differences in methylation between tumor and adjacent non-tumor were all 
highly significantly, with student’s t-test p-value less than 0.001 for both 
Infinium and pyrosequencing results. Also, the associations between 
Infinium’s β-values and pyrosequencing’s percentage of methylation were 
highly correlative, with R
2
 value ranging from 0.74 to 0.97. High concordance 
between two different platforms suggests that the methylation difference 
between tumor and adjacent non-tumor was highly reproducible.   
 
Table 3.2 Top 20 most significantly (A) hyper- and (B) hypo- methylated 










Figure 3.5 Validation of hypomethylated genes in tumors compared to 
adjacent non-tumors. Validation of methylation data was done using 
pyrosequencing. T-test was used to test the difference between tumors and 
adjacent non-tumors. Correlation between Infinium’s β-values and 
pyrosequencing’s percentage of methylation was measured using Pearson’s 
method.  R
2





Figure 3.6 Validation of hypermethylated genes in tumors compared to 
adjacent non-tumors. Validation of methylation data was done using 
pyrosequencing. T-test was used to test the difference between tumors and 
adjacent non-tumors. Correlation between Infinium’s β-values and 
pyrosequencing’s percentage of methylation was measured using Pearson’s 
method.  R
2




3.2.7 Overlapping CpG loci between three other independent studies 
Figure 3.7A showed the Venn diagrams of four independent studies that 
consist of our Singapore study and three previous studies, namely the Taiwan 
group [274] and two Germany groups [234, 259]. To control false positives on 
the overlapping CpG loci, we set a cutoff for multiple testing-corrected p-
value (p<0.01) and mean methylation difference (|∆β|>0.2) in all studies 
except the Taiwan group. As Shen et al used a more stringent multiple testing 
correction method [277] in their Taiwan report, we decided to reduce the 
cutoff for Taiwan study to Bonferroni corrected p-value < 0.05 and 
methylation difference, |∆β|>0.1.  Eventually, we identified 201 
hypermethylated CpG loci and 138 hypomethylated CpG loci that were 
consistently deregulated in all four studies (Figure 3.7B). As shown in Table 
3.3, successfully validated CpG loci were also among the top differentially 
methylated CpG sites in all four studies.  
 





Figure 3.7 Overlapping of CpG sites between other independent studies. 
(Continued…) (A) Venn diagrams for percentage of overlaps between our 
study and other group’s data. (B) Overall overlapping CpG sites within all 
four independent studies; hypermethylated CpG sites on left, hypomethylated 
CpG sites on right.  
 
Table 3.3 Overlapping CpG sites found in 4 independent studies. Twenty 
most significantly hypermethylated (A) and hypomethylated (B) CpG loci 
were listed according to FDR-adjusted p-value from our study. CpG sites that 








Currently, the role of aberrant DNA methylation in hepatocarcinogenesis is 
still not completely known. In this Chapter, we described the methylation 
profiling of 59 tumor and 59 adjacent non-tumor using Infinium 
HumanMethylation27 Beadchips. 4416 CpG loci were found differentially 
methylated between tumor and adjacent non-tumor. When hierarchical 
clustering based on these loci was performed, adjacent non-tumors were well 
separated from tumors. However, twelve tumors were clustered together with 
adjacent non-tumors (Figure 3.2A). These misclassified tumors seem to have a 
more non-tumorous-like methylation signature compared to majority of the 
tumors, thus suggesting the presence of tumor subtypes within these 59 
patients. This motivated us to further explore the possibility of tumor 
subtyping in Chapter 6. 
 
As mentioned earlier in the General Introduction Section, tumor suppressor 
genes such as CDH1, CDKN2A, GSTP1, RASSF1A, SOCS1, and SOCS3 are 
often hypermethylated in HCC. These genes were similarly methylated in this 
study as well. This confirms the observations of other independent reports 
[218, 219, 222, 223, 227-230]. In addition, we successfully validated the 
methylation levels of CpG loci in SPDY1, TSPYL5, ZNF154, PKDREJ, 
SPRR3 and CYP11B1. All six genes have not been reported to be associated 
with pathogenesis of HCC yet.  
 
SPDY1, also known as Speedy Homolog A, is a cell cycle regulator that 
enhances proliferation [278] and is associated with cancer [279].  However, 
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how methylation affects transcription of SPDY1 in HCC is still unknown.  
PKDREJ, an intronless gene, codes a protein which belong to the polycystin 
protein family [280]. Besides HCC, Masahiko et al reported CpG methylation 
in PKDREJ gene in lung cancer [281]. Generally, its function is still largely 
unknown. ZNF154 is a zinc finger protein but not much was known about this 
protein as well. Nonetheless, its CpG hypermethylation has been associated 
with bladder cancer [282] and renal cell carcinoma [283]. In fact, recently, 
ZNF154 has been proposed as possible biomarker for diagnosis for bladder 
cancer recurrence [284]. TSPYL5 is an interesting molecule because its 
expression was shown to suppress P53 in breast cancer [285] and involved in 
cell growth in lung cancer [286], but was methylated and silenced in glioma 
[287] and gastric cancers [288]. TSPYL5 is clearly methylated in HCC, but 
whether it is tumor suppressive or oncogenic, it is still not clear. SPRR3 is 
small proline-rich protein 3 that was shown to be stress-inducible [289] and 
involved in cellular differentiation [290].  Recently, its expression was 
associated with pathologic response to radiotherapy in esophageal squamous 
cell carcinoma [291]. It will be interesting to explore whether 
hypomethylation of SPRR3 will result its re-expression and thus enhance 
sensitivity towards radiotherapy in HCC patients. Lastly, CYP11B1 is a 
member of the cytochrome P450 superfamily and its deficiency was linked to 
diseases such as congenital adrenal hyperplasia [292]. CYP11B1 is expressed 
in normal liver, but whether hypomethylation of CpG loci in the promoter 
region of CYP11B1 will lead to its up-regulation still remains to be 
investigated. Clearly, the above mentioned genes as potential biomarkers are 
novel and not much is known about their functions in cancer. Their correlated 
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change of gene expression is crucial to further confirm their functional 
implication in cancer. Nonetheless, genome wide methylation analysis allows 
us to identify a plethora of aberrantly methylated genes more rapidly than 
before.  
 
On another note, six previous studies have reported HCC methylation profile. 
These studies involved patients from Japan, Germany, Taiwan, and Korea. 
The profiling platform used by Japan groups [231, 273] was different from 
ours, thus we did not use their data for meta-analysis. In addition, the Korean 
group [275] did not release their methylation data publicly, thus preventing us 
from using it for comparison as well. At the end, four studies, including ours, 
were used for comparison. Overall, the overlapping percentage of significantly 
methylated CpG loci among four studies range from 34% to 62% (Figure 
3.7A). Our study has the least overlap (34%, Figure 3.7A) with the study by 
Neumann et al, and this is probably due to the difference in the controls used 
in respective studies. They used ten normal livers from healthy individuals as 
controls, while our control samples consist of 59 adjacent non-tumor samples, 
which were resected from the same HCC patients’ liver. On the other hand, 
about half of our differentially methylated CpG loci were similarly found in 
the study by Ammerpohl et al. As their sample size was small and mostly 
Europeans, it is expected that there may be variance between both groups. Our 
study is most similar to Shen et al, in that about 62% of the significant CpG 
loci found in our study overlapped with those investigated by them. This is 
probably because the Taiwanese and Singaporean population share a more 
similar epigenetics profile compared to their European counterparts [293]. 
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Overall we saw 201 hypomethylated CpG loci and 138 hypermethylated CpG 
loci that are consistently deregulated in all four studies (Figure 3.7B). These 
CpG loci, of which six of them were validated in this study, could potentially 
link to genes that were important in the pathogenesis of liver cancer as shown 
by the Ingenuity Pathway Analysis (Figure 3.4). Again, genes that harbor 
aberrantly methylated CpG loci should be correlated with their expression 
level so that a more comprehensive view on their biological implications on 
liver cancer could be proposed. Results on integration between methylation 







Chapter 4: Integrated Analysis of Genome Wide Methylation and Gene 
Expression Profiles in Hepatocellular Carcinoma 
 
4.1 Introduction 
Methylation itself will not be functional without its association with gene 
expression change. Thus it is important to understand the correlation between 
DNA methylation and gene expression in the context of carcinogenesis so that 
we can uncover tumor suppressor genes that were repressed by methylation 
and oncogenes that were activated by hypomethylation.  
 
Previous findings were mostly performed by locus-specific methods, thus 
limiting the throughput of the experiments. With the advance of technology, 
researchers can now interrogate both methylation and expression profile in a 
genome-wide manner. Currently, only two HCC studies, namely Neumann et 
al and Yang et al, integrated genome wide gene expression analysis with 
genomic methylation data [234, 275]. Briefly, Neumann et al reported novel 
tumor suppressor genes based on their integrated data. Study by Yang et al, 
however, did not look into the genome wide characteristics of aberrant 
methylation and expression; instead, they focused solely on prognostic value 
of CpG methylation that deregulates gene expression in HCC.  
 
Surely, more study is needed to elucidate the implications of DNA 
methylation on gene expression in HCC. In this Chapter, we will correlate 
DNA methylation data with gene expression profiles in 59 HCC patients. This 





4.2.1 Different platforms used in expression profiling of 59 HCC patients 
Gene expression profiling were carried out in two different platforms, namely 
Illumina HumanWG-6 expression beadchip (Illumina, USA) for 39 pairs of 
HCC patients and Agilent Whole Human Genome Oligo Microarray (Agilent 
Technologies, USA) for 20 pairs of HCC patients. Detailed analyses were 
carried out by Thomas Thurnhurr et al (unpublished data). Briefly, accession 
numbers between Illumina and Agilent data sets were matched and batch 
correction was performed to remove differences due to different platforms. 
Figure 4.1A showed the PCA plots for tumor and adjacent non-tumor samples 
before and after batch correction. The variance caused by difference in 
profiling platforms was essentially removed after batch correction. As shown 
in Figure 4.1A, Illumina samples and Agilent samples were now clustered 
together. In addition, we profiled two HCC patients in both platforms so that 
we could ensure batch correction does not remove biological variance. The 
squared values of correlation coefficients (R
2
) between the repeated samples 
after batch correction range from 0.93 to 0.96 (Figure 4.1B). This indicates 
that although different platforms were used, the biological variance within the 
same sample was still preserved after batch correction. However, we noticed 
the distributions of log2 ratios of tumor over adjacent non-tumor were 
significantly reduced after batch correction, as shown by boxplots of 
representative samples in Figure 4.1C. Thus, the cutoff for subsequent analysis 
on relative fold change of tumor over adjacent non-tumor was lowered to 




Figure 4.1 Assessment of merged gene expression data from Illumina and 
Agilent platforms. (A) PCA plots before and after batch correction for 59 
tumor and adjacent non-tumor samples respectively. (B) Correlations of batch 
corrected and quantile normalized log2 intensities of the same patient sample 
profiled with different platforms. (C) Distribution of log2ratio of tumor over 
adjacent non-tumor samples, before and after batch correction on Agilent 
probes. Note: I=Illumina, A=Agilent, NT=Adjacent non-tumor, T=tumor. 
 
4.2.2 Expression profiling reveals differentially expressed genes in HCC 
R package limma [269] was used to identify differentially expressed genes 
between tumor and adjacent non-tumor samples. Using False Discovery Rate 
(FDR)-adjusted p-value (p<0.05) and expression fold change (|Fold-
change|>1.2) as cutoff, we identified 3185 genes that were significantly 
different between the two groups. Volcano plot in Figure 4.2B showed the 
number of significantly deregulated genes labeled in red. 1417 genes were 
down-regulated and 1768 genes were up-regulated in tumorous tissues 
compared to adjacent non-tumorous tissues. Figure 4.2A showed the heatmap 
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of the 3185 differentially expressed genes. Overall, these genes allow tumor 
and adjacent non-tumor to be clustered into separate groups, except for a few 
misclassified samples. In addition, Figure 4.2C showed that differentially 
expressed genes were randomly distributed across all chromosomes. 
 
 
Figure 4.2 Gene expression profiling of 59 HCC paired samples. (A) 
Hierarchical clustering of 3185 most significantly differentially expressed 
genes between tumors (T) and adjacent non-tumors (NT). (B) Volcano plot for 
gene expression profiling of 59 paired samples. Y-axis indicates the minus 
log10 of p-value for each gene, and X-axis shows log2 ratio of tumor over 
adjacent non-tumor. Genes that were statistically significant (adjusted p-
value<0.05) and have an absolute fold change of greater than or equal to 1.2 
were labeled in red.  (C) Manhattan plot shows the association between 
differentially expressed genes and chromosomes’ location. Y-axis shows the 
minus log10 of p-value for each gene, and X-axis represented the positions 





4.2.3 Effect of aberrant DNA methylation on gene expression 
An integrated analysis of DNA methylation and gene expression data of 59 
HCC patients was performed. Starburst plot in Figure 4.3A was constructed by 
plotting transformed significance level (p-value) of expression (Y-axis) versus 
methylation (X-axis) differences between tumor and adjacent non-tumor. This 
plot showed the relationship between gene expression and methylation. After 
filtering based on FDR-corrected p-value <0.05, 3221 genes (labeled as black 
dots in Figure 4.3A) that harbored aberrant CpG methylation were associated 
with significant change in gene expression. To reduce false positive, we 
increased the cutoff stringency and included only genes with change of β-
value ±0.1 and gene expression fold change of ±1.2 fold. Eventually, 536 
genes were shortlisted (labeled as red dots in Figure 4.3A). Detailed list can be 
found in Appendix I. About 44% of them have negative methylation-
expression correlations. Such relationship agrees with the conventional notion 
that hypermethylation leads to gene silencing and hypomethylation leads to 
up-regulation of expression. Interestingly, about 56% of the genes have 
positive methylation-expression correlations, where increase in methylation 
correlates with increase in gene expression and vice versa (Figure 4.3B). 
Possible explanation for this observation will be discussed in later section.  
 
4.2.4 Characteristics of aberrantly methylated CpG loci associated with 
536 deregulated genes  
Over 95% of the CpG loci were located in the promoter region, similar to the 
percentage of the array probes designed in this region. 86% of the 
hypermethylated loci were found in CGI, while 69% of the hypomethylated 
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loci were in non-CGI region (Figure 4.4). These observations were consistent 
with other reports in breast and lung cancer as well [294, 295]. This suggests 
that promoters with hypermethylation in CpG loci within CGI and 
hypomethylation in non-CGI are more likely to be functional and affect gene 
expression. 
 
Figure 4.3 Integrated analyses of methylation and gene expression profiles 
of 59 HCC samples.  
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Figure 4.3 Integrated analyses of methylation and gene expression profiles 
of 59 HCC samples. (Continued…) (A) Starburst plot was constructed by 
plotting transformed log10 p-value of differentially expressed genes (Y-axis) 
versus transformed log10 p-value of methylation difference (X-axis) between 
tumor and adjacent non-tumor. Genes with adjusted p-value <0.05 were 
labeled in black. Genes that have gene expression fold change of ±1.2 fold, 
difference in β-value of ±0.1 and met the statistical cutoff (adjusted p-value 
<0.05) were labeled in red. Directional change of expression and methylation 
were indicated by the black arrow head. (B) Percentage of genes with 
significant positive and negative correlations between gene expression and 
methylation data.  
 
 
Figure 4.4 Characteristics of methylation profile of 536 differentially 
expressed genes. Percentage of significantly hyper- or hypo- methylated CpG 
sites located in CGI (Brown) and promoter (Green) were compared against 
overall CpG sites in Infinium HumanMethylation27 array.    
 
4.2.5 Functional analyses of 536 deregulated genes  
Five hundred and thirty six genes that harbored differentially methylated CpG 





 System, www.ingenuity.com). Figure 4.5A showed 
the top biological functions that were affected by this dataset of 536 genes. 
Similar to previous Chapter (Figure 3.4), cellular movement and cell-to-cell 
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signaling were significantly affected. Also, we observed that functions such as 
cancer, gastrointestinal disease, and cellular growth and proliferation were all 
ranked top in the list. In addition, canonical pathways that are potentially 
perturbed (Figure 4.5B) were identified, they are pathways that play a role in 
liver function (e.g. LXR/RXR activation and FXR/RXR activation), pathways 
that involve the immune response (e.g. complement system, granulocyte / 
agranulocyte adhesion and diapedesis), and inflammation (e.g. LXR/RXR 
actvation and acute phase response signaling).  
 
Unlike IPA analysis in previous Chapter, current dataset contained gene 
expression information that could be analyzed by IPA to identify potential 
upstream regulators. IPA will compute and predict the likely upstream 
regulators that could possibly explain the change of gene expression in our 
dataset based on experimentally validated observations. Table 4.1 showed the 
list of top 20 most significant upstream regulators predicted by IPA. 
Interestingly, many of these potential upstream regulators were involved in 
inflammation pathway. In fact, many regulators were associated with NFkB 
network (highlighted in yellow, Table 4.1). As mentioned earlier, pathways 
that involved inflammation (e.g. LXR/RXR actvation and acute phase 
response signaling) were also similarly enriched in pathway analysis (Figure 
4.5). Figure 4.6A showed the proposed mechanistic network that was 
associated with most of the predicted upstream regulators. This mechanistic 
network showed that NFkB pathway was inhibited. Figure 4.6B outlined the 





Figure 4.5 Pathway analyses of 536 genes with significant and differential 
gene expression and methylation. (A) Top 10 biological functions that are 
most significantly enriched in this dataset. X-axis shows the minus log10 of p-
value for Fisher’s exact test. Values beyond orange line was significant based 
on FDR adjusted p-value <0.05. (B) Top 10 canonical pathways that are most 
significantly enriched. Bottom X-axis is the minus log10 of p-value for 
Fisher’s exact test, and top X-axis is the percentage of genes in our dataset that 
overlapped with molecules within a pathway (numbers in bold). Percentage of 
upregulated genes were labeled red and percentage of downregulated genes 









Figure 4.6 Proposed mechanistic network. (A) Potential upstream regulators 
NFkB, TNF and NFKB1, were proposed to form a mechanistic network based 
on overlapped target genes found in input datasets. (B) Target molecules 




4.2.6 Validation of genes silenced by hypermethylation 
In total, 235 genes (44%) have expression values that negative correlated with 
methylation. Table 4.2 reported subset of these negatively correlated genes. 
We are particularly interested in tumor suppressor genes that were silenced by 
methylation because many studies have reported the prognostic value of 
methylated tumor suppressor genes [275, 296] and its potential to be used as 
biomarker [142, 143]. For validation purpose, we chose six genes (TSPYL5, 
SPINT2, SH3YL1, CYB5R2, GSTP1, and TUBB6) that were silenced by 
hypermethylation. We included TUBB6, which is ranked 51
st
 out of the 536 
genes based on significance of differentially methylated CpG loci, so that we 
could test the robustness and sensitivity of the analysis. Due to limitation on 
patients’ gDNA availability, validation was done on 20 out of 59 patients.  
 
Table 4.2 Top 20 CpG sites that were most significantly hypermethylated 
and associated with down-regulation of gene expression in tumors. 
 
 
Top 20 most down-regulated and hypermethylated genes.












TSPYL5 cg15747595 0.38 2.47E-39 ILMN_1737972 -1.32 4.24E-08
LDHB cg06437004 0.49 5.31E-32 ILMN_1728132 -1.22 2.47E-02
SH3YL1 cg21825027 0.56 3.83E-29 ILMN_1712231 -1.43 8.81E-09
CYB5R2 cg03826976 0.30 3.13E-25 ILMN_1739576 -1.34 9.62E-05
SPINT2 cg15375239 0.50 6.56E-24 ILMN_1800739 -1.77 9.87E-05
TCTEX1D1 cg24110050 0.34 1.07E-23 ILMN_1751868 -1.59 4.54E-07
GRASP cg04034767 0.45 4.36E-23 ILMN_1705210 -1.48 4.69E-09
DOK1 cg26117023 0.45 2.56E-22 ILMN_1700086 -1.20 1.78E-04
KRTCAP3 cg11618577 0.24 2.90E-22 ILMN_1700728 -1.86 2.88E-11
PBX4 cg19996355 0.37 2.87E-21 ILMN_1700762 -1.21 3.03E-04
ULK2 cg12324629 0.18 3.70E-21 ILMN_1715482 -1.21 9.48E-07
GSTP1 cg04920951 0.39 7.19E-21 ILMN_1679809 -1.84 1.70E-08
SRD5A2 cg15403517 0.31 1.77E-20 ILMN_1788895 -3.85 1.18E-16
ADRA2B cg21542793 0.37 2.47E-20 ILMN_1677868 -1.38 6.65E-13
PODN cg23092823 0.29 1.24E-18 ILMN_1770800 -1.29 1.87E-04
RAB31 cg17982102 0.36 3.68E-18 ILMN_1660691 -1.24 7.13E-03
CFTR cg25509184 0.33 1.14E-17 ILMN_1705813 -2.03 3.09E-11
GNA14 cg17301902 0.32 6.50E-17 ILMN_1686227 -1.36 8.36E-14
RNF135 cg00948524 0.33 8.97E-17 ILMN_1700660 -1.24 1.69E-07
NR1H3 cg12613344 0.20 1.46E-16 ILMN_1814022 -1.33 3.12E-08
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As shown in Figure 4.7 A-F, methylation levels of all 6 genes were 
successfully validated in pyrosequencing, with good correlation between both 
platforms (R
2
 value ranging from 0.66 to 0.87). Relative expression of six 
genes obtained from microarray could also be reproduced in qPCR platform, 
except TSPYL5 gene. Nonetheless, we could observe that adjacent non-
tumors have a slightly higher TSPYL5 expression as compared to tumors, and 
that the outliers in tumor samples probably contributed the large p-value in the 
test of significance (Figure 4.7A). In the microarray data, TSPYL5 was 
significantly and differentially expressed between 59 tumors and adjacent non-
tumors (data not shown). Probably, a larger sample size is needed for 
validation of the expression of this gene.  The strength of negative correlation 
between methylation and gene expression was shown by R
2
 values in the 
scatter plots (Figure 4.7 A-F). In discovery phase, expression and methylation 
of TSPYL5 in 20 patients have a R
2 
value of 0.34. But in validation stage, 
TSPYL5 has very low coefficient of determination (R
2
=0.003). This is 
expected as we failed to validate its expression in qPCR platform. Also, as 
TUBB6 has the largest p-value among 5 other genes on methylation difference 
(i.e. ranked the lowest among the 6 validated genes in terms of significance), it 
has a low correlation coefficient value (R
2
=0.04 in discovery phase, and 
R
2
=0.05 in validation phase, Figure 4.7F) as well. As correlation does not 
























Figure 4.7 A-F. Validation results for TSPLY5, SH3YL1, CYB5R2, 
SPINT2, GSTP1 and TUBB6. (Continued…) Methylation and gene 
expression data were validated by pyrosequencing and qPCR respectively. T 
test was used to compare difference in methylation or gene expression 
between two groups; Pearson correlation was used to measure association 
between pyrosequencing and Infinium data, and between gene expression and 
methylation data.  
 
4.2.7 Candidate genes were re-expressed upon 5AzaDC treatment 
Previous studies used 5 Aza-2’-deoxycytidine (5AzaDC), a DNMT inhibitor 
that block DNA methylation, to verify that GSTP1 and SPINT2 were 
regulated by DNA methylation [297, 298]. We have previously profiled the 
expression and methylation levels of liver cancer cell line, HepG2 in a genome 
wide manner. We found that TSPYL5, SH3YL1, CYB5R2, SPINT2 and 
TUBB6 were all methylated and repressed.  Therefore, we treated HepG2 cells 
with 5AzaDC to examine whether these genes will be re-expressed when 
methylation is inhibited. As shown in Figure 4.8, genes were upregulated upon 
drug treatment. This further suggests that DNA methylation plays a role in 






Figure 4.8 Effect of 5AzaDC on gene expression of TSPYL5, SH3YL1, 
CYB5R2, SPINT2 and TUBB6 in HepG2 cells. 5AzaDC treatment was 
carried out as outlined in Material and Methods. SPINT2 was served as 
positive control in this experiment as it was previously reported to be re-




In this Chapter, we integrated methylation data with gene expression data of 
tumors and adjacent non-tumors of 59 HCC patients. We found 536 aberrantly 
methylated CpG loci that were associated with significant change in gene 
expression. Out of these, only 235 CpG loci were negatively correlated with 
gene expression. The other 301 CpG loci were positively correlated with 
expression. Conventionally, DNA hypermethylation is associated with gene 
silencing and hypomethylation at promoter region is associated with gene 
activation [23]. However, more recent studies indicated that the relationship 
between methylation and gene expression may be more complex than it was 
first perceived.  Hon et al found some hypomethylated regions were occupied 
by histone repressive marks. They showed that hypomethylation may be 
associated with gene repression [299]. Weber et al found promoters with lower 
GC content do not have significant correlation with expression, this suggests 
that transcription activity regulated by methylation may depend on CpG ratio, 
GC content and length of CGI [300]. Vlodrop et al further proposed that the 
location where CpG sites are methylated determines the outcome of gene 
silencing [301]. More studies also showed that hypermethylation is linked to 
gene activation in cancer [300, 302]. Clearly, the role of methylation on gene 
transcription could be more complex than previously reported, thus it warrants 
further investigation. Our subsequent discussion will focus mainly on the 
conventional inverse-correlated genes; nonetheless, we acknowledge the 




Overall, 67% of the negatively correlated genes were hypermethylated and 
silenced. Such observation was similarly observed in other cancers [51, 67].  
Genes that were previously reported to be methylated and repressed in HCC 
were found in this study as well. These genes include, but not limited to, 
SPINT2 [303], GSTP1 [227] , SOCS3 [230], ESR1 [304], and RECK [305].  
SPINT2 and GSTP1 were chosen as positive controls and successfully 
validated in this study. Two well-known tumor suppressor genes that are 
frequently repressed and methylated in HCC, namely RASSF1A and 
CDKN2A, were hypermethylated in our tumor samples but not differentially 
expressed when compared to adjacent non-tumorous samples. This could 
possibly be due to the sensitivity of the microarray probes in gene expression 
profiling. Many reports have used immunohistochemistry method instead to 
show the lower expression of RASSF1A and CDKN2A in tumors compared to 
normal liver [260, 306]. Thus, immunohistochemistry method may be a more 
appropriate experiment to measure the expression level of these two genes. 
 
Also, among the six validated genes in Chapter 3, namely SPDY1, TSPYL5, 
ZNF154, PKDREJ, SPRR3 and CYP11B1, only TSPYL5 was associated with 
deregulated gene expression. Previous studies have shown that ZNF154 [282, 
307] and SPRR3 [308] were repressed as a result of hypermethylation in 
cancer. However, these observations were irreproducible in this study. This 
may possibly due to our gene expression analysis that became less sensitive 
after batch correction as we observed a significant reduce of signal intensities 
(Figure 4.1C). Another possible explanation may be that probe designs for 
these genes were not optimal enough to detect the difference in expression, as 
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this was the case for CDKN2A and RASSF1A mentioned above. Certainly, 
alternative platform is required to validate these gene expressions in patient 
samples before we can further examine their implications in HCC. 
 
We have successfully validated the methylation and expression level of 
TUBB6, SH3YL1, and CYB5R2 using pyrosequencing and qPCR. We are the 
first to report SH3YL1, TUBB6 and CYB5R2 to be potentially regulated by 
methylation, and that they were hypermethylated and repressed in HCC. 
TUBB6 forms part of the microtubules and it was shown to be repressed in 
ovarian cancer [309]. However, other report showed that TUBB6 was highly 
expressed in colorectal cancer and that low TUBB6 expression was associated 
with colorectal cancers that are less aggressive [310]. It will be interesting to 
investigate the role of TUBB6 in different cancer type and explore whether 
DNA methylation is responsible for its cell type specific expression. SH3YL1 
is a protein that contains phosphoinositide-binding domain. It was shown to 
interact with SH2-containing 5'-inositol phosphatase (SHIP2) [311] and SHIP2 
is involved in cancer development [312]. In our study, SH3YL1 is silenced by 
methylation and how this will affect the interaction with SHIP2 remained 
unknown. CYB5R2 gene will be elaborated more in Chapter 5. Apart from 
these 3 validated genes, some of the genes found in Table 4.2 were reported to 
be methylated and repressed in other cancer, but yet to be associated with 
HCC. For instance, PTGS2 and LDHB in prostate cancer [313, 314], DOK1 in 
ovarian cancer [315] and HOXA4 in leukemia [316] were all methylated and 
repressed.  These genes may contribute towards HCC in a similar way like 




Ingenuity pathway analysis revealed that 536 correlated genes may be 
associated with NFkB pathway (Table 4.1). Inflammation often occurs in HCC 
because of viral infection or liver cirrhosis [317]. And studies have shown that 
chronic inflammation is linked to activation of NFkB pathway in cancer [318]. 
Our IPA result suggests that deregulation of methylation will result in 
expression change on a group of genes that associated with inhibition of NFkB 
pathway in HCC. Interestingly, primary response genes that involved in initial 
response to inflammation usually contain CpG islands that are readily 
available for recruitment of transcription factors [319, 320].  Methylation on 
these CpG islands may be deregulated during inflammation and eventually 
persist through the progression of cancer. Nonetheless, our hypothesis should 
be treated with caution as not all the 536 genes in our dataset are bona fide 
primary response genes of inflammation. Furthermore, the opposing effect 
predicted by IPA against the conventional NFkB activation in cancer has yet 
to be understood. More studies are required to validate these observations. For 
instance, we could analyze the expression change of major players in 
inflammation pathways and correlate them with methylation change in HCC 
with liver cirrhosis or HBV infection. 
 
Integrated studies of both methylation and gene expression profiles allow us to 
have a better understanding of the biological implications of aberrant 
methylation in HCC. We could uncover potential tumor suppressor genes that 
were methylated and silenced in cancer, and identify crucial biological 
functions that were deregulated in carcinogenesis using pathway analysis. 
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However, results obtained from this study possibly depict only one of the 
many aspects of the epigenomic change in cancer. With more integrated 
studies emerged [321-323], it will be soon that we will be able to map out the 





Chapter 5: Identification of Hypermethylated Genes That Are Implicated 
in Liver Carcinogenesis 
 
5.1 Introduction 
Previous studies have shown that DNA hypermethylation at promoter region 
affects tumor suppressor genes that were involved in Wnt signalling pathway 
[218, 219], cell cycle [222, 223], and DNA mismatch repair system [224]. 
Certainly, these are not the only genes affected by methylation in HCC. In this 
Chapter, using the integrated data of methylation and gene expression profile 
of HCC patients in Chapter 4, we seek to identify and characterize 
hypermethylated genes that are implicated in liver cancer.  
 
5.2 Results 
5.2.1 Candidate genes selected for downstream analysis 
Table 4.2 in Chapter 4 showed the 20 most significantly hypermethylated 
genes that were down-regulated in tumor. Here we focus only the top 5 
candidate genes, namely TSPYL5, LDHB, SH3YL1, CYB5R2 and SPINT2 
(Table 5.1). Based on NCBI Pubmed database, we found that LDHB and 
SPINT2 have been shown to be tumor suppressor genes that were repressed in 
cancer. Thus we proceed to profile only TSPYL5, SH3YL1 and CYB5R2 in 




Table 5.1 Top 5 most significantly hypermethylated genes with significant 
down regulation of gene expression.  
 
5.2.2 Characterize candidate genes in liver cancer cell lines 
We have previously shown that all three genes (TSPYL5, SH3YL1, and 
CYB5R2) were differentially methylated between tumor and adjacent non-
tumor using pyrosequencing. We also successfully validated their gene 
expression, except for TSPYL5 using qPCR method (Figure 4.7A-C). In order 
to characterize these genes, we decided to adopt liver cell line as our working 
model. Thus, we first examined the methylation and expression profile of 
these genes in three liver cancer cell lines (i.e. Huh7, HepG2 and Hep3B) and 
two immortalized normal liver cell lines (i.e. NeHepLxHT and THLE3). 
 
Overall, methylation levels of all 3 genes in immortalized liver cells were 
lower than cancer cells (Figure 5.1A). This observation is similar to what we 
observed in patient samples, where CpG sites of these genes were less 
methylated in adjacent non-tumors compared to tumors. We next asked 
whether the methylation level correlates with its expression level in respective 
cell lines. As shown in Figure 5.2B, TSPYL5 could hardly be detected in all 
cell lines except THLE3. Interestingly, despite low methylation level in 
NehepLxHT cells, TSPYL5 was not expressed, this suggest that mechanism 
other than methylation may be regulating this gene. On the other hand, 
SH3YL1 could be detected in all cell lines even though the CpG sites were all 
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highly methylated. Again, this suggests that other mechanism may be involved 
in regulating this gene. CYB5R2 is the only gene that has well correlated gene 
expression and methylation level. Thus, it was chosen to be further 
characterized. 
 
Figure 5.1 Methylation and gene expression profiling of CYB5R2, 
SH3YL1, and TSPLY5 in cell line models. (A) Methylation profiling of 3 
genes using pyrosequencing. (B) Gene expression profiling using conventional 
qPCR. Cancer cell lines were Hep3B, HepG2, and Hep3B; immortalized 
normal liver cell lines were NehepLxHT and THLE3.   
 
5.2.3 Methylation and expression level of CYB5R2 in 20 HCC patients 
Figure 5.2 showed another presentation of validated data for CYB5R2 gene in 
20 patient samples. Methylation level of tumors were all above 60%, while 
adjacent non-tumors have an average methylation level of 42% (t-test, 
p<0.0001). In our qPCR validation, all tumors have lower expression than 
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adjacent non-tumors except patient 7 and 14. Also, patient 9 and 10 have 
similar methylation level but their expressions were still significantly different 
between tumor and adjacent non-tumor. As HCC tissues were highly variable 
between individuals, we expected some differences between patients. 
 
Figure 5.2 Validation of methylation and expression status of CYB5R2 in 
20 HCC patients. (A) Methylation validation using pyrosequencing. (B) Gene 
expression validation using Fluidigm qPCR method. Tumor samples were in 
red, and adjacent non-tumors were in blue.  
 
5.2.4 CYB5R2 profiling in different cell lines 
We repeated the CYB5R2 profiling in respective liver cell lines, with 
inclusion of an additional liver cancer cell line SNU449. We showed that CpG 
loci at promoter region of CYB5R2 were hypermethylated in cancer cell lines, 
HepG2, Hep3B and SNU449 (Figure 5.3A). It was almost not expressed in 
transcript level, and totally not detected at protein level (Figure 5.3B-C). We 
detected CYB5R2 at both transcript and protein level in NehepLxHT, THLE3 
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and Huh7 cells. Interestingly, Huh7 cells have the highest expression CYB5R2 
among other cell lines (Figure 5.3B-C). Probably, Huh7 cells were derived 
from HCC tissue with high CYB5R2 expression, as what we seen in patient 7 
and 14, where its expression was relatively high in tumor (Figure 5.2B). To 
examine whether CYB5R2 is indeed regulated by DNA methylation, we 
treated the liver cancer cell lines with 5AzaDC. As shown in Figure 5.3D, 
CYB5R2 was upregulated upon 5AzaDC treatment in Hep3B, HepG2 and 
SNU449, but remained unchanged in NehepLxHT liver cells. Overall, our 
findings suggest that DNA methylation plays a role in regulating CYB5R2.   
 
Figure 5.3 Characterization of CYB5R2 in liver cell lines. Experimental 
validation of the methylation level (A), transcript level (B), protein level (C) 
and response to 5AzaDC treatment (D) of CYB5R2 were carried out in 






5.2.5 Potential transcription binding sites in CYB5R2 promoter 
Putative promoter region of CYB5R2 (-1 to -600 base pairs from TSS) was 
subjected to promoter analysis using Transfac
®
 Transcription binding site 
predictor (http://www.biobase-international.com/product/transcription-factor-
binding-sites). Figure 5.4 showed the results obtained from Transfac
®
. 
Interestingly, the CpG loci that were aberrantly methylated contained the 
binding sites for ZF5 (score: 0.872) and E2F (score: 0.919) transcription 
factors. We found 3 more putative ZF5 binding sites in other regions of 
CYB5R2 promoter, suggesting redundancy of binding sites for ZF5.  
 
 
Figure 5.4 Potential transcription binding sites predicted in putative 
promoter region of CYB5R2. Differentially methylated region that was 
validated by pyrosequencing was boxed in blue. CpG dinucleotides were 
labelled in red. Potential transcription binding sites with its score in 
parenthesis were predicted by Transfac
®
 Transcription binding site predictor.  






5.2.6 Optimization of adenoviral infection   
In this study, adenoviral vector containing CYB5R2 (AdCYB5R2) and control 
adenoviral vector (AdControl) were used. Such system was chosen as 
inactivated adenovirus infection has higher efficiency in entering into cells 
compared to normal transfection method (Figure 5.5).  
 
Figure 5.5 Transfection versus infection on NehepLxHT cells. NehepLxHT 
cells were transfected with 4ug of eGFP plasmid (left) and infected with 
inactivated adenovirus carrying eGFP adenoviral vector (MOI=50, right).  
Virus infection has higher efficiency in expressing eGFP as compared to 
transfection.  
 
During optimization step, HepG2, Hep3B and SNU449 cells were infected 
with either AdCYB5R2 or AdControl according to different multiplicity of 
infection (MOI) as shown in Figure 5.6 and cell lysate were extracted for 
Western blot (WB) analysis. Expression of zsGreen, CYB5R2 and GAPDH 
were detected (Figure 5.6A). The efficiency of infection was determined by 
the expression of zsGreen as both constructs contained this marker gene. 
AdCYB5R2 and AdControl samples need to have similar zsGreen expression 
so as to achieve same infection efficiency. Optimum CYB5R2 expression was 
also determined by its expression on WB, and GAPDH served as the loading 
control in this analysis. Post-infection cell photos (Figure 5.6B) were taken as 
well to ensure cells do not undergo apoptosis or other injuries due to excessive 
viral infection.  
 




Figure 5.6 Optimization of infection efficiency for AdControl and 
AdCYB5R2 in respective cell lines. (A) The efficiency of infection was 
determined by the Western blot analysis on expression of marker gene, 
zsGreen (35kDa) and CYB5R2 (31kDa). GAPDH (36kDa) was used as 
loading control in this analysis. (B) Pictures were taken 48 hours post 
infection to monitor cell morphology and zsGreen fluorescence intensities. 





Eventually, MOI 20 was chosen as appropriate infection condition for both 
AdControl and AdCYB5R2 in SNU449 cells; MOI 25 for AdControl and MOI 
20 for AdCYB5R2 in Hep3B cells. We noticed that CYB5R2 was not 
significantly expressed in HepG2 cells (Figure 5.6), probably it was rapidly 
degraded. The zsGreen was also relatively low compared to the other 2 cell 
lines. Therefore, HepG2 was excluded for subsequent analysis. We also 
observed that expression of CYB5R2 was much higher in SNU449 than in 
Hep3B cells despite having the same MOI. 
 
5.2.7 CYB5R2-expressing cells grew slower 
To examine the potential role of CYB5R2 on cell growth, we re-expressed it 
in Hep3B and SNU449 cells. As the doubling time for Hep3B and SNU449 
were 24 hours and 36 hours respectively, cells were monitored under 
microscope and images were captured every 2 hours to track their proliferation 
rate based on the surface area of zsGreen marker for the next 24 hours post 
infection. The green fluorescence area was captured and subsequently 
converted into percentage of confluence. The difference of percentage of 
confluence relative to time zero will be used a measurement of cell growth. As 
shown in Figure 5.7A, SNU449 and Hep3B cells with CYB5R2 expression 





Figure 5.7 Cells proliferated slower when CYB5R2 was re-expressed in 
SNU449 and Hep3B cells. (A) Infected cells were monitored under 
microscope and images were captured every 2 hours to track their proliferation 
rate based on the surface area of zsGreen fluorescence. Y-axis is the difference 
in confluence between time zero and at the time when next image was taken; 
X-axis is the number of hours post 24 hours infection. *t-test, p value<0.05 (B) 
Representative cell images at 24 and 48 hours post infection. 
 
5.2.8 Clinical parameters associated with expression of CYB5R2 
Expression level of CYB5R2 in tumors did not contribute to patients’ overall 
and disease-free survival time (Wilcoxon test, p>0.05; Figure 5.8), even 
though we observed a slight survival advantage for patients with high 
CYB5R2 expression. Patients with low CYB5R2 expression appeared to be 
associated with cirrhosis (Fisher’s exact test, p=0.0587; Table 5.2). As the p-
value slightly exceeded cutoff value of 0.05, more data is required to 
substantiate this claim. The rest of the clinical parameters were not 







Figure 5.8 Kaplan-Meier survival curves between patients with high and 
low CYB5R2 expression. Patients that exceeded the 3
rd
 quartile range of 
CYB5R2 expression were considered as patients with high CYB5R2 




Table 5.2 Correlation between patients of high and low CYB5R2 
expression with clinicopathological parameters in HCC samples. Fisher’s 







Previous DNA methylation studies in HCC have been mainly focused on 
single-locus-specific analyses [324, 325]. Here, we describe an alternative 
method to discover novel genes that are repressed by hypermethylation in liver 
cancer. Briefly, integrated data from genome-wide methylation and gene 
expression profile of HCC samples was used to shortlist potentially functional 
hypermethylated genes. Candidate genes were subsequently characterized in 
liver cancer cell lines. In this study, CYB5R2 was eventually selected for 
further analysis. 
 
CYB5R2 gene is cytochrome B5 reductase 2 that belongs to family of NADH-
cytochrome b5 reductases. Its function is still not fully known, even though it 
was shown to be ubiquitously expressed in different tissues [326]. One study 
proposed that it mediates the NADH-induced redox activity in human 
spermatozoa [327]. Our data showed that it is methylated and repressed in 
HCC. In addition, using NextBio Disease Atlas database (www.nextbio.com), 
CYB5R2 were similarly methylated and silenced in breast [328, 329] and 
brain cancer [330, 331]. Recent study further suggested that CYB5R2 may be 
a tumor suppressor gene that was repressed in nasopharyngeal carcinoma 
[332]. To explore its potential role in liver cancer, we re-expressed the gene in 
liver cancer cell lines using adenoviral vector and showed that it slowed down 
cell growth (Figure 5.8A). We aim to generate stable cell line that expresses 
CYB5R2 and green fluorescence protein (GFP) marker so that subsequent 
functional readouts will not be interfered by viral proteins or infections. Stable 
cell line with GFP marker will allow us to select cells with stably transfected 
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CYB5R2 by fluorescence-activated cell sorting (FACS) machine. Subsequent 
studies of cell growth, invasiveness, and apoptosis using these selected cells 
will give more valuable information.  
 
In our study, we found that patients with low or no CYB5R2 expression in 
their tumors were associated with liver cirrhosis (Fisher’s exact test, p=0.0587; 
Table 5.2). We also observed a slight survival advantage for patients with 
higher CYB5R2 expression (Figure 5.8). As both observations did not meet 
the statistical cutoff, more validation studies are required before we can further 
ascertain these associations. In addition, it is also important to note that 
CYB5R2 has not been reported in previous studies that attempted to identify 
marker genes for cirrhosis related HCC [333, 334]. This is probably due to 
low CYB5R2 expression in tumors. Based on upper quartile cutoff, our data 
showed that 15 out of 59 patients have higher CYB5R2 expression in tumors. 
However, only two out of the 15 tumors have comparable expression with 
their adjacent non-tumors (Figure 5.2B). In other words, CYB5R2 expression 
is generally low in tumors compared to adjacent non-tumorous tissues. This 
condition makes it unlikely to meet the stringent statistical cutoff in other 
studies when considering it as a candidate marker gene for cirrhosis-related 
HCC.  
 
We are also interested to know the transcription factors that bind to the 
methylated region and subsequently involve in the repression of this gene. The 
differentially methylated site in CYB5R2 promoter contains putative binding 
sites for ZF5 and E2F transcription factors (Figure 5.4). Both transcription 
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factors were shown to be associated with gene silencing machinery that bind 
to methylated CpG regions [335, 336]. In our patients’ gene expression data, 
E2F family was significantly upregulated in tumor compared adjacent non-
tumor (Fold change>1.2, FDR adjusted p-value<0.05), while ZF5 remained 
unchanged in both tumor and adjacent non-tumor (data not shown). 
Furthermore, three other ZF5 binding sites were predicted in the promoter of 
CYB5R2 gene, indicating its redundancy (Figure 5.4). Thus, E2F could 
potentially be the transcription factor that is involved in regulating CYB5R2 
expression. In order to ascertain the actual transcription factor that binds to 
this site, chromatin-immunoprecipitation assay is required. In addition, 
promoter assay is also needed to validate whether this binding site is 
functional.  
 
In short, CYB5R2 is just one example of many genes that could be potentially 
uncovered through integrated methylation and gene expression studies in HCC.  
Certainly, more studies are required before we can consider CYB5R2 as a 
bona fide tumor suppressor gene. By carefully characterizing methylated 
genes such as CYB5R2, we could separate the “passenger” genes from the 
“driver” genes of hepatocarcinogenesis that are repressed by methylation.   
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Chapter 6: Methylation Clustering Reveals Tumor Subgroups  
6.1 Introduction 
The approval of Sorafenib, a molecular targeted therapy for patients with 
advanced HCC, is one success story on how molecular characterization of 
HCC could lead to improvement of its clinical treatment [165, 166]. In fact, 
many studies seek to translate genome-wide data into molecular information 
that improves clinical management of HCC. Gene expression profiling is one 
the most commonly used platforms. It has been used to identify potential 
tumor subtypes and biomarkers that correlated with etiology, clinical 
parameters such as tumor size, disease recurrence and patients’ survival time. 
For detailed list of studies, see excellent reviews by Breuhahn et al and 
Hoshida et al [337, 338]. Currently, none of the gene expression studies have 
been adapted into clinical use yet. This is probably because results obtain from 
gene expression study often change according to different assay conditions 
such as variations in sample preparation, assay platforms, and methods in data 
analyses. The failure to achieve consistent results in these assays makes it 
difficult for meta-analysis and diagnostic purpose [337].   
 
DNA methylation is a more stable marker and less dependent on the sample 
preparation or assay condition. Methylation of CpG loci have been proposed 
as potential prognostic markers for HCC [339-347]. However, these studies 
were limited to only a few genes due to technical limitation. With the advent 
of array-based technology, genome-wide methylation profiling is made 
possible and has been used to associate with clinical outcomes [231, 246, 274, 
275]. Currently, no study has yet used methylation profile to subdivide HCC 
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patients into molecular subgroups.  Methylations of specific loci in subtype of 
gastric cancers [348], colorectal cancers [349], gliomas [331] and breast 
cancer [294] have been described recently. These subtypes of cancer were 
shown to have different clinical implications. In this Chapter, we will seek to 
identify tumor subtypes of HCC based on methylation profile of tumor 
samples in 59 patients and associate these subtypes with clinical parameters. 
 
6.2 Results 
6.2.1 Identification of HCC subgroups using methylation clustering 
As mentioned in Chapter 3, methylation levels of 59 tumors were profiled 
using Infinium HumanMethylation27 beadchips (Illumina, USA). To identify 
tumor subgroups, we chose the top 5% most variable probes across the 59 
tumors and performed consensus hierarchical clustering with iterative feature 
selection (CHC-IFS), a method that was previously used to identify gastric 
cancer subtypes [271]. CHC-IFS is a resampling based method that ensures 
the clusters generated were not due to accidental characteristics of the specific 
data used. Also, the iterative feature selection allows only the most 
informative probes to be included in clustering tumors. Figure 6.1B,D showed 
the cluster-consensus value of each cluster. It is calculated by taking the mean 
of all pairwise consensus indices within a cluster's members. The higher the 
Mean Consensus Value, the more stable the cluster is. Clearly, after iterative 








Results obtained from CHC-IFS suggested that three subgroups exist within 
the 59 tumors (Figure 6.1A). To validate this observation, we repeated the 
whole analysis with another independent clustering algorithm, which is K-
means consensus clustering. Iterative feature selection was performed as well. 
Cluster assignments using this algorithm were 91.5% (54/59) similar to the 
CHC-IFS assignments. Five tumors were assigned differently when different 
clustering algorithm was used (Figure 6.1E). Nonetheless, it is obvious that the 
59 tumors can be divided intrinsically into 3 subgroups as shown by high 
cluster-consensus value in each cluster (Figure 6.1B,D). As CHC-IFS have 
higher cluster-consensus values than K-means consensus clustering-IFS, 
subsequent discussion will focus solely on cluster assignments by CHC-IFS. 
Figure 6.2 showed the 2D hierarchical clustering of tumors using the probes 
identified in CHC-IFS, again, 3 groups of tumors were clearly seen.    
 
Figure 6.2 2D hierarchical clustering of tumors using the probes 
identified in CHC-IFS. 3 subgroups were identified and labeled as Group-1 




6.2.2 Biological and Clinical Characteristics of 3 subgroups 
Clinicopathological parameters such as age, gender, HBV status, tumor size, 
tumor grade, tumor stage, presence of cirrhosis, tumor multifocality, tumor 
encapsulation and AFP level were correlated with tumor subgroups. As shown 
in Table 6.1, none of the correlation was statistically significant.  
 
Table 6.1 Correlation between tumor subgroups and clinicopathological 
parameters in HCC samples. Fisher’s exact test was used to test the 
correlation between tumor subgroups and clinicopathological parameters. 
 
 
We then attempted to cluster their mRNA expression using CHC-IFS. 
However, the algorithm failed to provide clusters similar that of methylation 
profile. In fact, the clusters generated by gene expression profile were highly 
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unstable. As shown in Figure 6.3A, cluster number, K = 3, 4, and 5 all have 
very low cluster-consensus values. Even though clustering looked optimal, the 
cluster size was relatively small for one of the groups (Figure 6.3B-C). In 
addition, the three subgroups based on methylation profile could not be 
differentiated by gene expression pattern as well. No gene was shown to be 
significantly different between 3 subgroups.  
 
 
Figure 6.3 Clustering of 59 HCC tumors using gene expression profiles. 
(A) Mean cluster consensus for number of cluster, k=2, 3, 4, and 5 using 
consensus hierarchical clustering (CHC) before IFS. (B) Heatmap of the 
consensus matrices when k=2. (C) Hierarchical clustering of 59 tumors using 
genes identified by CHC-IFS. Green indicates low expression and red 





6.2.3 Group-2 (Group B) exhibited worse disease free and overall survival 
outcomes 
In the survival analysis, we saw some differences in survival outcomes among 
3 subgroups of patients. We observed that Group-2 patients consistently 
performed worse than Group-1 and Group-3 patients in terms of disease-free 
and overall survival. However, as survival analysis was done in the context of 
comparison between 3 groups, p-values computed from the analysis did not 
pass the statistical cutoff (Figure 6.4A).  
 
Nonetheless, we were interested to know whether Group-2 patients were 
indeed performed worse than the rest of the patients. Thus, we decided to 
proceed to test the survival difference between Group-2 (Group B) and 
combined data of Group-1 and Group-3, which we now named it as Group A.  
As shown in Figure 6.4B, Group B, which is also Group-2, performed 
significantly worse than Group A in terms of disease free (Wilcoxon p= 0.037) 
and overall survival (Wilcoxon p=0.049). Univariate analysis confirmed that 
Group B exhibited worse survival outcomes compared to Group A [Disease 
Free Survival, Wald’s p= 0.017, Hazard Ratio (HR)=4.73, 95% Confidence 
Interval (CI)=1.32 to 16.9; Overall Survival, Wald’s p=0.003; HR=3.99, 
CI=1.61 to 9.86] (Table 6.2).  In multivariate analysis, however, the difference 
in survival between two groups was not significant. This is probably because 
we over-fitted the variables into the Cox Proportional Hazard Model [350].  
We also found that tumor size and tumor stage contributed towards poorer 
disease free and overall survival of HCC patients. Tumor size and stage were 




Figure 6.4 Kaplan-Meier survival curves between tumor subgroups. (A) 
Survival curves for the original 3 subgroups identified by CHC-IFS. (B) 
Survival curve for Group B (i.e. Group-2) versus the rest of the patients 

























































































































6.2.4 Biological and clinical characteristics associated with Group A and 
Group B 
Clinicopathological parameters and tumor groups were not significantly 
correlated (Table 6.3). However, we could observe that Group B patients have 
tumors with more advanced stages compared to Group A (Fisher’s exact test, 
p=0.09), given that both groups do not have difference in terms of tumor size 
(Fisher’s exact test, p=0.67). To examine the functional relevance of these 849 
differentially methylated CpG loci between Group A and Group B (ANOVA, 
FDR p<0.05, |∆β|>0.1), genes associated with these probes were subjected to 
Ingenuity pathway analysis. Interestingly, cancer and gastrointestinal disease 
were among top most enriched biological functions in this gene set (Figure 
6.5A). In addition, functions such as organismal injury which linked to 
inflammation, cellular movement and cell-to-cell signaling were enriched, 
similar to what we observed in our functional analysis on genome wide 
methylation data (Figure 3.4) and integrated data (Figure 4.5) in previous 
Chapters. Figure 6.5B showed the significantly enriched signaling pathways in 
this dataset and Figure 6.5C presented the top scored network identified 
through IPA.  
 
We were intrigued by the top network which centered upon CDH1 (Figure 
6.5C). As methylation of CDH1 was widely known to be associated with 
tumor progression [353, 354], we were interested to know whether there were 
other prognostic factors in our gene set.  Using function annotation features of 
IPA, we identified forty four genes that were associated with either prognosis 
or progression of a disease (Table 6.4). Among these, notably, CDH1[218, 
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219] , GSTP1 [227], CCND2 [355], KLK10 [356], RECK [357] and RUNX3 
[358] were all significantly methylated in Group B compared to Group A 
(Figure 6.6). These genes were previously reported to be prognostic factor for 
HCC. 
 
Table 6.3 Correlation of Group A and Group B with clinicopathological 
parameters in HCC samples. Fisher’s exact test and Mann-Whitney U test 







Group A Group B Group A vs. B 
Age at diagnosis (Median=65.3)
≥65 y      ld 59 24 7 0.18b
<65 years old 24 4
Gender
Male 59 43 10 1.00a
Female 5 1
HBV status
postive 59 30 6 0.70a
negative 18 5
Tumor size 
≥5  m 59 27 6 0.67b
<5 cm 21 5
Differentiation (Edmonson)
I,II 59 21 7 0.32a
 III,IV 27 4
TNM staging
1 58 29 3 0.09a
2,3 19 7
Cirrhosis
Absent 58 31 6 0.50a
Present 16 5
Tumor Multifocality
Absent 55 37 8 1.00a
Present 8 2
Tumor Encapsulation
Absent 53 30 5 0.47a
Present 14 4
AFP level







Figure 6.5 Pathway analyses of genes that were significantly different in 
methylation between Group A and Group B. (A) Top 10 biological 
functions that are most significantly enriched in this dataset. X-axis shows the 
minus log10 of p-value for Fisher’s exact test. Values beyond orange line was 
significant based on FDR adjusted p-value <0.05. (B) Top 10 canonical 
pathways that are most significantly enriched. Bottom X-axis is the minus 
log10 of p-value for Fisher’s exact test, and top X-axis is the percentage of 
genes in our dataset that overlapped with molecules within a pathway 








Figure 6.6 Methylation profiles of six genes in HCC tumors that were 
associated with prognosis and disease progression. Infinium β-values were 
used in boxplots, and t test was used to test the difference between two groups. 
 
6.2.5 Validation of differentially methylated genes between Group A and 
Group B  
We randomly chose a few genes to be validated by pyrosequencing in 20 
patients’ tumors. As shown in Figure 6.7, all five genes were validated to be 
more methylated in Group B than Group A (Mann Whitney U test, p<0.05), 
except CYP4F2 where its p-value is almost significant (p=0.057). Since 
microarray gene expression analysis within tumors did not yield significant 
result, we decided to validate gene expression of these 5 genes using qPCR 
method. Three gene expressions (BOK, PEX11G and RUNX3) were 
significantly different between Group B and Group A, while two other genes 
(GSTP1 and CYP4F2) were not differentially expressed based on statistical 
cutoff. This observation suggests that there were gene expression difference 




Figure 6.7 Validation results for genes that were differentially methylated 
between Group A and Group B. Pyrosequencing was used to validate 
methylation level, and Fluidigm qPCR method was used to measure the gene 
expression of validation cohort. Mann-Whitney U test was used to test the 




In this Chapter, we utilized methylation information within tumors to cluster 
them into respective subgroups.  We identified one subgroup that exhibited a 
poorer survival outcomes compared to the rest of the tumors.  However, we 
were unable to reproduce the clustering results using corresponding gene 
expression data. Possible explanation for this could be that not much variation 
of gene expression were found within tumors. Also, as mentioned in earlier 
Chapters, due to the batch correction of different arrays used for gene 
expression profiling, intensity values were transformed and become less varied 
(Figure 4.1C). In addition, microarray profiling may not be sensitive enough to 
detect minute expression change between subgroups. This could possibly be 
the main reason as we managed to validate the expressions of 3 genes that 
were deregulated by methylation using more sensitive qPCR method (Figure 
6.7).  
 
We were also interested in studying the characteristic of tumor subtypes that 
leads to poorer patients’ survival. As gene expression analyses did not yield 
significant result, we could only infer the perturbed biological functions by 
investigating the genes where the aberrant methylation located. As shown in 
Figure 6.5, the enriched biological functions were similar to what we have 
earlier found in Chapter 3 and Chapter 4, namely we identified inflammation, 
cell-to-cell signaling and cellular movement to be consistently enriched in all 
three analyses. We hypothesize that deregulated methylation profiles of genes 
involved in these functions will drive tumor progression since Group B 
patients whom harbored these aberrant methylation performed worse in 
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survival outcome. Furthermore, when we functionally annotated the 849 
probes that were differentially methylated between Group A and Group B, we 
found that 44 genes were associated with the terms “cancer progression” or 
“prognosis” in IPA. Among them were previously reported prognostic factors 
for HCC, such as CDH1[218, 219] , GSTP1 [227], CCND2 [355], KLK10 
[356], RECK [357] and RUNX3 [358].   
 
Recent reports have suggested gene expression signatures that could be served 
as prognostic markers for HCC [359, 360]. Hoshida et al reported a 186-gene 
signature that associated with poor prognosis of HCC, while Nault et al used a 
5-gene signature to predict the survival outcome of HCC patients treated with 
liver resection. Certainly, a collective of gene markers seem to provide a more 
informative prognosis of the disease. Our study presented a subgroup of 
patients with poor survival outcome, and out of the 849 probes that define the 
subgroup, 44 genes were associated with prognosis of certain disease. We 
further indicated that hypermethylation of six out of these 44 genes have 
already being shown to be prognostic factors for HCC in previous studies 
(Figure 6.6). It will be interesting to investigate whether these methylation 
markers could also provide a similar power in predicting the prognosis of 
HCC.  However, to ascertain this hypothesis, validation step needs to be 
carried out in a larger cohort of HCC patients and a proper scoring system is 
required to measure the methylation status of these genes in each individual.  
 
Genomic information of individual patient will allow a better understanding of 
the molecular pathogenesis of the disease, and thus enable a more rationalized 
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and personalized treatment. Methylation data could potentially be one of the 
genomic information because of its discriminatory power in dissecting the 
pathogenesis of a disease. Here, we showed that methylation profile could 
divide HCC into different subgroups that differ in survival outcomes. 
Aberrantly methylated CpG sites from this tumor subtype may be potentially a 







Chapter 7: General Discussion and Future Work 
Hepatocellular Carcinoma (HCC) is one of the most common human cancers 
in the world and it caused more than 695,000 deaths annually [93].  Despite its 
high mortality rate, the molecular pathogenesis of HCC remained unclear. In 
this thesis, we studied one of the epigenetic changes in HCC, which is DNA 
methylation. We seek to elucidate the implications of aberrant DNA 
methylation in HCC. In Chapter 3, we described the methylation profile of 59 
tumors and 59 adjacent non-tumors of HCC patients. We were able to validate 
array data through pyrosequencing. Tumor samples clearly have a distinct 
methylation signature compared to adjacent non-tumors. In Chapter 4, we 
integrated the methylation data with their respective gene expression profile, 
and identified a subset of genes which were deregulated as a result of aberrant 
methylation. These genes were shown to be enriched in inflammation pathway. 
We also used this integrated data to uncover potential tumor suppressor genes. 
In Chapter 5, we characterized one such candidate gene, CYB5R2 which was 
methylated at the promoter region and repressed in tumor samples. Lastly, we 
attempted to subdivide the tumors into different subtypes based on 
methylation clustering in Chapter 6. We showed that one group of patients 
exhibited worse survival outcomes compared to the rest of the patients. 
 
Methylation profiles of HCC patients provide crucial understanding on the 
complexity of epigenetic mechanism underlying HCC. Our data provides 
insights into potential tumor suppressor genes and oncogenes that were 
repressed or activated by aberrant methylation. Pathway analysis further 
revealed the biological processes that were affected specifically by 
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methylation. However, DNA methylation and expression data would not be 
sufficient to explain the pathogenesis of HCC. Recently, more genome-wide 
data become publicly available, and one good example is The Cancer Genome 
Atlas (TCGA) project (http://cancergenome.nih.gov/) launched by the 
National Cancer Institute (NCI), USA. We could now access RNA sequence, 
miRNA expression, chromosome copy number, single nucleotide 
polymorphism (SNP) and clinical data of 148 HCC patients through the 
TCGA data portal. It would be interesting to integrate our methylation data 
with these genomic data so that we can functionally characterize this disease 
better. Of course, the bottleneck is always the analysis of high throughput 
data. Proper statistical and computational methods are thus required. Data 
normalization between platforms, batch correction between sample cohorts, 
and data annotations are just some recurrent topics that we need to carefully 
look into when performing integrated analyses. Nonetheless, such analysis is 
forthcoming, as what we have seen in the case of colorectal cancer [361]. 
 
Currently, Sorafenib remained the only molecular targeted drug approved as 
standard therapy for advanced HCC patients. This is because patients with late 
stage HCC are not qualified for surgical resection or liver transplant, and other 
therapies do not improve patients’ survival [166]. With the approval 
of  DNMT-inhibiting cytosine nucleoside analogs such as Zebularine and 
Decitabine in treating myelodysplastic syndromes (MDS) and acute myeloid 
leukemia (AML) [362], many researchers began to explore the possibility of 
using such drugs on solid tumors like HCC. Our study described the mapping 
of methylation and corresponding gene expression profile of 59 HCC patients. 
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It provides a priori knowledge on genes that were likely to respond to these 
demethylating drugs. In addition, clustering of tumors based on methylation 
data allows identification of tumor subtypes that could have different drug 
response. In fact, recent study has reported that only subgroups of HCC 
tumors will response to Zebularine treatment [363]. It will be interesting to 
investigate whether our tumor subtypes of an Asian population will respond 
differently towards this drug as well. To do so, we need to uncover the 
response genes and demethylating signature derived from this drug and 
correlate them with the methylation profiles of tumor subtypes.  Certainly, 
more studies are required to translate the knowledge on aberrant methylation 
to clinical use.  
 
Another pertinent question that always associated with DNA methylation is 
the root cause of such change in HCC. Many studies have dwelt into this 
subject [364], and we are particularly interested in HBV infection as it is 
closely associated with HCC in Asia population [365]. More specifically, we 
are interested in elucidating the function of Hepatitis B virus X protein (HBx) 
in deregulating methylation profile in HCC. HBx is a well-known positive 
regulator of hepatocarcinogenesis [104], and many studies have recently 
showed that it is involved in deregulation of DNA methylation in HCC [201, 
251, 255, 366-369]. It would be interesting to correlate the HBx expression 
with methylation profile in tumors, and also to elucidate the effect of HBx on 
DNA methylation regulators such as DNMTs. Understanding the pathological 
effect of HBV on DNA methylation will certainly assist future research on a 




In conclusion, HCC methylation profile is not only beneficial to the 
understanding of the epigenetic changes implicated in HCC, but also provides 
insights into tumor subtypes that exhibit different biological and clinical 
characteristics. In the near future, as more sequencing and array data become 
publicly available, coupled with well annotated patients’ clinical parameters, 
we are entering into an exciting field of translational research, where 
molecular targeted therapy and personalized medicine for HCC patients will 
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Appendix B. PCR program for Bisulfite PCR. 
 
 



















PCR program for Bisulfite PCR





























Appendix D. Program for qPCR.  
 
 
Appendix E. Taqman probes used in Fluidigm qPCR. 
 
 



















*Data acquisition performed during the extension step. 
Program for qPCR
+Melting Curve Analysis









Antibody Catalogue Number, Company Dilution Used
Actin #SC-1616, Santa Cruz 1:10000
GAPDH #ABS16, Millipore 1:2000
CYB5R2 #H00051700-B02P, Novus Biologicals 1:500
zsGreen #632474, Clontech 1:500
HBx produced by own lab 1:5000
Goat anti mouse IgG, peroxidase conjugated #AP124P, Millipore 1:50000
Rabbit anti goat IgG, peroxidase conjugated #SC-2768, Santa Cruz 1:50000
Goat anti rabbit IgG, peroxidase conjugated #SC-2030, Santa Cruz 1:50000
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Appendix H. pAdenoX-ZsGreen1 (Linear) vector map. 
  















Probeset ID Illumina ID SYMBOL Mean Difference (T-NT) Adjusted P-value (Methylation) Fold Change (T/NT) Adjusted P-value (Gene Expression)
cg15747595 ILMN_1737972 TSPYL5 0.38 2.47E-39 -1.32 4.24E-08
cg04809136 ILMN_1703720 SF3B14 0.53 1.49E-33 1.39 5.22E-11
cg06437004 ILMN_1728132 LDHB 0.49 5.31E-32 -1.22 2.47E-02
cg25119415 ILMN_1738992 MNDA -0.24 1.50E-30 -1.40 2.95E-07
cg00705255 ILMN_1661631 LILRA3 -0.15 1.88E-30 -1.24 1.20E-07
cg21825027 ILMN_1712231 SH3YL1 0.56 3.83E-29 -1.43 8.81E-09
cg23865698 ILMN_1660808 WFDC1 -0.27 1.91E-26 -1.32 3.89E-08
cg21643045 ILMN_1657234 CCL20 -0.31 2.68E-26 3.42 2.78E-09
cg02813121 ILMN_1748915 S100A12 -0.36 7.10E-26 -1.39 5.82E-08
cg17703554 ILMN_1768454 WDR21C -0.26 1.10E-25 1.42 7.93E-04
cg03826976 ILMN_1739576 CYB5R2 0.30 3.13E-25 -1.34 9.62E-05
cg26813458 ILMN_1712522 CEACAM6 -0.33 4.38E-25 -1.20 4.16E-02
cg15375239 ILMN_1800739 SPINT2 0.50 6.56E-24 -1.77 9.87E-05
cg13164309 ILMN_1714592 CDA -0.21 7.79E-24 -1.82 3.33E-12
cg24110050 ILMN_1751868 TCTEX1D1 0.34 1.07E-23 -1.59 4.54E-07
cg20520725 ILMN_1756849 HIST1H2AE 0.35 1.27E-23 1.26 3.19E-05
cg04034767 ILMN_1705210 GRASP 0.45 4.36E-23 -1.48 4.69E-09
cg01598642 ILMN_1796678 HBG1 -0.29 9.91E-23 -1.30 2.03E-05
cg02755525 ILMN_1760849 NETO2 0.52 1.17E-22 1.46 1.89E-10
cg06244417 ILMN_1668063 FCN1 -0.29 2.34E-22 -1.48 8.75E-07
cg26117023 ILMN_1700086 DOK1 0.45 2.56E-22 -1.20 1.78E-04
cg11618577 ILMN_1700728 KRTCAP3 0.24 2.90E-22 -1.86 2.88E-11
cg12949760 ILMN_1656079 KCNQ1 -0.28 3.77E-22 -1.23 1.62E-07
cg02876062 ILMN_1758672 FAM107B -0.28 1.79E-21 -1.29 8.69E-06
cg19996355 ILMN_1700762 PBX4 0.37 2.87E-21 -1.21 3.03E-04
cg12324629 ILMN_1715482 ULK2 0.18 3.70E-21 -1.21 9.48E-07
cg22477971 ILMN_1796409 C1QB -0.25 6.96E-21 -1.63 5.41E-05
cg04920951 ILMN_1679809 GSTP1 0.39 7.19E-21 -1.84 1.70E-08
cg20070090 ILMN_1729801 S100A8 -0.21 1.09E-20 -2.91 3.27E-11
cg17484237 ILMN_1693826 HAVCR2 -0.18 1.77E-20 -1.21 1.41E-02
cg15403517 ILMN_1788895 SRD5A2 0.31 1.77E-20 -3.85 1.18E-16
cg18741908 ILMN_1662846 GPR160 0.28 1.79E-20 1.24 3.33E-04
cg21542793 ILMN_1677868 ADRA2B 0.37 2.47E-20 -1.38 6.65E-13
cg02442161 ILMN_1693192 PI3 -0.22 4.31E-20 1.26 9.94E-06
cg10604168 ILMN_1806403 RASL12 0.33 5.55E-20 1.33 2.13E-09
cg12188860 ILMN_2405628 TOP1MT -0.32 5.76E-20 1.37 2.36E-05
cg08268099 ILMN_1742025 OLFM1 -0.24 6.35E-20 -1.48 4.51E-08
cg01564343 ILMN_1690783 TREML1 -0.28 1.07E-19 -1.47 1.98E-11
cg02431964 ILMN_1731503 MARCO -0.28 2.44E-19 -4.54 3.10E-25
cg09580336 ILMN_1731783 ATP1A1 0.25 3.76E-19 1.44 3.13E-06
cg06621358 ILMN_1691290 CELSR3 0.31 3.94E-19 1.95 1.25E-13
cg05828624 ILMN_1802441 REG1A -0.22 6.21E-19 1.29 2.48E-02
cg20649991 ILMN_2339294 LILRB5 -0.27 8.01E-19 -1.62 8.62E-14
cg11393848 ILMN_1785902 C1QC -0.11 8.71E-19 -1.47 2.52E-04
cg24355048 ILMN_1680424 CTSG -0.17 9.49E-19 -1.26 5.04E-03
cg23092823 ILMN_1770800 PODN 0.29 1.24E-18 -1.29 1.87E-04
cg11846236 ILMN_1751161 COL7A1 0.35 1.29E-18 1.49 6.84E-06
cg01796228 ILMN_1709094 LIFR -0.21 1.67E-18 -1.48 1.92E-16
cg20018806 ILMN_1768469 TCN1 -0.20 1.78E-18 -1.26 2.39E-02
cg26029902 ILMN_1786976 RAB22A 0.30 1.96E-18 1.35 1.02E-07
cg17982102 ILMN_1660691 RAB31 0.36 3.68E-18 -1.24 7.13E-03
cg08430598 ILMN_1753449 CST1 -0.30 4.43E-18 1.21 3.14E-02
cg24929737 ILMN_1703852 EFNB2 0.39 7.32E-18 1.34 1.18E-07
cg25509184 ILMN_1705813 CFTR 0.33 1.14E-17 -2.03 3.09E-11
cg03843978 ILMN_1777397 MSX1 0.19 1.18E-17 1.44 3.27E-10
cg22218909 ILMN_2165289 DEFA3 -0.25 1.40E-17 -1.78 1.94E-08
cg05026186 ILMN_1656940 ABLIM3 -0.12 1.75E-17 -1.50 3.00E-07
cg08999895 ILMN_1691048 SLC22A18AS -0.27 2.14E-17 1.44 1.17E-05
cg15357945 ILMN_1729314 PRG2 -0.21 2.99E-17 -1.32 6.38E-06
cg06421800 ILMN_2376723 CDKN2B 0.18 3.59E-17 1.31 3.88E-06
cg11158374 ILMN_1663919 TFF2 -0.27 5.35E-17 -1.31 1.68E-02
cg04828792 ILMN_2231928 MX2 -0.27 5.47E-17 -1.29 1.80E-04
cg01076838 ILMN_2049417 TMEM86B -0.25 5.66E-17 -1.62 6.96E-11
cg17301902 ILMN_1686227 GNA14 0.32 6.50E-17 -1.36 8.36E-14
cg15868302 ILMN_1789400 FOXD2 0.14 8.55E-17 1.51 3.47E-10
cg00948524 ILMN_1700660 RNF135 0.33 8.97E-17 -1.24 1.69E-07
cg03954858 ILMN_1683231 FAM83F -0.23 1.07E-16 -1.33 1.84E-12
cg12613344 ILMN_1814022 NR1H3 0.20 1.46E-16 -1.33 3.12E-08
cg15746445 ILMN_1661637 TRPM8 -0.18 1.81E-16 -2.60 4.70E-13
cg22456522 ILMN_1784884 LILRB3 -0.20 2.57E-16 -1.46 1.35E-05
cg13802966 ILMN_1727762 CASP1 -0.13 2.68E-16 -1.31 3.97E-08
cg22984277 ILMN_1771664 CLEC4E -0.11 3.73E-16 -1.23 2.88E-04
cg14757492 ILMN_1762225 DDX49 -0.23 4.05E-16 1.38 4.26E-07
cg14444710 ILMN_1653793 PDPK1 -0.22 4.84E-16 1.42 1.58E-10
cg02946850 ILMN_1729212 GRM8 -0.26 4.88E-16 -1.46 2.09E-07
cg26164184 ILMN_1714057 FCN2 -0.21 4.88E-16 -2.48 1.87E-22
cg02978737 ILMN_2069224 PVALB -0.23 5.25E-16 -1.40 2.24E-17
cg15821095 ILMN_1673024 RBM15B -0.24 6.10E-16 1.32 7.86E-12
cg22228134 ILMN_1731233 GZMH -0.21 7.47E-16 -1.34 4.68E-05
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Probeset ID Illumina ID SYMBOL Mean Difference (T-NT) Adjusted P-value (Methylation) Fold Change (T/NT) Adjusted P-value (Gene Expression)
cg02812142 ILMN_1727091 ACMSD -0.16 1.36E-15 -1.65 3.96E-06
cg19099850 ILMN_1803788 LGALS3 0.45 2.17E-15 1.37 1.10E-03
cg07364841 ILMN_1701468 HGFAC 0.19 2.82E-15 -8.28 1.83E-22
cg21238457 ILMN_1662188 WNT11 0.26 2.99E-15 -1.36 3.79E-05
cg13801416 ILMN_1701731 AKR1B1 0.40 3.56E-15 1.57 1.02E-03
cg13246269 ILMN_1738494 AQP7 -0.14 5.89E-15 -1.36 1.03E-07
cg09558502 ILMN_1734542 OVGP1 -0.15 6.23E-15 -1.30 5.24E-04
cg02168291 ILMN_1766925 CDH13 -0.22 7.71E-15 1.76 2.64E-15
cg23710218 ILMN_1741404 MSC 0.25 1.50E-14 1.29 3.19E-03
cg20368904 ILMN_1727689 TNFAIP2 0.15 1.57E-14 -1.22 3.72E-03
cg19132372 ILMN_2107004 GPR1 -0.23 1.87E-14 -1.40 2.96E-08
cg21831174 ILMN_1809537 MASP1 0.14 2.44E-14 -2.65 7.33E-23
cg01892689 ILMN_2058795 PGCP -0.18 3.05E-14 1.60 1.68E-08
cg12782180 ILMN_2207505 LEP 0.25 3.57E-14 -1.36 8.34E-06
cg06397837 ILMN_1731349 HOXA13 0.28 3.80E-14 1.72 9.82E-08
cg13745346 ILMN_1657627 CBFA2T3 -0.21 4.23E-14 -1.26 1.37E-09
cg07233761 ILMN_2212878 ESM1 -0.15 4.58E-14 2.34 4.58E-14
cg06118312 ILMN_1779324 GZMA -0.16 4.65E-14 -1.30 1.01E-02
cg24311282 ILMN_1674593 SIGLEC11 -0.24 4.85E-14 -1.50 4.70E-13
cg04582295 ILMN_1741007 SGCA -0.21 5.89E-14 -1.39 2.47E-09
cg05384917 ILMN_1677693 GPR109B -0.25 6.54E-14 -1.20 6.00E-03
cg14473145 ILMN_2142185 CLEC14A 0.21 6.82E-14 1.28 1.17E-03
cg03665605 ILMN_2307883 ATP5J2 -0.17 7.43E-14 1.45 2.19E-11
cg26661481 ILMN_1652825 IL10RA -0.25 8.46E-14 -1.44 1.92E-05
cg03600318 ILMN_1768575 SFTPD -0.15 1.01E-13 -1.30 4.39E-13
cg20850981 ILMN_2377991 ZNF323 -0.17 1.02E-13 1.44 5.02E-07
cg27159719 ILMN_1674402 TMEM71 -0.15 1.16E-13 -1.47 1.00E-06
cg25659818 ILMN_1674563 CCL4 -0.20 1.25E-13 -1.55 5.26E-11
cg20774846 ILMN_1749324 DPYS -0.11 1.45E-13 -1.68 4.84E-05
cg26808784 ILMN_2148527 H19 -0.27 2.49E-13 -2.75 5.24E-06
cg11054936 ILMN_1769388 GJB2 -0.12 2.51E-13 -1.64 2.20E-06
cg14709481 ILMN_1670302 HK3 -0.17 3.30E-13 -1.49 9.68E-13
cg26952662 ILMN_1725090 CTHRC1 0.36 3.71E-13 1.84 6.61E-06
cg05714219 ILMN_1722524 GALNT14 0.32 4.22E-13 -1.40 5.32E-12
cg19264571 ILMN_1656951 APCDD1 0.18 4.22E-13 -1.35 3.00E-04
cg20226764 ILMN_1685858 MLN -0.17 4.22E-13 -1.27 3.48E-13
cg13718960 ILMN_1795183 RNASE1 -0.17 4.88E-13 1.23 1.07E-02
cg27377450 ILMN_1664016 ARHGEF18 -0.12 5.41E-13 1.20 1.33E-03
cg26359240 ILMN_2112755 HSDL1 -0.14 6.84E-13 1.25 1.38E-07
cg14743462 ILMN_1779648 HIST3H2A 0.28 8.69E-13 1.20 2.21E-04
cg27619475 ILMN_1755649 SLC16A5 0.15 1.04E-12 -1.37 9.52E-07
cg16626670 ILMN_2193817 CLEC4G -0.21 1.05E-12 -7.64 7.90E-32
cg18506679 ILMN_1761425 OLFML2A -0.16 1.31E-12 1.33 1.24E-05
cg17108819 ILMN_1760374 CD8A 0.33 1.32E-12 -1.23 8.09E-04
cg12019109 ILMN_1797154 AZGP1 -0.16 2.06E-12 -2.55 1.40E-14
cg14472601 ILMN_1679666 SCGB3A1 -0.23 2.08E-12 -1.47 1.60E-04
cg11693019 ILMN_1672148 AKR1B10 -0.17 2.08E-12 7.72 4.94E-11
cg19177941 ILMN_1807439 ALDH1A3 0.26 2.36E-12 -1.47 2.12E-06
cg04797323 ILMN_1798926 SOCS2 0.35 2.82E-12 -2.58 6.86E-14
cg21530890 ILMN_1789244 SOX8 0.29 3.62E-12 -1.27 7.02E-07
cg00840403 ILMN_1696590 CHST4 0.15 3.76E-12 -2.33 5.47E-12
cg17207590 ILMN_1767816 APH1B 0.22 4.13E-12 1.36 2.12E-05
cg17040807 ILMN_1758128 CYGB 0.17 4.58E-12 -1.59 3.69E-13
cg07862358 ILMN_2232712 MYO10 0.30 6.02E-12 -1.30 9.20E-11
cg20919799 ILMN_1718565 CDKN1C 0.34 6.17E-12 -1.35 1.09E-03
cg00108454 ILMN_1737918 C1QA -0.10 6.48E-12 -1.34 9.80E-04
cg10321723 ILMN_1708341 PDZK1 -0.18 6.58E-12 1.70 4.59E-08
cg07441272 ILMN_1712413 RPL39L 0.30 7.36E-12 1.30 1.50E-02
cg14564494 ILMN_1652237 CBR3 0.19 8.83E-12 1.27 3.22E-05
cg09027725 ILMN_1815634 COX4I2 -0.15 9.32E-12 1.25 2.00E-12
cg16708012 ILMN_1738116 TMEM119 0.12 9.39E-12 1.22 9.99E-03
cg11376198 ILMN_1702696 AFAR3 -0.20 1.30E-11 -1.42 1.32E-06
cg25020204 ILMN_1746220 DBH -0.18 1.38E-11 -4.74 2.05E-23
cg24287460 ILMN_1751099 CCDC48 -0.17 1.43E-11 -1.21 7.10E-07
cg27342801 ILMN_1757504 REG3A -0.21 1.54E-11 1.24 1.82E-02
cg20845050 ILMN_2137066 ZNF7 -0.12 1.60E-11 1.57 5.57E-13
cg11520395 ILMN_1692896 JMJD4 -0.15 1.67E-11 1.25 4.93E-09
cg25852715 ILMN_1802151 OSBPL5 -0.17 1.72E-11 -1.24 1.17E-04
cg13986130 ILMN_2054297 PTGS2 0.19 2.08E-11 -2.50 6.04E-12
cg15928398 ILMN_2384496 ST6GAL1 0.20 2.33E-11 -1.32 6.44E-04
cg09207718 ILMN_1683607 CYP1A2 -0.19 2.38E-11 -13.70 7.93E-22
cg19517525 ILMN_2053178 ACTG1 0.35 2.93E-11 1.23 6.08E-05
cg12727795 ILMN_1815057 PDGFRB 0.19 3.13E-11 1.31 1.80E-02
cg27596068 ILMN_1751028 SERPINH1 -0.12 3.50E-11 1.28 3.21E-05
cg07207789 ILMN_1790689 CRISPLD2 -0.17 3.69E-11 -1.70 1.08E-06
cg23173910 ILMN_1795325 ACTG2 -0.16 3.85E-11 2.32 5.15E-08
cg23089840 ILMN_1795055 LRRC3 0.17 3.86E-11 -1.33 3.32E-11
cg22373112 ILMN_1769665 RAB5C 0.18 3.94E-11 1.30 1.14E-05
cg17067005 ILMN_2073307 IL10 -0.20 4.05E-11 -1.46 1.28E-07
cg00237010 ILMN_1731745 NINJ2 0.16 4.10E-11 1.36 3.48E-03
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cg14603345 ILMN_1713964 BTBD3 -0.20 4.21E-11 1.23 4.26E-05
cg02545192 ILMN_2373119 TERT 0.27 4.26E-11 1.39 1.09E-05
cg15083233 ILMN_1675507 AKAP2 0.21 4.35E-11 -1.40 1.87E-09
cg27347104 ILMN_1752755 VWF -0.15 4.44E-11 2.37 1.46E-08
cg04355435 ILMN_1685709 TMEM125 0.24 4.46E-11 -1.22 1.04E-04
cg19000186 ILMN_1786353 CNGA1 -0.17 4.57E-11 -1.91 3.52E-10
cg21808053 ILMN_2174215 DIRAS3 -0.21 5.09E-11 -1.29 3.49E-09
cg10541755 ILMN_1735151 EIF5A2 0.30 5.21E-11 1.34 1.59E-05
cg22294577 ILMN_1760087 SLC26A3 -0.16 5.33E-11 1.35 7.71E-03
cg01989224 ILMN_1692058 NDN -0.16 6.60E-11 -1.30 5.05E-03
cg14023451 ILMN_1765419 GPLD1 -0.16 6.66E-11 -1.31 1.53E-02
cg09009111 ILMN_1697268 EMILIN2 0.29 6.94E-11 1.25 1.92E-02
cg24495017 ILMN_1674386 PITX1 0.25 7.55E-11 1.68 2.01E-06
cg23165541 ILMN_1791847 DAPK2 -0.18 8.24E-11 1.30 2.88E-08
cg08331313 ILMN_1796734 SPARC 0.20 8.34E-11 1.20 4.15E-02
cg13857100 ILMN_2172890 SLC18A1 -0.13 1.02E-10 -1.52 2.40E-11
cg16080552 ILMN_1739001 TACSTD2 0.20 1.05E-10 -3.41 1.78E-11
cg18279742 ILMN_2218277 RPS2 -0.14 1.12E-10 1.44 2.39E-07
cg01536400 ILMN_1759729 NDUFA8 -0.14 1.13E-10 1.20 4.57E-05
cg00141162 ILMN_1727402 HCLS1 0.20 1.14E-10 -1.67 1.72E-05
cg09022993 ILMN_1667948 SPATA18 0.21 1.21E-10 -1.86 2.94E-15
cg00563932 ILMN_1664464 PTGDS -0.17 1.65E-10 -2.04 5.35E-08
cg13066963 ILMN_1806710 ESPN 0.22 1.71E-10 -1.39 2.46E-05
cg16967583 ILMN_1709796 AGXT -0.10 1.85E-10 -2.35 1.67E-09
cg10494770 ILMN_2393765 IGLL1 -0.12 1.87E-10 -4.05 2.84E-10
cg18320336 ILMN_1733094 STEAP1 0.16 1.97E-10 1.37 2.74E-03
cg12259537 ILMN_1681829 ZNF606 0.19 2.05E-10 1.25 9.11E-08
cg24751129 ILMN_1736238 GNMT -0.20 2.42E-10 -4.02 2.88E-13
cg23363832 ILMN_1656837 RBP1 0.28 2.43E-10 -2.92 2.65E-10
cg18793806 ILMN_2215211 ZNF514 0.17 2.82E-10 1.25 2.79E-08
cg18994063 ILMN_1750678 TIMD4 -0.13 2.96E-10 -2.24 3.23E-11
cg06005396 ILMN_1659150 HCN2 0.17 3.02E-10 -1.21 1.53E-05
cg27494383 ILMN_1799871 LTK 0.19 3.73E-10 -1.29 1.71E-10
cg10149836 ILMN_1681467 RAB11FIP4 0.21 3.85E-10 1.28 1.06E-09
cg12832565 ILMN_1742001 CD160 0.11 3.99E-10 -1.32 3.98E-10
cg17031727 ILMN_1776993 COG2 0.19 4.14E-10 1.30 1.18E-08
cg23181170 ILMN_1689146 GABRP -0.13 4.88E-10 -1.29 6.72E-08
cg08465862 ILMN_1805737 PFKP 0.24 5.06E-10 1.23 6.31E-03
cg15320474 ILMN_1678841 UBD -0.17 5.78E-10 5.14 1.92E-13
cg02807948 ILMN_1699867 IGF2 -0.12 5.82E-10 -2.46 3.37E-07
cg20576510 ILMN_1786720 PROM1 -0.18 6.50E-10 -1.52 1.68E-08
cg26259363 ILMN_1698995 DES -0.14 6.63E-10 -1.21 2.30E-05
cg24620905 ILMN_1769299 MTMR11 -0.11 6.69E-10 2.03 3.10E-10
cg27292431 ILMN_1715742 SLC22A1 0.18 6.85E-10 -5.52 4.66E-16
cg15988792 ILMN_1752269 ACSS1 0.23 7.10E-10 1.25 1.58E-05
cg21115977 ILMN_1760363 GDF2 -0.18 8.85E-10 -1.48 2.56E-15
cg17691309 ILMN_1789196 TPM2 0.21 9.79E-10 1.43 7.37E-04
cg07307078 ILMN_1702636 TUBB6 0.24 1.05E-09 -1.22 3.37E-03
cg08319991 ILMN_1757387 UCHL1 0.18 1.12E-09 1.28 2.89E-02
cg05248470 ILMN_1734234 LILRB2 -0.11 1.13E-09 -1.31 8.56E-10
cg13605579 ILMN_1693789 ALPP -0.15 1.19E-09 -1.40 3.84E-06
cg25152631 ILMN_1766528 SLC25A36 0.26 1.29E-09 -1.20 6.72E-04
cg02417264 ILMN_2065745 RAMP3 -0.12 1.29E-09 -1.78 3.08E-14
cg03993463 ILMN_1675756 KCNJ15 -0.13 1.38E-09 -1.21 1.80E-05
cg04048249 ILMN_1722070 APOC3 -0.12 1.58E-09 -1.71 6.01E-06
cg12271671 ILMN_1693009 FGL2 0.15 1.76E-09 -1.63 1.21E-08
cg26301689 ILMN_1798327 PAQR9 -0.19 1.90E-09 1.62 2.61E-08
cg24309555 ILMN_1664024 APOB -0.11 1.98E-09 -1.39 2.26E-05
cg18755783 ILMN_1801236 SPG20 0.23 2.41E-09 -1.27 2.57E-09
cg03242666 ILMN_1659312 PMP22 -0.13 2.43E-09 -1.22 1.24E-04
cg21522797 ILMN_1815719 PLCG2 -0.13 2.62E-09 -1.34 1.27E-03
cg24215443 ILMN_1766712 TCF21 0.20 2.89E-09 -1.28 3.14E-09
cg07671949 ILMN_1678535 ESR1 0.22 2.90E-09 -2.73 2.20E-20
cg04337944 ILMN_1700541 FBLN1 -0.17 2.92E-09 1.32 6.90E-03
cg10876928 ILMN_1663042 SDC4 -0.14 3.36E-09 -1.72 1.51E-11
cg02214188 ILMN_1673360 BDH2 -0.11 3.45E-09 -1.59 2.23E-15
cg24974599 ILMN_1810910 CFH 0.11 3.45E-09 -1.56 8.03E-05
cg04378886 ILMN_1809850 RCN3 0.12 3.83E-09 -1.21 1.73E-05
cg18661868 ILMN_1693650 FES 0.20 3.88E-09 -1.68 2.21E-09
cg09906458 ILMN_1684795 PRND -0.11 4.01E-09 1.32 1.29E-05
cg07679836 ILMN_1805990 BAK1 0.19 4.07E-09 1.24 1.16E-08
cg26907768 ILMN_1720373 SLC7A5 0.16 4.14E-09 -1.27 7.47E-03
cg18809289 ILMN_1792150 ALOX5 0.20 4.23E-09 -1.38 3.08E-08
cg23317501 ILMN_2133038 UGT3A1 0.13 4.49E-09 -1.29 9.30E-03
cg04577715 ILMN_1787266 SPINK1 -0.20 4.66E-09 11.76 3.05E-11
cg06577005 ILMN_2405642 DHDDS 0.17 4.81E-09 1.24 3.32E-08
cg07937272 ILMN_1718558 PARP12 0.14 5.41E-09 1.56 2.77E-12
cg10925082 ILMN_1678143 ARHGDIB -0.14 5.50E-09 -1.36 4.94E-04
cg01871995 ILMN_2366192 FGL1 -0.12 5.68E-09 -1.61 3.21E-03
cg22511633 ILMN_1764489 TBL2 0.20 5.80E-09 1.42 1.52E-13
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cg23064554 ILMN_1748730 CTRC -0.11 5.96E-09 -1.21 2.27E-05
cg13043509 ILMN_1769383 GIMAP5 0.17 6.39E-09 -1.21 1.01E-02
cg07361385 ILMN_1730625 AHSG -0.17 6.81E-09 -1.40 5.89E-04
cg14404298 ILMN_1669802 CYP8B1 -0.11 7.00E-09 -2.71 2.01E-06
cg18602314 ILMN_1709674 GFPT2 0.21 7.62E-09 -1.21 8.95E-04
cg09088576 ILMN_2371280 CSF3R 0.14 7.75E-09 -1.78 7.17E-10
cg20357806 ILMN_1767281 PPBP -0.14 7.76E-09 -1.21 2.43E-07
cg26491484 ILMN_1688642 LAMC3 -0.17 8.04E-09 -1.52 1.83E-07
cg21529533 ILMN_1656670 HLA-G 0.21 8.18E-09 1.59 1.36E-07
cg13311440 ILMN_2061043 CD48 -0.16 8.26E-09 -1.21 3.78E-02
cg06638433 ILMN_1733807 IGF2BP1 0.22 1.06E-08 1.31 4.17E-05
cg02661879 ILMN_1715748 FLNC 0.25 1.11E-08 1.39 1.02E-03
cg02902770 ILMN_1810844 RARRES2 -0.12 1.14E-08 -1.33 2.17E-03
cg22335801 ILMN_2112256 TNFRSF4 -0.20 1.19E-08 1.31 5.26E-11
cg03752628 ILMN_1743130 PTGFRN -0.12 1.21E-08 1.32 8.30E-08
cg04353769 ILMN_1797731 MS4A6A -0.13 1.21E-08 -2.29 1.24E-13
cg17274742 ILMN_1801205 GPNMB -0.14 1.26E-08 1.57 2.40E-03
cg24169822 ILMN_3251370 HOXA4 0.19 1.32E-08 -1.20 5.99E-05
cg24335895 ILMN_1662419 COX7A1 0.11 1.35E-08 -1.34 3.35E-04
cg02860342 ILMN_1790810 HCN4 0.17 1.49E-08 -1.51 2.96E-11
cg18060199 ILMN_1763638 BCAR3 0.25 1.63E-08 1.30 1.43E-05
cg13364756 ILMN_1673591 CYP3A43 -0.15 1.78E-08 -3.11 8.47E-18
cg00194146 ILMN_1778240 GFOD1 0.25 1.92E-08 -1.36 5.79E-04
cg04706338 ILMN_1691127 VTN -0.13 1.97E-08 -1.38 6.35E-06
cg04705866 ILMN_1710734 GZMK -0.11 2.13E-08 -1.57 6.93E-07
cg09191232 ILMN_1781819 PAPSS1 0.15 2.17E-08 1.35 2.12E-08
cg23410627 ILMN_1741021 CH25H 0.21 2.57E-08 -1.64 4.59E-05
cg08418978 ILMN_1737096 CLDN10 -0.16 2.64E-08 -1.43 1.45E-12
cg22129364 ILMN_1726030 GPX7 0.22 2.71E-08 1.40 6.13E-07
cg16954341 ILMN_1789648 SCGN 0.17 2.88E-08 1.98 5.65E-05
cg15983520 ILMN_1795257 GPT -0.12 2.95E-08 -2.36 1.61E-13
cg02436686 ILMN_1711617 GMFG -0.13 2.99E-08 -1.51 1.07E-07
cg17264470 ILMN_1772789 FGF21 -0.18 3.15E-08 1.28 3.10E-02
cg04700814 ILMN_1685115 HEXIM1 0.13 3.45E-08 -1.45 4.04E-11
cg19591881 ILMN_2341229 CD34 0.19 3.70E-08 2.22 3.02E-19
cg02512860 ILMN_1682226 CLDN15 -0.21 3.73E-08 1.93 3.17E-10
cg18429742 ILMN_1694514 ZDHHC11 -0.15 3.85E-08 -1.57 3.92E-06
cg27383362 ILMN_2231569 ATAD3C -0.13 3.98E-08 -1.21 2.11E-07
cg01747665 ILMN_2188966 IGFALS 0.13 4.03E-08 -7.58 1.93E-27
cg22171829 ILMN_1684982 PDK4 -0.11 4.15E-08 -2.25 3.86E-10
cg27050763 ILMN_1809139 AHCTF1 -0.21 4.27E-08 1.20 2.20E-04
cg23587449 ILMN_1673491 LRAT 0.19 4.35E-08 -1.29 3.14E-14
cg05101920 ILMN_1808272 KCNJ10 0.16 4.55E-08 -1.23 8.17E-07
cg05788638 ILMN_1793628 SERPINA10 -0.16 4.58E-08 -1.85 7.87E-09
cg23681213 ILMN_1770850 PNMA1 0.21 4.71E-08 1.28 5.81E-05
cg11105610 ILMN_1659688 LGALS3BP 0.12 4.82E-08 -1.27 3.82E-02
cg02210887 ILMN_2131177 GUCY1A3 -0.11 4.87E-08 -1.40 2.37E-11
cg21122774 ILMN_1704973 SARDH -0.14 5.70E-08 -1.90 7.62E-16
cg07197059 ILMN_1765248 EFS -0.18 6.14E-08 -1.23 7.75E-08
cg24127874 ILMN_1694268 HES6 0.20 6.85E-08 1.65 9.71E-13
cg22633722 ILMN_1804735 CBS 0.21 6.88E-08 -2.05 4.36E-09
cg24680602 ILMN_2139351 ZNF232 0.21 7.31E-08 1.31 3.02E-10
cg06613840 ILMN_1749662 GPX1 -0.12 7.34E-08 1.31 3.27E-03
cg20786074 ILMN_1735877 EFEMP1 0.15 8.21E-08 -1.40 2.92E-02
cg23036025 ILMN_1725366 SLC27A5 -0.10 8.69E-08 -2.87 8.09E-10
cg03533058 ILMN_1661178 NR4A1 -0.13 8.99E-08 -1.65 7.53E-15
cg06134964 ILMN_1755251 ITIH1 -0.15 9.22E-08 -1.78 1.00E-08
cg10212621 ILMN_1815203 HMGCS2 -0.11 9.27E-08 -1.71 2.36E-07
cg14170423 ILMN_2375319 RASGRP2 0.14 1.05E-07 -1.37 2.01E-05
cg13823701 ILMN_1684614 TNXB -0.11 1.07E-07 -1.62 2.73E-16
cg26956535 ILMN_1813338 LAG3 0.10 1.10E-07 -1.35 1.50E-05
cg02554564 ILMN_1809364 NTF3 -0.11 1.11E-07 -2.00 2.17E-19
cg15423862 ILMN_1744968 KCNAB1 -0.16 1.13E-07 -1.26 3.59E-07
cg22670329 ILMN_2161577 CXCL6 0.14 1.14E-07 -1.30 8.97E-03
cg06948294 ILMN_1750912 STXBP6 0.14 1.21E-07 1.78 1.97E-14
cg00400028 ILMN_1706598 ACPL2 0.18 1.26E-07 1.26 3.01E-05
cg10126923 ILMN_1682993 NKG7 -0.17 1.30E-07 -1.38 9.15E-06
cg25870420 ILMN_1813117 ITGA9 0.21 1.31E-07 -1.35 3.01E-13
cg00392257 ILMN_2090397 ISG20L2 -0.16 1.37E-07 1.21 2.16E-05
cg19280968 ILMN_1683044 PPP1R2 0.23 1.40E-07 1.22 9.06E-04
cg05403071 ILMN_1758086 SNAI1 0.20 1.42E-07 -1.36 4.93E-09
cg18055007 ILMN_1770787 DDAH2 0.17 1.48E-07 1.31 4.31E-04
cg03447931 ILMN_1747650 BMP6 0.23 1.49E-07 -1.24 1.62E-06
cg12343082 ILMN_1731292 CA5A -0.14 1.65E-07 -2.03 1.45E-09
cg00468146 ILMN_1721758 ID4 0.20 1.89E-07 -1.29 3.56E-05
cg25527547 ILMN_1774836 PLOD3 -0.13 1.91E-07 1.86 3.25E-17
cg17142134 ILMN_1755720 SLC2A2 -0.15 1.93E-07 -1.90 9.03E-06
cg19428417 ILMN_2186137 RRAD 0.13 2.23E-07 -1.25 1.86E-05
cg18110483 ILMN_1736078 THBS4 0.16 2.23E-07 2.25 1.33E-08
cg20199333 ILMN_3249291 F2 -0.14 2.33E-07 -1.65 1.82E-08
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cg21264055 ILMN_1750167 PRR3 0.19 2.39E-07 1.21 2.30E-09
cg15696781 ILMN_1707337 MSTO1 0.17 2.58E-07 1.22 7.68E-08
cg20657383 ILMN_1664330 CEACAM1 -0.12 2.64E-07 1.38 4.53E-05
cg02157083 ILMN_1754055 APOA5 0.14 2.65E-07 -3.80 1.42E-13
cg02611419 ILMN_1717702 KCNK17 -0.17 2.78E-07 -1.43 1.65E-11
cg23400451 ILMN_1729251 MYH4 -0.11 2.79E-07 1.21 2.25E-02
cg27485921 ILMN_1810235 ATP6V1E2 -0.11 2.89E-07 1.41 4.97E-11
cg02212836 ILMN_1807825 LY86 -0.17 3.02E-07 -1.27 8.17E-04
cg06692050 ILMN_1790026 SFRP5 0.14 3.07E-07 -1.47 9.17E-14
cg14021073 ILMN_1708496 BRSK2 0.15 3.08E-07 -1.23 8.08E-03
cg27418851 ILMN_1762464 MBL2 -0.12 3.40E-07 -3.52 4.14E-12
cg17412258 ILMN_1652975 DLK1 0.18 3.44E-07 1.35 4.13E-02
cg09210315 ILMN_1727200 SLCO4A1 -0.10 3.49E-07 -1.29 3.18E-05
cg24441911 ILMN_2103024 RBP5 -0.16 3.55E-07 -1.85 1.36E-07
cg12332316 ILMN_1671766 F12 -0.14 3.56E-07 -1.82 1.95E-06
cg17741572 ILMN_1774287 CFB -0.14 3.62E-07 -1.35 4.94E-04
cg21820890 ILMN_1808487 PLA2G12B -0.16 3.72E-07 -1.20 8.06E-03
cg17391877 ILMN_1795484 PGC -0.12 3.98E-07 1.57 7.95E-03
cg12508624 ILMN_1779875 THY1 0.18 4.15E-07 2.24 3.81E-15
cg23213217 ILMN_1780058 DEGS1 -0.17 4.29E-07 1.27 1.07E-03
cg02126753 ILMN_1736178 AEBP1 0.15 4.32E-07 -1.71 9.91E-06
cg12091331 ILMN_1738742 PLAT 0.15 4.33E-07 -1.25 6.94E-03
cg06356454 ILMN_1757036 AQP12A -0.14 4.47E-07 -1.52 1.47E-12
cg24490338 ILMN_1697567 TPM3 -0.13 4.48E-07 1.61 2.77E-14
cg24480859 ILMN_1671337 SLC2A5 -0.13 4.73E-07 2.07 6.56E-08
cg22568540 ILMN_2055271 A1BG -0.16 4.83E-07 -1.21 1.14E-03
cg16408565 ILMN_1731785 ORM2 -0.18 5.71E-07 -1.63 2.76E-06
cg00689010 ILMN_1735180 NCSTN -0.13 5.87E-07 1.48 1.78E-08
cg06151165 ILMN_1755734 VSX1 0.18 6.38E-07 -1.21 2.89E-06
cg20645065 ILMN_1701603 ALPL 0.21 6.46E-07 -2.03 2.02E-09
cg17100322 ILMN_2249920 FYN 0.23 6.52E-07 -1.31 1.45E-06
cg04387658 ILMN_1714602 CD86 -0.12 6.60E-07 -1.26 1.46E-03
cg19139729 ILMN_1692983 SULT2A1 -0.10 6.71E-07 -2.15 1.12E-06
cg09450238 ILMN_1744725 BTBD6 0.12 6.71E-07 -1.38 9.67E-06
cg24910675 ILMN_1760778 ENG 0.13 8.42E-07 -1.53 3.14E-07
cg01580681 ILMN_2064902 HAND2 0.19 8.67E-07 -1.36 2.04E-14
cg22202141 ILMN_1703679 FCGR3A -0.12 9.77E-07 -1.40 2.90E-10
cg25729716 ILMN_2366212 CD79B -0.10 9.95E-07 -1.28 2.63E-05
cg12858460 ILMN_1760509 EOMES 0.18 1.00E-06 -1.36 8.68E-05
cg05755779 ILMN_1662962 COLEC10 -0.16 1.06E-06 -1.85 2.41E-17
cg25690265 ILMN_1730117 TMC5 -0.12 1.07E-06 1.23 1.76E-02
cg18265887 ILMN_1709795 RAC2 0.16 1.17E-06 -1.36 1.22E-02
cg14380517 ILMN_1707339 BTG3 0.18 1.19E-06 1.39 3.49E-05
cg20503329 ILMN_1768940 COL15A1 -0.14 1.25E-06 2.22 9.12E-15
cg19614321 ILMN_1812139 RASSF2 0.15 1.27E-06 -1.31 5.98E-08
cg20373326 ILMN_1808713 HSD17B2 -0.10 1.29E-06 -2.78 2.34E-12
cg17711541 ILMN_1792689 HIST1H2AC 0.11 1.39E-06 1.38 5.39E-04
cg00563926 ILMN_1784287 TGFBR3 0.13 1.46E-06 -1.53 6.68E-06
cg03421300 ILMN_1806607 SFN -0.11 1.54E-06 1.30 5.99E-05
cg23968383 ILMN_1802974 ZNF572 -0.18 1.55E-06 1.27 2.22E-08
cg04567009 ILMN_1728639 FCGR3B -0.12 1.59E-06 -1.32 5.75E-05
cg08722122 ILMN_1729369 FGFR1 -0.15 1.65E-06 -1.39 1.04E-11
cg01827098 ILMN_1776678 GIMAP7 -0.15 1.73E-06 -1.38 1.17E-05
cg01806928 ILMN_1728496 SYT9 0.15 1.86E-06 -1.23 7.01E-07
cg06646021 ILMN_1677824 RAB4A -0.12 2.05E-06 1.34 3.77E-07
cg23287547 ILMN_1698225 MYO5A 0.14 2.11E-06 1.30 2.07E-05
cg23496260 ILMN_1651826 BASP1 0.14 2.27E-06 -2.15 1.63E-10
cg16159313 ILMN_1683883 ACY1 -0.17 2.47E-06 -1.25 1.14E-02
cg25374854 ILMN_1657045 ABR 0.15 2.48E-06 -1.22 1.04E-05
cg22463915 ILMN_2108735 EEF1A2 0.15 2.52E-06 2.19 1.28E-05
cg25778166 ILMN_2344283 FMO3 -0.12 2.74E-06 -2.10 1.07E-05
cg11880010 ILMN_1810628 KIAA0367 -0.12 2.74E-06 -1.23 1.55E-04
cg23653712 ILMN_2194467 SGCB 0.16 2.80E-06 -1.28 1.12E-05
cg11695266 ILMN_1793770 DNAJB6 0.16 3.09E-06 1.49 3.34E-09
cg24269657 ILMN_1740559 F7 -0.13 3.13E-06 -1.65 2.00E-09
cg07986525 ILMN_2049766 NFE2L3 0.20 3.13E-06 1.21 5.58E-07
cg17561435 ILMN_3307916 BMPER 0.17 3.40E-06 -1.43 3.27E-14
cg07039113 ILMN_1750974 S100A9 -0.16 3.68E-06 -1.60 1.46E-03
cg08221207 ILMN_1779071 FEZ1 0.13 3.79E-06 -1.53 1.03E-09
cg23877385 ILMN_1712082 GCNT3 -0.12 3.82E-06 1.69 2.34E-05
cg01109219 ILMN_1727045 RASGRP3 -0.11 3.98E-06 1.25 9.53E-05
cg20713492 ILMN_2090004 AQP10 -0.12 4.00E-06 1.25 5.74E-03
cg08453096 ILMN_1716592 ABCG5 -0.13 4.06E-06 -1.29 1.13E-03
cg20993403 ILMN_1716507 EPB41L1 -0.13 4.12E-06 -1.25 2.49E-05
cg12717594 ILMN_2067269 RECK 0.19 4.23E-06 -1.21 4.66E-03
cg08690031 ILMN_1737184 CDCA7 0.18 4.30E-06 1.46 3.49E-06
cg07967308 ILMN_2078599 ACP5 -0.10 4.52E-06 -1.36 4.37E-03
cg02399455 ILMN_1682054 SRI -0.12 4.82E-06 1.22 9.48E-07
cg20001829 ILMN_1651745 TMEM25 0.15 4.96E-06 -1.40 2.23E-08
cg01733599 ILMN_1812700 LIPC -0.11 5.03E-06 -2.21 4.67E-11
cg25101936 ILMN_2305407 ZBTB16 0.13 5.05E-06 -1.74 7.60E-09
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cg13234643 ILMN_1748352 CTSL2 0.19 5.33E-06 1.55 2.15E-06
cg08700306 ILMN_2127605 LRP3 -0.11 5.64E-06 -1.45 2.55E-07
cg26581729 ILMN_2199313 NPDC1 -0.15 6.80E-06 -1.24 8.66E-09
cg19355190 ILMN_1743199 EGR2 0.17 6.82E-06 -2.28 1.50E-10
cg26718585 ILMN_1687721 PROC -0.12 6.90E-06 -1.69 2.03E-10
cg15089387 ILMN_1662884 TSLP 0.15 7.11E-06 -1.36 1.11E-06
cg01962086 ILMN_1669703 TNK2 0.16 7.26E-06 -1.33 7.52E-07
cg21146268 ILMN_1687947 HIST1H2BE 0.12 7.37E-06 1.31 7.76E-07
cg03462055 ILMN_1680874 TUBB2B 0.15 7.68E-06 1.28 1.47E-04
cg24127989 ILMN_1676515 IMPDH1 0.17 7.77E-06 1.22 2.59E-03
cg05766474 ILMN_2045324 CCL16 -0.15 8.31E-06 -1.29 1.94E-02
cg25894551 ILMN_1781045 FXYD2 -0.14 8.86E-06 -1.51 3.40E-09
cg25734864 ILMN_1664565 PROZ -0.13 9.45E-06 -2.92 1.23E-13
cg15982419 ILMN_1791840 RALBP1 0.15 9.46E-06 1.30 1.96E-08
cg09326702 ILMN_1735386 SLC22A11 -0.12 9.52E-06 1.55 6.51E-05
cg14540150 ILMN_1781031 CTBP2 0.15 9.99E-06 -1.35 5.60E-09
cg06361108 ILMN_1773119 CCNF 0.16 1.03E-05 1.37 8.54E-14
cg02523400 ILMN_1707975 SERPIND1 -0.12 1.04E-05 -1.21 1.10E-02
cg10055471 ILMN_2220978 NR0B2 -0.13 1.08E-05 -2.02 5.76E-10
cg07744166 ILMN_1810797 WASF3 0.12 1.08E-05 -1.25 1.23E-02
cg13705707 ILMN_1684850 PRKAR2B 0.12 1.13E-05 -1.23 4.58E-08
cg11027330 ILMN_1712583 METRN 0.13 1.28E-05 -1.34 5.39E-04
cg13042288 ILMN_1763837 ANPEP -0.11 1.32E-05 -1.68 1.99E-08
cg27238470 ILMN_1680814 EDN2 -0.11 1.35E-05 -1.22 3.01E-05
cg02255609 ILMN_1678140 TTC4 0.16 1.40E-05 1.23 1.44E-05
cg09201719 ILMN_1760554 CYP17A1 -0.11 1.45E-05 1.49 3.04E-04
cg13030582 ILMN_1766914 MFAP4 0.10 1.50E-05 -4.51 3.78E-19
cg20249919 ILMN_1768577 PCSK6 -0.12 1.52E-05 -1.45 7.19E-05
cg01013324 ILMN_1695606 EFNB3 0.14 1.56E-05 -1.30 3.31E-13
cg19615059 ILMN_2362346 TRPV4 0.18 1.61E-05 -1.28 5.26E-10
cg20879959 ILMN_1671054 HLA-A 0.13 1.82E-05 1.23 7.65E-03
cg01555431 ILMN_1684836 AKAP12 0.17 1.83E-05 -1.27 6.20E-04
cg03368758 ILMN_1800697 LDB2 -0.11 1.93E-05 -1.43 1.09E-07
cg23886551 ILMN_1723145 TMEM121 0.14 2.03E-05 -1.39 7.93E-12
cg04219321 ILMN_1722829 HLF 0.18 2.08E-05 -1.81 6.34E-09
cg00436603 ILMN_1665437 CYP2E1 -0.10 2.51E-05 -5.04 5.97E-11
cg17127769 ILMN_1658962 LCP2 -0.11 2.59E-05 -1.33 3.05E-08
cg09949775 ILMN_1677636 COMP 0.18 2.67E-05 1.37 3.15E-04
cg07327347 ILMN_1713462 AQP8 -0.12 2.69E-05 1.22 4.57E-03
cg08121954 ILMN_1716859 TDO2 0.11 2.76E-05 -2.78 2.65E-09
cg03853151 ILMN_1654441 OAT 0.20 2.78E-05 -2.50 3.54E-09
cg04569804 ILMN_1686623 CSF1R -0.10 2.81E-05 -1.67 5.41E-07
cg18338296 ILMN_1794844 THRSP 0.14 2.84E-05 -4.68 7.50E-10
cg13797282 ILMN_1743714 CARD10 -0.13 3.09E-05 1.21 1.74E-03
cg25421647 ILMN_1677877 UBE2L3 0.14 3.20E-05 1.27 1.19E-05
cg07986773 ILMN_1725612 NUP50 -0.15 3.22E-05 1.22 7.72E-05
cg23141855 ILMN_2068104 TFPI2 0.11 3.26E-05 -1.78 2.18E-15
cg26099316 ILMN_1757461 ITIH3 -0.10 3.41E-05 -1.22 3.98E-02
cg18084554 ILMN_1670130 ARID3A 0.11 3.56E-05 1.22 2.34E-02
cg13818573 ILMN_1716957 C1QL1 0.17 3.61E-05 1.20 1.00E-03
cg26777475 ILMN_1707070 PCOLCE -0.10 3.96E-05 -1.81 1.12E-05
cg25971347 ILMN_1680973 FOXF1 0.15 4.02E-05 -1.23 4.59E-07
cg20270599 ILMN_1657373 LEPREL1 0.11 4.05E-05 -2.15 4.84E-20
cg06722216 ILMN_2087629 NOL4 0.11 4.06E-05 -1.29 1.25E-04
cg10613381 ILMN_1678690 UPB1 -0.11 4.07E-05 -1.65 1.60E-05
cg21838334 ILMN_1738147 NES 0.14 4.12E-05 1.28 3.78E-07
cg02077702 ILMN_1747593 ISLR -0.11 4.22E-05 -1.45 3.20E-05
cg02548238 ILMN_1695880 LOX 0.17 4.42E-05 1.31 1.30E-04
cg06630567 ILMN_1695446 AMBP -0.11 5.00E-05 -1.47 1.43E-05
cg17129388 ILMN_1752658 NGFR -0.12 5.28E-05 -1.51 2.20E-17
cg20673481 ILMN_2175112 KCNS3 0.15 5.32E-05 -1.24 7.59E-03
cg13854874 ILMN_1674231 CHAF1B 0.15 5.40E-05 1.47 3.53E-08
cg01615704 ILMN_2063168 MALL 0.15 6.24E-05 1.31 2.60E-06
cg06394229 ILMN_1694034 LGALS4 -0.12 6.40E-05 1.69 6.92E-03
cg07007400 ILMN_2163723 KRT7 0.11 6.62E-05 -1.25 1.69E-03
cg20925811 ILMN_1796316 MMP9 -0.11 7.53E-05 2.04 1.01E-04
cg02164442 ILMN_1681945 ITGAD -0.12 7.86E-05 -1.60 1.09E-08
cg26955850 ILMN_1735124 OXT 0.13 8.08E-05 -2.13 1.03E-13
cg10025865 ILMN_2215418 SERPINA6 -0.10 8.25E-05 -1.36 4.56E-03
cg08704509 ILMN_2065690 GRAMD3 0.14 9.36E-05 -1.28 1.18E-06
cg12928668 ILMN_1713529 SEMA6A 0.12 1.00E-04 -1.45 1.99E-06
cg10764357 ILMN_1766169 BCAT1 0.12 1.03E-04 1.60 1.11E-06
cg24901042 ILMN_1791123 TMPRSS2 0.14 1.03E-04 -1.99 7.74E-10
cg10795646 ILMN_2046730 S100A10 -0.10 1.04E-04 2.07 1.88E-13
cg10281478 ILMN_1690397 DYNC1I1 0.11 1.14E-04 1.25 3.17E-03
cg10681065 ILMN_1724738 TFR2 -0.11 1.19E-04 -2.01 9.16E-12
cg06885524 ILMN_1712305 CYBRD1 0.13 1.20E-04 -1.46 9.52E-05
cg00622677 ILMN_1799028 TSPAN5 0.11 1.27E-04 1.30 1.79E-03
cg18392783 ILMN_1793476 PRKCDBP 0.11 1.27E-04 1.23 5.34E-06
cg25514503 ILMN_1660986 PER3 -0.10 1.32E-04 -1.29 1.07E-05
cg01968793 ILMN_1657750 CNNM1 0.13 1.46E-04 1.25 7.08E-05
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cg24844534 ILMN_2380237 C1QTNF1 0.13 1.52E-04 -2.10 2.56E-13
cg03278643 ILMN_1762735 EVC2 -0.13 1.53E-04 -2.11 1.30E-14
cg17571291 ILMN_1691436 BLVRA 0.11 1.53E-04 1.48 1.12E-04
cg15669092 ILMN_1791726 TUBB3 0.13 1.54E-04 1.20 5.58E-04
cg24155668 ILMN_1749327 MAPK13 0.13 1.63E-04 1.32 3.05E-03
cg17410236 ILMN_1769615 FLRT2 0.14 1.79E-04 -1.23 1.82E-07
cg17498321 ILMN_1658926 NOTCH3 0.13 1.85E-04 1.40 1.98E-11
cg00625425 ILMN_1776936 ANKRD38 -0.12 1.85E-04 -1.52 4.68E-04
cg02589695 ILMN_2362902 RASSF5 0.15 2.20E-04 -1.22 1.52E-05
cg01617750 ILMN_1710124 CMTM8 -0.11 2.66E-04 1.22 4.94E-03
cg09480837 ILMN_1784447 PLCE1 -0.13 2.90E-04 1.38 5.05E-06
cg09947274 ILMN_1810992 CAD -0.10 3.06E-04 1.28 3.19E-10
cg05254747 ILMN_1764629 SLC39A14 -0.10 3.06E-04 -1.66 8.58E-10
cg20267005 ILMN_1778977 TYROBP -0.12 3.24E-04 -1.31 8.93E-03
cg18234011 ILMN_1702447 IGF2BP2 0.14 3.31E-04 1.61 1.61E-05
cg05662500 ILMN_1694106 GPD1L 0.14 3.32E-04 1.32 6.09E-04
cg07490776 ILMN_1676946 AP3M2 0.13 3.53E-04 1.46 1.87E-14
cg21099488 ILMN_1780132 PELI2 0.10 3.56E-04 -1.27 4.01E-05
cg09637363 ILMN_1688480 CCND1 0.10 3.79E-04 -1.30 6.40E-03
cg22740783 ILMN_1774722 CGREF1 0.16 3.83E-04 1.51 1.26E-10
cg20276750 ILMN_1657810 PPM1M 0.15 3.87E-04 1.20 1.26E-03
cg19001226 ILMN_1717381 HOXD1 0.12 3.99E-04 1.36 3.35E-05
cg13439730 ILMN_1796461 PRSS8 0.10 4.18E-04 -1.71 3.18E-09
cg08101264 ILMN_1679600 ACOT8 0.13 4.53E-04 1.25 7.31E-08
cg25811575 ILMN_1722781 EGR3 0.12 4.63E-04 -1.32 6.93E-07
cg18618334 ILMN_1791447 CXCL12 -0.14 6.60E-04 -5.25 9.64E-21
cg18931815 ILMN_2102330 COL8A2 -0.12 6.87E-04 -1.32 6.24E-07
cg08555612 ILMN_1775257 PROK2 0.11 7.63E-04 -1.48 3.85E-05
cg11038843 ILMN_1794072 B3GAT1 0.11 7.93E-04 -1.71 1.45E-13
cg21975377 ILMN_1659297 FZD6 0.11 9.75E-04 1.21 6.02E-04
cg16869108 ILMN_1801984 VHL -0.13 9.87E-04 1.30 4.35E-10
cg14916213 ILMN_1712455 RBM4 0.12 1.09E-03 1.35 2.06E-13
cg21376883 ILMN_1654422 ACTN2 0.10 1.28E-03 1.26 2.31E-03
cg08918749 ILMN_1786444 LPL 0.11 1.33E-03 1.25 5.31E-04
cg15522719 ILMN_2188722 GLS 0.10 1.42E-03 1.26 3.13E-05
cg21513553 ILMN_1765017 COL6A2 0.12 1.59E-03 -1.25 3.71E-08
cg07309102 ILMN_1779857 KLF4 0.13 1.61E-03 -1.40 3.56E-06
cg03262773 ILMN_1658027 RAD54L 0.13 1.72E-03 1.58 1.22E-13
cg06352750 ILMN_1715991 SDPR 0.12 1.89E-03 -1.56 1.08E-08
cg20377673 ILMN_1807074 MIF 0.12 2.00E-03 1.35 6.16E-04
cg20315136 ILMN_2197365 RGS2 0.11 2.19E-03 -2.34 8.19E-09
cg05385377 ILMN_1674985 TMEM51 0.11 2.27E-03 -1.22 2.49E-02
cg05732530 ILMN_1712959 DUSP2 0.10 2.29E-03 -1.31 2.66E-06
cg03998173 ILMN_1657949 RHEB 0.11 2.47E-03 1.67 1.92E-13
cg26842024 ILMN_1735930 KLF2 0.13 2.59E-03 -1.53 3.20E-07
cg16112050 ILMN_1803676 ENOSF1 -0.10 3.02E-03 -1.21 9.08E-04
cg02248486 ILMN_1753613 HOXA5 0.12 3.27E-03 1.23 1.88E-03
cg06240124 ILMN_1736176 PLK1 0.12 3.94E-03 1.37 1.47E-12
cg15146752 ILMN_1699354 EPHA2 0.11 4.06E-03 -1.79 1.34E-14
cg14424530 ILMN_1683859 SLC7A1 0.10 6.06E-03 1.22 7.33E-03
cg26189983 ILMN_1764788 TNFRSF1B 0.10 6.82E-03 -1.40 1.09E-04
cg18676162 ILMN_1800634 NME4 0.11 7.22E-03 -1.21 1.89E-02
cg27637521 ILMN_1781001 SOCS3 0.13 1.12E-02 -2.13 3.34E-09
cg04482110 ILMN_3249244 TMEM106A 0.12 1.44E-02 -1.42 1.20E-07
cg07109287 ILMN_1807016 LHX2 0.10 2.13E-02 -2.25 2.85E-15
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Permission to use Figure 1 Epigenetic regulation of gene expression integrates 





Permission to use Figure 4. 'Dashboard' of histone modifications for fine-
tuning genomic elements. 
 
 




Permission to use Figure 3 Schematic representation of the progress of the 
enzyme reaction in liquid-phase pyrosequencing.  
 
Permission to use Figure 9. Age-Standardized Liver Cancer Incidence Rates 
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